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Novel psychoactive substances (NPS) are compounds similar to common drugs of 
abuse with slight modifications to their chemical structure. These modifications can be 
dangerous and sometimes fatal due the lack of knowledge and/or studies of their adverse 
effects. NPS are sometimes marketed as “legal highs” or “research chemicals” in order to 
mimic effects of illicit drugs while simultaneously bypassing legislation. Although there 
are many drugs that are classified as NPS, novel synthetic opioids and synthetic 
cannabinoids are the focus of this research. Since little is known about these novel 
psychoactive substances difficulties may arise when analyzing toxicological samples 
suspected to contain NPS. To address the emergence of novel psychoactive substances, it 
is necessary to properly identify issues that could hinder analyses by assessing 
prevalence, examining instability, determining pharmacology, and identifying potential 
metabolites.  
The goals of this study were to 1) develop and validate a method to quantify novel 
synthetic opioids (NSO), buprenorphine, and heroin markers in oral fluid and apply the 
method to the analysis of oral fluid collected from detainees; 2) using the acquisition 
method from the oral fluid method, validate a blood method for the NSO and perform a 
long term stability study; 3) develop and validate a method to detect a NSO (U-47700) 
and its metabolites in plasma using a small sample volume (100 µL) and cross validate in 
rat plasma for a pharmacokinetic study in rats; and 4) identify metabolites for two 
 
v 
prominent synthetic cannabinoids in vitro verify metabolism with analysis of authentic 
urine samples.  
A method was validated for the quantification of morphine, 6-acetylmorphine, 
buprenorphine, U-47700, U-49900, U-50488, AH-7921, MT-45, W-18, and W-15 in oral 
fluid and was deemed acceptable according to Scientific Working Group for Forensic 
Toxicology (SWGTOX) guidelines. This method was applied to analysis of oral fluid 
collected from detainees (n=20) in Texas detention centers participating in a drug 
recognition evaluatoion (DRE) certification program. Although NSO were not detected, 
valuable data were collected that reinforced oral fluid as viable matrix when compared to 
presumptive urine results and impairment observations.  
 A blood method was validated for seven NSO and then applied to assess  the 
stability of these analytes over a 36-week study at four temperature conditions (-
20°C,4°C, 25°C , and 35°C). The results showed minimal effect on stability at the 
elevated temperature during the first two weeks, indicating that these analytes would be 
stable in the event of improper transport/handling within this timeframe. 
 A method was validated for the quantification of U-47700, N-desmethyl-U-
47700, and N,N-didesmethyl-U-47700 in human and rat plasma. This method was 
applied to a pharmacokinetic study where rats were injected with 0 (saline), 0.3, 1.0 or 
3.0 mg/kg U-47700.  Blood samples were collected at 15, 30, 60, 120, 240, 480 min after 
injection for quantification of U-47700 and its metabolites. Pharmacodynamic effects 
were also assessed at the same time points. It was determined that doses of U-47700 had 
a positive correlation with the behaviors observed which further demonstrates the 
analgesic effects of this novel synthetic opioid. 
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 Finally, a metabolic study utilizing human liver microsomes was conducted to 
investigate 5F-MDMB-PICA and 5F-MDMB-PINACA in vitro metabolism. In vitro 
metabolites were verified in vivo by analyzing authentic case specimens. Additionally, 
the potency and efficacy of 5F-MDMB-PICA and 5F-MDMB-PINACA were identified 
by examining activity at the CB1 receptor. The EC50 at the CB1 receptor for 5F-MDMB-
PICA and 5F-MDMB-PINACA were found to be comparable to each other and JWH-
018. There were 22 metabolites identified for 5F-MDMB-PICA and 21 metabolites 
identified for 5F-MDMB-PINACA.  
These studies have sought to identify toxicological issues that could arise when 
detecting a new NPS while providing the necessary data to the forensic toxicology 
community to further understand the activity and prevalence of such compounds. The 
challenges that arise when faced with a newly emerged NPS may be detrimental for 
forensic analysis and thorough characterization of new compounds is necessary for 
proper identification and detection.   
 






This project was partially supported by [Award No. 2017-R2-CX-0019], awarded 
by the National Institute of Justice, Office of Justice Programs, U.S. Department of 
Justice. The opinions, findings, and conclusions or recommendations expressed in this 
publication are those of the author(s) and do not necessarily reflect those of the 




TABLE OF CONTENTS 
Page 
DEDICATION ................................................................................................................... iii 
ABSTRACT ....................................................................................................................... iv 
ACKNOWLEDGEMENTS .............................................................................................. vii 
TABLE OF CONTENTS ................................................................................................. viii 
LIST OF TABLES ............................................................................................................ xii 
LIST OF FIGURES .......................................................................................................... xv 
CHAPTER I:   INTRODUCTION ................................................................................... 1 
Emergence of New Psychoactive Substances .............................................................. 1 
Statement of the Problem ........................................................................................... 39 
References .................................................................................................................. 41 
CHAPTER II:   QUANTITATIVE ANALYSIS OF NOVEL SYNTHETIC 
OPIOIDS, MORPHINE AND BUPRENORPHINE IN ORAL 
FLUID BY LC–MS-MS1 ....................................................................... 62 
Abstract ...................................................................................................................... 63 
Introduction ................................................................................................................ 64 
Materials and Methods .............................................................................................. 66 
Results and Discussion .............................................................................................. 72 
Conclusion ................................................................................................................. 82 
References .................................................................................................................. 83 
 
ix 
CHAPTER III:   ORAL FLUID AND DRUG IMPAIRMENT: PAIRING 
TOXICOLOGY WITH DRUG RECOGNITION EXPERT 
OBSERVATIONS1 ................................................................................ 89 
Abstract ...................................................................................................................... 90 
Introduction ................................................................................................................ 92 
Methods ..................................................................................................................... 94 
Results and Discussion .............................................................................................. 98 
Conclusion ............................................................................................................... 108 
References ................................................................................................................ 109 
CHAPTER IV:   QUANTIFICATION OF SEVEN NOVEL SYNTHETIC OPIOIDS 
IN BLOOD USING LC-MS/MS1 ........................................................ 112 
Abstract .................................................................................................................... 113 
Introduction .............................................................................................................. 115 
Materials and Methods ............................................................................................ 117 
Results and Discussion ............................................................................................ 122 
Conclusions.............................................................................................................. 132 
Compliance with Ethical Standards ......................................................................... 132 
References ................................................................................................................ 133 
CHAPTER V:   LONG-TERM STABILITY OF NOVEL SYNTHETIC OPIOIDS 
IN BLOOD1 ......................................................................................... 137 
Abstract .................................................................................................................... 138 
Introduction .............................................................................................................. 139 




Discussion ................................................................................................................ 148 
Conclusions.............................................................................................................. 149 
Funding .................................................................................................................... 149 
References ................................................................................................................ 150 
CHAPTER VI:   QUANTIFICATION OF U-47700 AND ITS METABOLITES IN 
PLASMA BY LC-MS/MS1 ................................................................. 154 
Abstract .................................................................................................................... 155 
Introduction .............................................................................................................. 157 
Materials and Methods ............................................................................................ 161 
Results and Discussion ............................................................................................ 167 
Conclusions.............................................................................................................. 176 
Acknowledgements .................................................................................................. 177 
References ................................................................................................................ 178 
CHAPTER VII:   PHARMACOKINETICS AND PHARMACODYNAMICS OF U-
47700 AND ITS METABOLITES ...................................................... 183 
Abstract .................................................................................................................... 184 
Introduction .............................................................................................................. 185 
Materials and Methods ............................................................................................ 187 
Results and Discussion ............................................................................................ 190 
Conclusion ............................................................................................................... 200 
References ................................................................................................................ 201 
 
xi 
CHAPTER VIII:   5F-MDMB-PICA METABOLITE IDENTIFICATION AND 
CANNABINOID RECEPTOR ACTIVITY1 ....................................... 206 
Abstract .................................................................................................................... 207 
Introduction .............................................................................................................. 209 
Materials and Methods ............................................................................................ 211 
Results...................................................................................................................... 216 
Discussion ................................................................................................................ 223 
Conclusion ............................................................................................................... 226 
Acknowledgement ................................................................................................... 227 
References ................................................................................................................ 228 
CHAPTER IX:   CONCLUSIONS .................................................................................. 231 
REFERENCES ............................................................................................................... 233 
APPENDIX ..................................................................................................................... 263 
IRB Consent forms .................................................................................................. 276 
VITA ............................................................................................................................... 278 
 
xii 
LIST OF TABLES 
                                                                                                                              Page 
Table 1.1 Analytical methods for U-series drugs ............................................................. 17 
Table 1.2 Postmortem concentrations of U-47700 reported in literature ......................... 22 
Table 1.3 Antemortem concentrations of U-47700 in literature ...................................... 27 
Table 2.1 Optimized liquid chromatography-tandem mass spectrometry parameters 
for morphine, 6-acetylmorphine, U-47700, AH-7921, buprenorphine, U-
49900, U-50488, MT-45, W-18, W-15 and deuterated internal standards. .... 70 
Table 2.2 Linearity, limits of detection (LOD), and lower and upper limits of 
quantification (LLOQ, ULOQ) for morphine, 6-acetylmorphine, U-
47700, AH-7921, buprenorphine, U-49900, U-50488, MT-45, W-18, and 
W-15 in oral fluid............................................................................................ 74 
Table 2.3 Bias and precision data for morphine, 6-acetylmorphine, U-47700, AH-
7921, buprenorphine, U-49900, U-50488, MT-45, W-18, and W-15 in 
oral fluid at three concentrations across the linear range. ............................... 78 
Table 2.4 Mean extraction recovery and matrix effect for morphine, 6-
acetylmorphine, U-47700, AH-7921, buprenorphine, U-49900, U-50488, 
MT-45, W-18, and W-15 in oral fluid. ........................................................... 79 
Table 2.5 Fortified and extracted samples stability (% difference) for morphine, 6-
acetylmorphine, U-47700, AH-7921, buprenorphine, U-49900, U-50488, 
MT-45, W-18, and W-15 in oral fluid under different conditions at two 
concentrations. ................................................................................................ 80 
Table 3.1 Subject demographics ...................................................................................... 94 
 
xiii 
Table 3.2 Analytes included in PCDL categorized by DRE classification (n=64) .......... 96 
Table 3.3 Toxicological findings paired with DRE opinion ............................................ 99 
Table 3.4 Vitals, nystagmus, psychophysical tests, and physical response for 
subjects .......................................................................................................... 105 
Table 4.1 Optimized liquid chromatography-tandem mass spectrometry parameters 
for U-47700, AH-7921, U-49900, U-50488, MT-45, W-18, W-15, and 
internal standards, U-47700-d6, MT-45-d11, and W-18-d4. ........................ 120 
Table 4.2 Common drugs of abuse for interference studies ........................................... 121 
Table 4.3 Limit of detection (LOD), lower limit of quantification (LLOQ), upper 
limit of quantification (ULOQ), and mean y-intercept, slope, and 
coefficient of determination (R2) for U-47700, AH-7921, U-49900, U-
50488, MT-45, W-18, and W-15 .................................................................. 124 
Table 4.4 Bias results at three quality control (QC) concentrations for U-47700, AH-
7921, U-49900, U-50488, MT-45, W-18, and W-15 .................................... 127 
Table 4.5 Imprecision at three QC concentrations for U-47700, AH-7921, U-49900, 
U-50488, MT-45, W-18, and W-15 .............................................................. 127 
Table 4.6 Ionization suppression and enhancement and extraction efficiency results 
for U-47700, AH-7921, U-49900, U-50488, MT-45, W-18, W-15, 
U47700-d6, MT45-d11, and W18-d4 .............................................................. 129 
Table 4.7 Bias results for the stability of U-47700, AH-7921, U-49900, U-50488, 
MT-45, W-18, and W-15 at 24 h room temperature, 72 h 4°C, and 72 h in 
a refrigerated autosampler ............................................................................. 130 
Table 4.8 Concentrations of U-47700 in postmortem blood samples ............................ 130 
 
xiv 
Table 6.1 Optimized mass spectrometry parameters; Q1 –quadrupole 1, Q3 – 
quadrupole 3, CE - collision energy, RT - retention time, ITSD – internal 
standard; quantifying transitions are italicized ............................................. 164 
Table 6.2 Linearity, limit of detection (LOD), limit of quantification (LOQ) and 
linear range for U-47700 and metabolites in human plasma ........................ 169 
Table 6.3 Bias and Precision data for analytes in human plasma at three quality 
control (QC) concentrations over the linear range ........................................ 170 
Table 6.4 Extraction efficiency and matrix effects evaluated at 50 ng/mL in human 
plasma ........................................................................................................... 170 
Table 6.5 Fortified and processed sample stability at two quality control (QC) 
concentrations in human plasma stored in various conditions...................... 171 
Table 6.6 Bias, precision, extraction efficiency and matrix effects for U-47700 and 
metabolites in rat plasma .............................................................................. 173 
Table 6.7 Post mortem blood concentrations for U-47700 and its dealkylated 
metabolites .................................................................................................... 174 
Table 7.1 Pharmacokinetic constants (mean±SEM) for plasma U-47700, N-
desmethyl-U-47700, and N,N-didesmethyl-U-47700 after subcutaneous 
U-47700 administration at 0.3, 1.0, and 3.0 mg/kg to rats (N=5-6 per 
group ............................................................................................................. 192 
Table 8.1 5F-MDMB-PICA metabolite identification in order of retention time .......... 220 
Table 8.2 Effective concentrations for synthetic cannabinoids ...................................... 223 
 
xv 
LIST OF FIGURES 
    Page 
Figure 1.1 Structures of common aminoindanes ............................................................... 2 
Figure 1.2 Structures of two designer benzodiazepines ..................................................... 3 
Figure 1.3 Structures of three designer dissociatives ......................................................... 4 
Figure 1.4 Structure of three common designer psychedelic compounds ......................... 5 
Figure 1.5 Structures of two common designer piperazines .............................................. 6 
Figure 1.6 Structure of mitragynine ................................................................................... 7 
Figure 1.7 Structures of synthetic cathinones .................................................................... 9 
Figure 1.8 Structures of two synthetic cannabinoids ....................................................... 10 
Figure 1.9 Structures of compounds from the U-series ................................................... 13 
Figure1.10 Predicted metabolic pathway for U-47700 by Krotulski et al ....................... 31 
Figure 1.11. Structure of MT-45 ...................................................................................... 34 
Figure 1.12 Structures of three compounds in the W-series ............................................ 38 
Figure 2.1 Extracted ion chromatogram of morphine (A), 6-acetylmorphine (B), U-
47700 (C), AH-7921 (D), buprenorphine (E), U-49900 (F), U-50488 (G), 
MT-45 (H), W-18 (I), and W-15 (J) at 10 ng/mL; *Shared transitions of 
structural isomer AH-7921 ............................................................................. 76 
Figure 3.1 Positive identifications of analytes for urine (n=18) and oral fluid (n=20). . 102 
Figure 4.1 Structures of seven synthetic opioids dealt with in this study ...................... 116 
Figure 4.2 Multiple reaction monitoring chromatograms for quantifying transitions 
for a U-47700, b AH-7921, c U-49900, d U-50488, e MT-45, f W-18, 
 
xvi 
and g W-15 at their LLOQs (0.25 ng/mL for U-47700, AH-7921, U-
49900, U-50488, MT-45, and W-15 and 1 ng/mL for W-18) ....................... 126 
Figure 5.1 Structures of seven novel synthetic opioids ................................................. 140 
Figure 5.2 Frozen blood stability of U-47700, U-49900, AH-7921, U-50488, MT-
45, W-18, and W-15 at a) 0.75 ng/mL (2.5 ng/mL for W-18) (LQC) and 
b) 80 ng/mL (HQC) ...................................................................................... 144 
Figure 5.3 Refrigerated blood stability of U-47700, U-49900, AH-7921, U-50488, 
MT-45, W-18, and W-15 at a) 0.75 ng/mL (2.5 ng/mL for W-18) (LQC) 
and b) 80 ng/mL (HQC) ................................................................................ 145 
Figure 5.4 Room temperature blood stability of U-47700, U-49900, AH-7921, U-
50488, MT-45, W-18, and W-15 at a) 0.75 ng/mL (2.5 ng/mL for W-18) 
(LQC) and b) 80 ng/mL (HQC) .................................................................... 146 
Figure 5.5 Room temperature stability of U-47700, U-49900, AH-7921, U-50488, 
MT-45, W-18, and W-15 at a) 0.75 ng/mL (2.5 ng/mL for W-18) (LQC) 
and b) 80 ng/mL (HQC) ................................................................................ 147 
Figure 6.1 Structure of U-47700 (top), N-desmethyl-U-47700 (bottom, left) and 
N,N-didesmethyl-U-47700 (bottom, right). Metabolic pathways follow N-
demethylation ................................................................................................ 159 
Figure 6.2 Comparison of ddm-U-47700 eluted with acetonitrile (left) and methanol 
(right) to separate interferant (*) ................................................................... 167 
Figure 7.1. Concentration-time profiles for U-47700, N-desmethyl-U-47700, and 
N,N-didesmethyl-U-47700 after sc injection of U-47700. Data are mean ± 
SEM for n=5-6 rats per group. ...................................................................... 191 
 
xvii 
Figure 7.2 Comparison of expected vs observed AUC for U-47700, N-desmethyl-U-
47700, and N,N-didesmethyl-U-47700 after subcutaneous U-47700 
injection at 0.3, 1.0, and 3.0 mg/kg to rats (N=5-6 per group). Data are 
mean ± SEM. ................................................................................................ 195 
Figure 7.3 Pharmacodynamic data for rats receiving saline or subcutaneous U-47700 
injection of 0.3, 1.0, and 3.0 mg/kg (N=5-6 per group).   Data are mean ± 
SEM. ............................................................................................................. 198 
Figure 7.4 Relationship between values from catalepsy and hot plate latency studies 
(mean, n=5-6) and mean plasma U-47700 concentrations in rats after sc 
U-47700 injection at 0.3, 1.0, and 3.0 mg/kg doses. Arrows represent 
hysteresis curve progression over time for 480 min. .................................... 199 
Figure 8.1 Extracted Ion Chromatograms (EIC) of hepatocyte incubations and urine 
samples yielding the most metabolites: 1a) first hour incubation of 5F-
MDMB-PICA with hepatocytes, 1b) metabolites found in antemortem 
case 4 urine, 2a) first hour incubation of 5F-MDMB-PINACA with 
hepatocytes, 2b) metabolites identified in case 3 urine ................................ 217 
Figure 8.2 Proposed metabolic pathway for 5F-MDMB-PICA ..................................... 219 
Figure 8.3 Receptor curves normalized to digitonin for JWH-018, 5F-MDMB-PICA, 







The United States has been plagued by the abuse of illicit drugs for decades. 
According to the National Institute on Drug Abuse (NIDA), in 2013, 9.4 percent of the 
American population had used an illicit drug in the past month (1). Just as illicit drugs are 
abused, prescription drugs can also be habit forming and misused. Drug abuse can 
sometimes stem from addiction developed from inappropriate prescription drug use. 
Opioids are one of the drug classes that are commonly misused due to their pain relieving 
effects. Traditional opioids possess analgesic effects by binding to the µ, δ, and/or κ 
opioid receptor.  The abuse of these addictive drugs can be partially attributed to 
practitioners over prescribing. According to the Food and Drug Administration (FDA), 
between 2014 and 2016 over 23 billion dollars were spent on analgesic opioid products 
(2). To combat this issue, a majority of the state governments in the United States have 
implemented legislation to produce prescription-drug monitoring programs (3). Although 
strategies have been formed to mitigate this crisis, drug-seeking individuals have found 
alternatives to fuel their addiction.  
Emergence of New Psychoactive Substances  
New psychoactive substances (NPS) are compounds similar to common drugs of 
abuse with slight modifications to their chemical structure. These modifications can be 
dangerous and sometimes fatal due the lack of knowledge and/or studies of the adverse 
effects. NPS are sometimes marketed as “legal highs” or “research chemicals” in order to 
mimic effects of illicit drugs while simultaneously bypassing legislation. In the United 
States alone, there were over 300 NPS reported to the United Nation Office on Drugs and 
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Crime (UNODC) by 2018 (4).  NPS include drugs from the following categories: 
aminoindanes, designer benzodiazepines, dissociatives, psychedelic compounds, 
piperazines, plant-based substances, synthetic cathinones, synthetic cannabinoids, and 
novel synthetic opioids (5-7).   
Aminoindanes 
These compounds were studied in 1973 by Solomons and Sam in which they 
discovered the analgesic properties these compounds possessed (8). Nichols et al. studied 
the structure of MDMA (3,4-methylenedioxy-N-methylamphetamine) and synthesized 
MDAI (5,6-methylenedioxy-2-aminoindane) in the 1990s, which was one of the first 
aminoindanes (9).  Other aminoindanes followed such as 2-AI (2-aminoindane), 5-IAI (5-
iodo-2-aminoindane),  MDMAI (5,6-methylenedioxy-N-methyl-2-aminoindane), MEAI 
(5-methoxy-2-aminoindane), and MMAI (5-methoxy-6-methyl-2-aminoindane) (10). 
Structures of some of these compounds are shown in Figure 1.1  
 
Figure 1.1 Structures of common aminoindanes 
 
These compounds have similar adverse effects as stimulants such as 
hyperhidrosis, dehydration, hyperthermia, and bruxism (11). MDAI has been involved in 
fatal cases with concentrations in blood ranging from ~120 to 26,300 ng/mL (11,12). The 
case involving the highest concentration (26,300 ng/mL), the cause of death was 
determined to be toxicity of self-ingested MDAI (11). Other compounds such as 5-IAI 












Designer Benzodiazepines  
In 2016, the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) reported that more than half a million tablets were seized that contained 
designer benzodiazepines such as etizolam, fonazepam, diclazepam, flubromazolam, and 




Some of these compounds have higher binding affinity to γ-aminobutyric acid 
(GABA)A receptors than traditional benzodiazepines, which can be dangerous if 
consumed with other central nervous system (CNS) depressants (15).  A prominent 
designer benzodiazepine, etizolam, had 898 drug reports to National Forensic Laboratory 
Information System (NFLIS) in 2018 (16). Fatalities and acute intoxications involving 
designer benzodiazepines have been reported. Etizolam has been identified in fatalities 
with blood concentrations ranging from 25.8 ng/mL to 300 ng/mL (17-19). In a study by 
Høiseth et al, samples from drivers and individuals suspected to be impaired were 
analyzed for designer benzodiazepines (20). Blood concentrations for etizolam ranged 
Figure 1.2 Structures of two designer benzodiazepines 
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from 19.0-170 ng/mL (n=14). The study also concluded that tetrahydrocannabinol (THC) 
and amphetamine were often found in combination with designer benzodiazepines (20).   
Dissociatives  
Phencyclidine (PCP) and ketamine analogs are examples under the drug category 
of dissociatives. Adverse effects include confusion, delirium, and dysphoria (21).  
Analogs such as 3- and 4- methoxy PCP and methoxetamines were found to have higher 
binding affinity to the glutamate N-methyl-D-aspartate (NMDA) receptor. Structures for 




 The NMDA receptor is pharmacologically key for both PCP and ketamine 
(22,23). In Bäckberg et al, non-fatal intoxications (n=7) were reported as single substance 
intoxications involving 3-methoxy PCP (24). From these cases, hypertension was 
observed in every subject and most displayed other symptoms such as tachycardia, 
confusion, and hallucinations. These symptoms were also seen in other studies (25). Fatal 
intoxications described in Johansson et al, ranged from 0.05-0.38 µg/g in blood. An 
intoxication case from the same study detected 0.14 µg/g 3-methoxy PCP in blood (25). 
Methoxetamine, a ketamine analog, has been reported to have similar adverse 
(cardiovascular symptoms) and toxic effects to PCP analogs (26,27). Similar to PCP 
analogs, methoxetamine has also been found in fatalities and intoxications (26,28).  
Figure 1.3 Structures of three designer dissociatives 
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Psychedelic Compounds    
NPS compounds that have emerged that possess psychedelic properties include 
synthetic phenethylamines and tryptamines. Users seek these compounds for 
hallucinogenic effects, but are unaware of the potential toxic effect that accompanies that 
desired experience. Structures of common designer psychedelic compounds are shown in 
Figure 1.4 below. 
  1-(8-bromofuro[2,3-f][1]benzofuran-4-yl)-2-propanamine (Bromo-DragonFly) 
is a synthetic phenethylamine that was involved in a mass intoxication (n=29) at an 
esoteric weekend seminar (29). Some subjects displayed agitated reactions and had to 
be sedated in route to the hospital, while others had life-threatening reactions such as 
seizures. The blood concentrations ranged from 0.6-2.0 ng/mL (29). Bromo-DragonFly 
is a strong agonist to the serotonin receptor 5-HT2A, which is the receptor that 
traditional psychedelic drugs such as lysergic acid diethylamide (LSD) interact with to 
produce psychedelic effects (30). Other intoxications and a fatality have also been 
associated with Bromo-DragonFly (31,32). Similar to Bromo-DragonFly, 5-methoxy-N, 
N-dipropyltryptamine (5-MeO-DPT) and 5-methoxy-N, N-dimethyltryptamine (5-MeO-


















DMT) produce psychedelic effects due to their interactions with 5-HT receptors (33). 
Adverse effects for some of these tryptamine analogs include restlessness, muscle 
tension, and insomnia (34). In Sklerov et al, an autopsy case of a 25 year old male 
found concentrations of 5-MeO-DMT ranging from 0.15-201.6 ng/mL in postmortem 
matrices (blood, stomach contents, bile, urine). Concentrations in the urine and 
peripheral blood were 9.59 and 1.20 ng/mL, respectively. The cause of death was ruled 
as hallucinogenic amine intoxication (35). As of 2011, 5-MeO-DMT, is a Schedule I 
controlled substance (36). 
Piperazines  
 In the early 2000s, designer piperazines arose on the internet and in night clubs, 
including N-benzyl-piperazine (BZP) and 1-(3-trifluoromethylphenyl)piperazines 
(TFMPP) (37). Both act as agonists on 5-HT1 receptor as their mechanism of action 
(38,39).  These drugs became popular due to their CNS stimulant-like (dilated pupils, 
increased heart rate and blood pressure) effects (40,41). Structures of common designer 





 In a study by Schechter et al, drug-seeking rats (trained to discriminate MDMA) 
chose TFMPP over MDMA when given the choice, which suggests that the drug 
possessed similar desired effects (42). It is not uncommon that designer piperazines are 








Figure 1.5 Structures of two common designer piperazines 
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(43). Fatalities and nonfatal intoxications involving either of these designer piperazines 
are present in literature (44,45). As of 2003, both BZP and TFMPP are classified as 
Schedule I controlled substances in the Controlled Substance Act in the United States 
(46) 
Plant-Based Substances  
Although most NPS are synthetic derivatives of existing drugs of abuse, there are 
plant-based substances that fall under the category of NPS as well.  Amidst the current 
opioid epidemic that plagues the United States, opioid users have turned to Kratom as a 
“legal” way to get their fix (47).  Kratom is derived from Mitragyna speciosa Korth, 
which is comprised of many alkaloids with mitragynine being the most abundant alkaloid 
(48). The structure of mitragynine is show below in Figure 1.6. 
 
 In Matsumoto et al, it was concluded that mitragynine might inhibit stimulation 
of 5-HT2A receptors and/or bind to post-synaptic alpha-2 adrenergic receptors (49). 
Compared to morphine, mitragynine’s antinociceptive effect is 13 times more potent 
(50,51). Trakulsrichai et al, performed a human study to investigate the pharmacokinetics 









Figure 1.6 Structure of mitragynine 
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given an exact dose of Kratom tea for 7 days and on the 8th days various amounts of 
Kratom tea were given and samples were collected at different times intervals. It was 
concluded that the pharmacokinetics of mitragynine are linear and follow a two 
component model (52). According to NFLIS, mitragynine was first reported to their 
system in 2010. From its initial report until 2014, there were 488 reports of mitragynine 
to their alert system (53). Since then, several fatalities involving accidental poisonings 
have occurred (54-57). Other substances such as O-desmethyltramadol, quetiapine, or 
propylhexedrine, have been found in fatalities in postmortem specimens (58-60). 
Intoxications involving mitragynine (including suspected driving under the influence of 
drugs (DUID)) have also been reported and in some cases naloxone has been used to 
reverse the effects of mitragynine (61-63). Buprenorphine accompanied with naloxone 
has been found to help Kratom users transition from their dependence of the drug (64). 
Synthetic Cathinones  
Synthetic cathinones emerged in the early 2000’s and were sold via the internet or 
local smoke shops as “Bath Salts” (65). These compounds are often abused due to their 
euphoric effects by users looking for a drug similar to MDMA. Adverse effects include, 
but not limited to, hypertension, paranoia, agitation, and delusions (66,67). According to 
EMCDDA, there have been 130 total synthetic cathinones identified as of 2018 (14). This 
is the second largest substance group that the EMCDDA monitors (synthetic 
cannabinoids being the first) (14). Some of the first synthetic cathinones that emerged 
include mephedrone, methylone, and methylenedioxypyrovalerone (MDPV). Structures 
of these compounds are shown in Figure 1.7.  
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One of the first fatalities associated with MDPV involved a 40 year old man who had 
injected and snorted “bath salts”. After consuming the “bath salts”, the man ran outside 
and was aggressive and delusional. He was shocked with an electronic device three times 
by police in order to detain him. At the hospital, the decedent went into cardiac arrest and 
died from complications afterwards (68). MPDV toxicity and excited delirium syndrome 
played a role in the decedent’s death. A similar case involving mephedrone intoxication 
was reported for a 36 year old man in the Netherlands (69). The decedent also displayed 
major signs of aggression (breaking windows) prior to his death. Mephedrone was 
detected in the femoral blood (5.1 ng/mL) of the decedent, along with cocaine and 
MDMA. Lusthof et al concluded that the fatal intake of mephedrone likely led to the 
excited delirium. The decedent also suffered blood loss from wounds associated with 
breaking the windows in his agitated state (69). Both MDPV and mephedrone were 
placed as Schedule I controlled substances in 2011 (70). 
Synthetic Cannabinoids 
Out of the other categories of NPS, synthetic cannabinoids appear to have the 
largest number of derivatives. As of 2017, there have been 179 synthetic cannabinoids 
reported to the EMCDDA. In 2017, 60% of drug-related deaths in Turkey had synthetic 
cannabinoids present (71). According to the 2018 NFLIS midyear report, there were 
Figure 1.7 Structures of synthetic cathinones 
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10,598 synthetic cannabinoid occurrences reported to them by June 2018. The most 
prominent of the synthetic cannabinoids was 5F-MDMB-PINACA or 5F-ADB 
accounting for 38% of the total synthetic cannabinoids identified (72).  
5F-MDMB-PINACA is an indazole synthetic cannabinoid with a tert-leucinate 
group that has gained popularity in recreational use (73). In 2017, it was controlled as a 
Schedule I substance under the Controlled Substance Act in the United States (74). 
Banister et al examined cannabinoid receptor activity of several closely related synthetic 
cannabinoids and found that 5F-MDMB-PINACA was a CB1 receptor full agonist with 
greater potency than the other compounds in the study (73). The fluorine substitution on 
the pentyl chain may increase binding affinity to the CB1 receptor, possibly accounting 
for this increased potency (75). As a CB1 receptor agonist, 5F-MDMB-PINACA should 
produce similar effects as THC. Adverse effects could also occur and have a greater 
chance of being severe due to the full agonist properties and its otherwise unknown 















Figure 1.8 Structures of two synthetic cannabinoids 
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One of the first identifications of 5F-MDMB-PINACA was by Hasegawa et al. 
Specimens (body fluids and tissues) from a postmortem case and herbal blend packages 
were analyzed. The highest concentration of 5F-MDMB-PINACA was found in the 
stomach contents, while other fluids were below the detection limit, which might indicate 
a rapid death before distribution to blood. The levels of 5F-MDMB-PINACA found in 
the packages ranged from 0.00077-49.2 mg/g (77).  
Fatalities and intoxications involving 5F-MDMB-PINACA have risen since this 
first identification (77-81). However, parent structures of synthetic cannabinoids are often 
difficult to detect in biological matrices, so metabolism studies are needed to improve 
detection of newly emerging synthetics.  Barceló et al identified two phase I metabolites 
from five urine samples of 5F-MDMB-PINACA intoxications: products of ester 
hydrolysis and oxidative defluorination, respectively (78). In another study, Kusano et al 
was able to identify two additional phase I metabolites in a postmortem urine sample, 
ester hydrolysis in combination with oxidative defluorination and ester hydrolysis in 
combination with oxidative defluorination to pentanoic acid, while confirming the ester 
hydrolysis product (79). Both of these studies used structural elucidation of potential 
metabolites in authentic urine specimens. Human liver microsomes were utilized to 
identify possible metabolites of 5F-MDMB-PINACA by Yeter et al (82). From this 
study, 20 metabolites were identified with a recommendation of ester hydrolysis, ester 
hydrolysis in combination with oxidative defluorination to pentanoic acid, and 
hydroxylation on the aliphatic chain as suitable urine markers. Limited studies have 
confirmed metabolites with enzyme incubation using reference standards, but no studies 
have confirmed the formation of potential metabolites by human hepatocytes.  
12 
 
Although 5F-MDMB-PINACA has been present in fatalities and intoxications, 
according to the Center of Forensic Science Research and Education (CFSRE) there were 
no identifications of this synthetic compound in the second quarter of 2019 (83). This 
trend report also noted that 5F-MDMB-PICA had 64 positive samples during the second 
quarter. 5F-MDMB-PICA is structurally similar to 5F-MDMB-PINACA with the 
indazole replaced with an indole. Studies involving 5F-MDMB-PICA are limited. The 
first identification of 5F-MDMB-PICA was by Risseeuw et al from packages labelled as 
herbal incense (84). There has been one metabolism study performed by Mogler et al, 
using pooled human liver microsomes (HLM) (85). There were 12 potential phase I 
metabolites identified using the HLM and urine specimens (n=24). Of the 12 identified, 
ester hydrolysis was the most prominent metabolite detected (85). Receptor studies have 
also been reported for 5F-MDMB-PICA, indicating high potency at the CB1 receptor 
(73,86). 
Synthetic Opioids  
The current phase of the opioid epidemic in the United States is driven by 
synthetic opioids. Synthetic opioids can be divided into two groups, fentanyl derivatives 
and non-fentanyl derivatives. The fentanyl derivatives are highly potent, which makes 
small amounts of the substances dangerous. In the past ten years, the EMCDDA has 
reported 34 fentanyl derivatives (71). Cyclopropylfentanyl and methoxyacetylfentanyl 
were investigated in 2018 in a risk assessment and it was determined that these 
compounds were associated with over 90 deaths and present in over 180 seizures by law 
enforcement (71).  In 2017, there were 1,300 seizures of synthetic opioids reported to the 
European Union (EU) Early Warning System. Although fentanyl derivatives made up the 
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majority of these seizures, non-fentanyl derivatives such as U-47700 were also present 
(71). 
U-Series 
The Upjohn Company originally developed a series of drugs in the 1970’s with 
the intent of being used as possible analgesics.  The first prominent U-series drug that 
was abused was U-47700. Structures of some of the prominent compounds in the U-
series are shown below in Figure 1.9. 
 
 A structural isomer of U-47700, AH-7921, was also developed in the 1970’s as a 
potential analgesic by Allen and Hanbury (87). Other U-series drugs that have appeared 
on the illicit drug market are U-49900, U-50488, U-48800, and U-47921 E. 
Prevalence   
The first reported seizure of U-47700 was in October 2015 in the United States, 
while U-47700 emerged on the EMCDDA EWS in June 2016 (88,89). Once the threat of 
this substance was identified, it was placed into Schedule I of the Controlled Substances 
Figure 1.9 Structures of compounds from the U-series 
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Act in November 2016 (89). Between 2016 and 2017, over 80% of the states in the US 
had at least one seizure report of U-47700 (90). Ohio had the largest reporting (n=943) in 
2017 in the United States. AH-7921 was placed under control by the EU in September 
2014 (91). Similar to U-47700, AH-7921 was placed into Schedule I of the Controlled 
Substances Act in 2016 (92). It was first reported to NFLIS in 2013 and between 2009 
and 2014, had 2 reports to NFLIS (53). To combat the challenges of legislation, other U-
series drugs have appeared. According to the National Drug Early Warning System 
(NDEWS) synthetic opioids U-48800, U-49900, and U-50488 have appeared on the 
cryptomarket. These drugs are advertised to produce similar effects to U-47700 and other 
U-series drugs (93). Between 2018 and 2019, there were 19 cases where U-48800 was 
detected in a biological sample submitted to National Medical Services (NMS) (94). To 
date, there has only been one case were U-49900 was detected (95). The diethyl analog of 
U-47700 (U-49900) has not been scheduled in the United States. There has also been a 
report of substance found at a scene of an overdose that screened positive for U-49900, 
U-48800, and U-7931 E (96). 
Pharmacology  
The U-series drugs produce effects by binding to opioid receptors (µ, κ, or δ). U-
47700 and U-48800 were found to be selective µ- opioid agonists (97). The µ receptor 
has been shown to be responsible for the analgesic effects morphine possesses, but also is 
responsible for the adverse effects of respiratory depression, dependence, and addiction 
associated with opioids (98). When compared to morphine, U-47700 and U-48800 are 
approximately 7.5 as potent (97). There have been no pharmacological studies performed 
involving U-47700 or other U-series drugs. Due to the receptor binding, it is 
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hypothesized that U-47700 and U-48800 are abused due to potential analgesic and 
euphoric effects. U-50488 and U-48800 are selective κ-opioid receptor ligands (99,100).  
AH-7921 is an agonist to both µ and κ opioid receptors, with equipotency to morphine 
found in rat studies (101,102).  One study calculated the estimated half-life for U-47700 
using blood serums at different time points of a patient on mechanical ventilation. It was 
approximated that the half-life of U-47700 is 6 hours (103). On international drugs 
forums, AH-7921 is said to produce mild sedatives effects, as well as vomiting, nausea, 
urine retention, reduced/ slow motor skill, and slight respiratory depression (104).   
Analytical Methods 
With the emergence of the U-series, various analytical methods have been 
developed to identify these compounds. In Table 1.1, methods are shown for detecting 
and/or quantifying compounds from the U-series.  Of the 14 methods shown, most (n=10) 
use liquid chromatography (LC) for their separation of analytes. Although gas 
chromatography (GC) is commonly used in crime laboratories, compounds could be 
subjected to thermal degradation. The use of LC coupled with mass spectrometry (MS) 
offers improved sensitivity compared to GC/MS. Shoff et al highlights the differences 
between a previously used GC/MS method compared to the newly prepared LC-MS/MS 
method (105). There were 134 cases of carfentanil identified using the new LC method 
with 104 of those identifications were missed using the previous GC/MS method (105). 
Since little is known about NPS, eliminating the possibility of thermal degradation during 
analysis is key to properly identifying these compounds.  
The methods described in Table 1.1 utilize a wide variety of extraction 
techniques, including solid phase extraction (SPE), liquid-liquid extraction (LLE), and 
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protein precipitation.  LLE is commonly used in forensic toxicology laboratories and 
long-standing analytical techniques and offers a cost-effective approach to sample 
preparation. Although SPE is more expensive, the benefit of eliminating some 
interferences from the matrix could prove advantageous, particularly for LC-MS 
techniques. As the pKa of NPS are generally unknown, SPE is better equipped to isolate 




Table 1.1 Analytical methods for U-series drugs  
Matrix Analytes Internal 
Standard 

















AH-7921-d3 SPE LC-MS/MS 1-100 
30-500 
0.5 - (107) 






















BL U-47700 Fentanyl-d5 LLE LC-MS/MS 1.6-63.5 1.6 1.6 (110) 
BL U-47700 Not Specified LLE HPLC-DAD 312.5-
5000 
50 312.5 (111) 








Matrix Analytes Internal 
Standard 






















































SPE LC-HRMS 25-3000 5 25 (116) 




Matrix Analytes Internal 
Standard 












U-47700 Not Specified LLE LC-HRMS N/A 1 N/A (118) 
U U-47700 Norporopoxy
phene-d5 
SPE LC-MS/MS 1-1250 1 1 (119) 
LOD=Limit of Detection, LOQ=Limit of quantitation, LLE= Liquid-Liquid Extraction, SPE= Solid Phase Extraction, 
PP=Protein Precipitation, LC=Liquid Chromatography, GC=Gas Chromatography, MS=Mass Spectrometry, HR= High Resolution, 
HP= High Performance, DAD=Diode Array Detector, NPD=Nitrogen-Phosphorous Detector, BL=Blood, LV=Liver, U=Urine, 
SC=Stomach Contents, BF=Bile Fluid, BR=Brain, KD=kidney, VF=Vitreous Fluid, H=Hair, OF=Oral Fluid, LOD and LOQ are in 




The methods described in Table 1.1 analyzed U-series compounds in traditional 
specimens for forensic toxicology, including blood and urine. Some of the methods used 
for postmortem casework also incorporated tissues (liver, kidney, brain). Using tissues 
may allow for estimations of postmortem redistribution (PMR), which is frequently 
unknown for NPS. There is only one method that uses oral fluid as a matrix of interest. 
Griswold et al was able to qualitatively identify synthetic opioids in both urine and oral 
fluid (118). When comparing the matrices, it was concluded that oral fluid was 
comparable to urine to the detection of synthetic opioids. Oral fluid is an appealing 
alternative matrix that possesses many advantages over blood and urine such as ease of 
use, no need for a trained professional to collect, and less likely to be subjected to 
adulteration. Oral fluid may also be ideal for testing individuals who are suspected for 
DUID as drug presence may be indicative of recent use and more likely to correlate with 
impairment. Alabama was the first to implement a state-wide program for incorporating 
oral fluid into routine DUI/D casework. 
Cases  
Of the compounds associated with the U-series, U-47700 is responsible for the 
most intoxications and fatalities reported in literature. There are minimal reports of other 
U-series compounds. Studies involving postmortem analysis are shown in Table 1.2 
below.  Most cases also involve fentanyl derivatives such as furanylfentanyl and other 
illicit drugs (cocaine, methamphetamine, etc.) in addition to U-series compounds. In 
Garneau et al, one case was shown that had multiple fentanyl derivatives present. There 
was a total of six fentanyl derivatives (acetylfentanyl, despropionylfluorofentanyl, 
isobutyrylfentanyl, p-fluorofentanyl, valerylfentanyl, and furanylfentanyl) were present in 
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biological samples. In addition, U-47921 E was present in the urine of the decedent. 
Powders found at the scene were screened and came back positive for U-47700, U-




Table 1.2 Postmortem concentrations of U-47700 reported in literature  




Matrix Other Illicit Drugs 
Present 
Notes Reference 





(10.9 ng/mL BL) 
Evidence of inhaling a white powder  (110) 
1 26 Male 340  
190   
170 







None Found dead in bedroom, lethal 
intoxication with U-47700 as only 
drug present  
(114) 
16 18-40 Male 17-490   BL Certain cases had 
fentanyl derivatives also 
present 
Five cases had both furanyl fentanyl 
and U-47700 present, one case had 






525-1347   
1393-1848  










Methoxyphenidine Both decedents were found dead in 
their beds  
(120) 
1 27 Male 146  BL Ketamine and cannabis Illicit drug user found dead at home  (111) 
2 18,28 Male 547, 189  BL Etizolam 
Oxycodone 
(67 ng/mL) 
Both decedents were found dead at 
home. There was drug paraphernalia 
present such as plastic bags labelled 









Matrix Other Illicit Drugs 
Present 
Notes Reference 
1 19 Male 3040  




(41.7 ng/mL BL, 
62.8 ng/mL U) 
Decedent was found at home with 
tablets of paroxetine present. 
Paraoxetine was present  (170 
ng/mL), but within a therapeutic 
range   
(116) 
1 34 Male 360  PBL 3-Fluorophenmetrazine 
(2400 ng/mL FBL) 
Found at home, unresponsive and 
slumped over 
(112) 
1 28 Male 330 BL Flubromazepam 
(10 ng/mL) 
Diclazepam (70 ng/mL) 
Decedent had a history of illicit drug 




Male 380  BL None History of drug addiction, found 
supine at apartment 
(117) 
1 24 Male 370 SR Flubromazepam 
(830 ng/mL) 
Found suffering from apnea, 
decedent was reanimated and 
hospitalized. 6 days later, mechanical 









Matrix Other Illicit Drugs 
Present 
Notes Reference 
1 51 Male 290   
1250  














None Found on hotel bathroom floor next 
to the toilet, spoon and syringe were 
present 
(123) 








(339 ng/mL BL, 
>5000 ng/mL U) 
Methoxy-PCP 
(1.0 ng/mL BL, 
31.8 ng/mL U)  
There was white powder found at the 
scene, testing confirmed it was U-
49900 
(95,124) 






Furanyl fentanyl was 
present in all three cases. 
The case of 29 year old 
male also had acetyl 
fentanyl, despropionyl 
fluorofentanyl, 
All three cases involved persons who 
had previous history of drug abuse or 
alcoholism. The case of 29 year old 
male was found with syringe in hand 
and empty bottles of steroids were 
present 
(96) 













Matrix Other Illicit Drugs 
Present 
Notes Reference 









47931 E. Additionally 
substances found 
screened positive for U-
49900 and U-48800 
2 63 Male 24  BL Cycloproyl fentanyl 
(31.5 ng/mL BL) 
Cocaine 
(25 ng/mL BL) 
Benzoylecognine 
(58 ng/mL BL )  
Decedent had a history of drug and 
was found dead at home  
(125) 
57 Male 7.8  BL Cyclopropyl fentanyl 
(18.5 ng/mL BL) 
Cocaine 
(130 ng/mL BL) 
Benzoylecognine 
(910 ng/mL BL) 
Fentanyl 
(6.2 ng/mL BL) 
Norfentanyl 
(5.5 ng/mL BL) 
Found unresponsive in vehicle and 
was transported to hospital, was 
pronounced dead on arrival 
PBL=Peripheral Blood, CBL=Central Blood, CSF=Cerebrospinal Fluid, SR=Serum, BL=Blood, LV=Liver, LG=Lung 
U=Urine, SC=Stomach Contents, BF=Bile Fluid, BR=Brain, KD=kidney, VF=Vitreous Fluid, H=Hair 
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The concentrations for U-47700 in postmortem casework reported ranged from 7-
3040 ng/mL in blood, with a majority of the cases having concentrations <500 ng/mL. 
Richeval et al presented a case with the highest concentration of U-47700 detected in 
peripheral blood. The authors hypothesized reasons behind an unusually high 
concentration of U-47700 present. Paroxetine tablets were present at the scene and in 
biological specimens, therefore it was thought perhaps a paroxetine/U-47700 interaction 
may have occurred that would inhibit metabolism of U-47700 and increase 
concentrations. Another suggestion was that a high amount of U-47700 was administered 
prior to death.  
While less commonly reported, non-fatal intoxications occurring with U-series 
compounds are also present in literature. Antemortem cases of U-series intoxications are 
shown in Table 1.3 below. Most concentrations are below 100 ng/mL, with only three 
cases where the concentrations were above 200 ng/mL. These cases are within 
concentrations that were found in postmortem cases. Without proper knowledge of the 
pharmacology of these compounds, the “therapeutic” window for these compounds is 
unknown. One case worth noting was reported by Vogliardi et al (131). This study 
involves a man in his thirties that was found unresponsive and was comatose upon 
admission to the hospital. Blood was drawn from this subject shortly after admission with 
94 ng/mL U-47700 present. The next day, another sample of blood was drawn which had 
a concentration of 5.2 ng/mL of U-47700. Pubic hair was also analyzed in this case and 
showed that the subject was a frequent drug user as common drugs of abuse (cocaine, 




Table 1.3 Antemortem concentrations of U-47700 in literature 




Other illicit Drugs 
Present Notes Reference 
2 26, 24 Male Female 
0.1  (U) 
Not tested (U) 
None  Both were together when using substances 
and were taken to hospital, Male presented 
symptoms of opioid toxidrome, Female 
presented uncontrollable anxiety   
(126) 
1 40 Female 7.6 (SR) 
Fentanyl (15.2 ng/mL 
in serum) 
After ingesting 3 tablets thought to be 
"Norco", subject was hospitalized and had 
symptoms of opioid use such as pinpoint 
pupils and respiratory depression  
(127) 
1 22 Male Positive (U) None  
User had a history of heroin abuse and was 
found unconscious by mother  (128) 
1 23 Female 394 (SR) 228 (U) None  
Subject was cyanotic with respiratory 
depression in ambulance (129) 
1 29 Male 240 (SR) 
Phenazepam 
(1400 ng/mL in 
serum) 
Found unresponsive and regained 
consciousness before getting to the hospital  (130) 
1 30s Male 
94 BL after intake 
5.2 BL a day after 
3.02 ng/mg (H) 








Found unresponsive and in a comatose 










Other illicit Drugs 
Present Notes Reference 
1 26 Male 351 (BL) 
THC 
(3.3 ng/mL in blood) 
Clonazepam  
(6.8 ng/mL in blood)  
Also positive for 
citalopram and 
midazolam  
Found unconscious at home with white 
powder residue in plastic bags, was taken 
to hospital and put on ventilation, subject 







 There are minimal studies addressing the stability of these U-series compounds. 
Unknown stability of a compound can be detrimental to analysis if samples are 
mishandled during transport and/or improperly stored. Most stability information about 
the U-series compounds was acquired during assessing method validation. The stability 
of U-47700 and U-50488 in blood was evaluated when performing a fit-for-purpose 
validation by Mohr et al (107) . The two conditions that were evaluated were refrigerated 
and frozen over 10 days. Of the two concentrations tested (5 and 80 ng/mL), both were 
stable at the two temperature conditions over the 10 days assessed. In Qin et al, U-47700, 
N-desmethyl-U-47700, U-50488, and U-48800 were evaluated in whole blood during 
validation with other fentanyl derivatives (108). The temperature conditions that were 
evaluated were 24 hr at 4 °C and room temperature, three freeze/thaw cycles, and 1 
month in the freezer at three concentrations (0.2, 5, and 30 ng/mL). All analytes were 
found to be stable at all temperature conditions and concentrations. At 25 ng/mL, U-
47700 and its metabolites were evaluated at three temperatures (-30 °C, 3 °C and 20 °C) 
in blood for three weeks by Rojek et al (109). It was determined that U-47700 was stable 
at all temperatures. In Soh and Elliot et al, AH-7921 was found to be stable at room 
temperature in blood and plasma for 28 days at a very high concentration of 2000 ng/mL 
(133). These studies were able to successfully determine stability for some compounds of 
the U-series, but most were short-term stability assessments. There is no available 




Metabolism studies are key for identifying any NPS that emerges. They provide 
information of what potential biomarkers could be used to confirm use of a substance 
when the parent compound is no longer able to be detected. Metabolism for U-47700 was 
predicted in two studies by analyzing authentic specimens. It was suspected that 
demethylation occurs at the tertiary amine group and is followed hydroxylation on the 
cyclohexane ring (111,129). The first metabolic study of U-47700, which also included 
U-49900, was performed by Krotulski et al. Metabolites for U-47700 and U-49900 were 
first generated in vitro using human liver microsomes (HLM), then verified in vivo using 
authentic urine samples. The predicted metabolic pathway for U-47700 is shown in 










































The prominent metabolite for U-47700 was identified as N-desmethyl-U-47700. 
U-49900 follows a similar metabolic pathway in which N-dealkylation occurs at the 
tertiary amine followed by hydroxylation on the cyclohexane ring or additional 
dealkylation or demethylation at the amide bridge (124). The prominent metabolite for U-
49900 was identified was N-deethyl-U-47700. Richeval et al, also performed a metabolic 
study on U-47700 using HLMs to predict in vitro metabolites and verified in vivo using 
authentic samples (116). This study identified the same metabolites that were previously 
found, including a positional isomer of the hydroxylation on the cyclohexane ring 
metabolite. Rojek et al, developed and validated a method to quantitate U-47700 and two 
of its predicted metabolites (N-desmethyl-U-47700 and N,N-didesmethyl-U-47700) in 
blood. Only two metabolites were included as there were no commercially available 
reference standards for the hydroxylated metabolites. This method was then applied to 12 
authentic case samples where various concentrations were identified. The use of 
retrospective analysis was incorporated to analyze a sample presented by Partridge et al 
(122). Using the molecular formula for the metabolites of U-47700, it was possible to go 
back in a previously analyzed sample and identify the presence of U-47700 metabolites. 
A metabolism study using hepatocyte incubations to identify metabolites for AH-7921 
coupled with in vivo data from authentic urine was performed by Wohlfarth et al (134). 
As mentioned before, AH-7921 is a structural isomer to U-47700 and therefore it is not 
surprising that the two share similar abundant biotransformations. In this study, 12 
metabolites were identified via hepatocyte incubations and 11 of the 12 were present in 
authentic urine samples. The increase in amount of metabolites produced compared to the 
U-47700 can be attributed to human hepatocytes used in this experiment, while the other 
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experiments used HLMs (116,124). Hepatocyte incubations produce metabolites closer to 
the abundance that occurs in the human body and are also able to produce phase II 
metabolites. The two most abundant metabolites identified in this study were desmethyl-
AH-7921 and didesmethyl-AH-7921 (134)  
Recently, a metabolic study using human liver S9 fraction on U-48800 was 
published by Gampfer et al (135). This study investigated the toxicokinetics of U-48800 
by determining metabolic stability, isozyme mapping, and plasma protein binding. There 
were 12 phase I metabolites involving demethylation, hydroxylation, and combinations of 
the two identified during the in vitro study and 2 additional phase I metabolites identified 
in rat urine. Rats were used as there were no authentic human samples available to verify 
the predicted metabolites. It was also discovered that the isozymes CYP2C19 and 
CYP3A4 were responsible for the most abundant metabolites and concluded that poor 
metabolizers of those isozymes would be prone to higher concentrations of U-48800 and 
potentially toxicity (135).  
MT-45  
In the 1970’s, the Dainippon Pharmaceuticals Company developed MT-45 as a 
possible alternative analgesic to morphine (136). A structure of MT-45 can be seen below 










Unlike the other synthetic opioids, MT-45 is a piperazine derivative. The 
Dainippon Pharmaceuticals Company also developed another piperazine derivative in the 
1970’s named AD-1211, which possessed analgesic and narcotic antagonist properties 
(137).  
Prevalence   
MT-45 was first reported to the EMCDDA EWS towards the end of 2013. The 
substance was also first report to NFLIS in 2013 (53). Shortly after, it was placed under 
control across the EU in 2015 (138). In 2017, the United States placed MT-45 as 
Schedule I controlled substance under the Controlled Substance Act (139). Between 2011 
and 2016, there were three seizures of MT-45 reported to NFLIS (140). According to the 
EMCDDA, there were 28 fatalities involving MT-45 in Sweden between November 2013 
and July 2014 (141).  
Pharmacology  
In 1978, Fujimura et al, investigated receptor activity and analgesic properties of 
MT-45. It was determined that MT-45 is 3.5 times more potent than morphine (142).  




Figure 1.11. Structure of MT-45 
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that it was a MOR-1 selective agonists (143). Unusual side effects were observed by 
subjects presented in Helander et al. In these non-fatal intoxications, subject experienced 
loss of hearing, increased liver enzymes, and dermatitis with hair loss. Some subjects also 
displayed signs of thallium poisoning (Mee’s lines), but no other symptoms/sign of 
thallium poisoning and no thallium detected (144). This is the only synthetic opioid that 
had these unusual side effects reported. Users on drug forums provided potential effective 
dosages for new users depending on the route of administration chosen. A low dose for 
oral administration was reported as 10 mg and a high dose of 200 mg was suggested 
(104). For intranasal administration, the recommended dose was 50 mg. Users also 
reported increased happiness and significant nodding while on the substance (104).   
Methods  
There is only one published validated method for MT-45. Papsun et al performed 
a fit-for-purpose validation to quantitate MT-45 using an ultra-performance liquid 
chromatography (UPLC)-MS/MS in blood (18). The established linear range was 1-100 
ng/mL with a limit of detection of 1 ng/mL. The extraction method utilized was a 
traditional LLE. The precision and accuracy of their method was within ±20% CV and 
difference.  
Cases   
As previously mentioned, there were 28 fatalities reported to EMCDDA from 
Sweden between 2013 and 2014 (141). Of these 28 fatalities, the concentrations ranged 
between 8.3 and 1989 ng/mL. Using the validated method previously mentioned, Papsun 
et al, determined the concentrations of MT-45 present in single fatality case of a 35 year 
old man. The concentration of MT-45 was determined to be 520 ng/mL. There also the 
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presence of etizolam (35 ng/mL) detected in the decedents blood. Although both of these 
compounds were present, it was suggested that MT-45 played a more significant role in 
the fatality (18). Another fatality was presented by Fels et al that involved MT-45 (145). 
This case involved a 24 year old man that had been a known user of amphetamine. The 
decedent was found by his mother in his room where he was slumped over in a chair by a 
desk. There were several bags present at the scene that were labelled MT-45, 
methoxymetamine, and methoxphenidine. The femoral blood had a concentration of 2900 
ng/mL of MT-45 present. When compared to the other fatality concentrations previously 
mentioned, this concentration is remarkably high. It was concluded that due to the 
concentration of MT-45 detected in the decedent’s blood, that MT-45 had a major role in 
the death of the individual (145). Backberg et al presented a non-fatal intoxication of a 30 
year old man. It was suspected that the 30 year old individual was under the influence of 
flubromazepam and MT-45. The urine of the 30 year old tested positive for 3-MeO-PCP, 
MT-45, N-ethylbuphedrone, flubromazepam, methiopropamine, α-PBP, α-PPP, and 4F-
PVP. The subject was discharge within 24 hrs after fully recovering (146).  
Stability 
 The only stability reported on MT-45 is the stability that was assessed during 
Papsun et al fit-for-purpose validation (18). The stability study did not specify the 
concentration of MT-45 that was used, but it concluded that MT-45 was stable in fortified 
blood for 30 days in the following conditions: refrigerated, room temperature, and frozen. 
The study also observed a possible instability of MT-45. Authentic blood samples were 
retested approximately 12 months after initial analysis and had degraded ~50%. Due to 
the unknown stability of MT-45, the authors could not conclude if this degradation was 
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due to the nature of the sample or the possible instability of the compound in authentic 
specimens (18). 
Metabolism  
There have been two metabolism studies involving MT-45 that have been 
published.  Montesano et al conducted a metabolic study using rat hepatocytes and then 
verified the predicted metabolites with CD-1 mice urine of animals previously dosed with 
MT-45. Metabolites were first predicted in silico before proceeding with the in vitro 
experiments. From the hepatocyte incubations, there were 14 phase I and phase II 
metabolites identified. All of these metabolites were present in the in vivo experiments 
with hydroxy-MT-45 being the most abundant metabolite present. This study also 
assessed the mice behavior through tail flicks. It was determined that MT-45 produced 
comparable respiratory depression and analgesia to that of morphine. This was the first 
study to predict the metabolites for MT-45, but due to use of rat hepatocytes there could 
be differences compared to human isozymes.  
McKenzie et al investigated the metabolism of MT-45 and an analog of MT-45 
(2F-MT-45) using an array of metabolic methods (HLMs, human hepatocytes, mouse 
hepatocytes, and mouse and authentic human urine) (147). There was a total of 15 
metabolites identified through both in vivo and in vitro experiments for MT-45.  There 
were 12 metabolites identified for 2F-MT-45 following the in vitro and in vivo studies. 
The major metabolites for both compounds consisted of hydroxylations or N-
dealkylation. From both of these studies, hydroxylated metabolites were suggested as 





Of the previously mentioned synthetic opioids, the W-series has the least amount 
of previous literature available. Developed in the 1980’s at the University of Alberta, the 
W-series consists of 32 compounds (148). There are three prominent compounds that are 
in the W-series. The structures of these compounds are shown below in Figure 1.12. W-
18 gathered media attention when reports came out that this drug was “10,000 times 
stronger than morphine”(149) as a result of suspected involvement in 213 overdose 
deaths in Canada in 2015. There was no peer reviewed data to back these claims.  
Prevalence   
There has been a single fatality report associated with W-18 in literature. 
According to NDEWS, National Medical Services laboratories had a case of a 30 year 
old man who died from an apparent overdose in May 2016 (150). The lab was able to 
detect W-18 in blood through their general screen on their LC-quadrupole time of flight 
(QTOF). Once screened positive for W-18, it was confirmed in both urine and blood. The 
decedent had a history of drug abuse and also had 400 ng/mL of morphine and 13 ng/mL 






















Figure 1.12 Structures of three compounds in the W-series 
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a Schedule I controlled substance (151). None of the W-series compounds are scheduled 
in the United States. In 2017, there were still forums mentioning experiences or desires of 
W-18 and other NPS (152). In 2019, a powder labeled “heroin #3” was analyzed by a lab 
in Belgium and was found to contain W-18 with a fentanyl analog (ocfentanil) (153). 
There have been no published methods for the detection of any of the W-series 
compounds.  
Pharmacology  
As mentioned before, original reports suggested that W-18 was a very potent 
opioid, but this was proven otherwise by Huang et al. This study concluded that there 
was no detectable opioid activity at the μ, δ, κ receptors from either W-18 or W-15. They 
also evaluated the metabolism of W-18 using both mouse liver microsomes and HLMs. 
They sought to see if any of the identified metabolites would perhaps have activity at any 
of the opioid receptors. It was concluded that W-18 is extensively metabolized. 
Transformation included dealkylation, hydroxylation, and nitro-reduction. Surprisingly, 
none of the metabolites displayed any activity to the opioid receptors.   
Statement of the Problem 
NPS continue to be a worldwide problem and new compounds are constantly 
emerging. Helander et al described the challenge of NPS perfectly by calling it “the 
hydra monster”. This Greek mythology beast would spawn three heads when one was cut 
off. Just like NPS, when the forensic community thinks that they are able to detect or 
schedule a new NPS, three new ones emerge. Although this is an extreme challenge for 
the forensic community, seemingly an endless fight, there are certain ways to combat 
these challenges in an effort to get ahead of the curve. First would be to establish the 
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prevalence of the compounds, in an effort to truly identify the compounds of interest that 
truly pose potential threats. One such mechanism for assessing prevalence is to screen 
oral fluid from individuals under the influence of drugs or from sensitive populations 
subject to routine drug testing. Next, studies evaluating the stability of compounds can 
help determine proper storage of samples suspected to contain NPS. Often times, a 
laboratory may be backlogged or lack a specific method to identify potential NPS so 
testing may not be complete in a timely fashion. Another way to mitigate the challenge of 
NPS would be to determine the pharmacology of the compounds. Understanding the 
pharmacokinetics and pharmacodynamics of compounds is needed in order to understand 
safety profiles and possible toxicity for drug users. Finally, evaluating the metabolism of 
a compound is useful for identifying biomarkers of recent use, particularly if the parent 
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The opioid epidemic has become a national health emergency in the United 
States. While heroin and prescription opioid abuse is not uncommon, synthetic opioid use 
has risen dramatically, creating a public safety concern. Like traditional opioids, novel 
synthetic opioids are abused due to their analgesic and euphoric effects. Some adverse 
side effects include respiratory distress, nausea, and decreased consciousness. Synthetic 
opioids have emerged into the illicit and online drug market, including AH-7921, MT-45, 
U-series, and W-series. Though originally developed by pharmaceutical companies, these 
substances are not well studied in humans and comprehensive analytical methods for 
detecting and quantifying these opioids are limited. Oral fluid is a useful biological 
matrix for determining recent drug use, does not require a trained medical professional, 
and can be collected under direct observation, deterring adulteration. The purpose of this 
research was to develop and validate a comprehensive analytical method for the detection 
and quantification of morphine, 6-acetylmorphine, buprenorphine, U-47700, U-49900, U-
50488, AH-7921, MT-45, W-18, and W-15 in oral fluid collected via Quantisal™. This 
was achieved by solid-phase extraction followed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). The limits of detection and quantitation were 5 ng/mL and 
10 ng/mL, respectively. Linearity was observed between 10 and 500 ng/mL (R2≥0.9959). 
Bias and imprecision were <±11.1%. Matrix effects ranged from −21.1 to 13.7%. No 
carryover was detected following injection of the highest calibrator. All analytes were 
stable (within ±15% change from baseline) under all tested conditions (24 h at room 
temperature, 72 h at 4 °C, and in the autosampler for 60 h at 4 °C). 
 




The United States is experiencing an opioid epidemic, leading to record high 
number of overdoses. According to the Drug Enforcement Administration (DEA), there 
was a 576% increase in deaths related to synthetic opioids and fentanyl from 2004 to 
2015 (1).  Novel synthetic opioids (NSO) have the potential to be hundreds of times more 
potent than morphine. The increase in NSO use is due to ease of online purchasing, but 
also by the presence in counterfeit narcotic pills or heroin unbeknownst to the user (2). 
The U-series drugs were originally developed by Upjohn (“U”) Company as 
possible analgesics in the 1970s, but did not advance to clinical trials. Currently, the most 
prevalent compounds are U-47700, U-49900, and U-50488. U-47700 is a selective µ-
opioid agonist approximately 7.5 times more potent than morphine (3). Street names that 
have been associated with this drug are “U4”, “pink”, and “pinky”. While no human 
pharmacological studies have been conducted, it is believed that U-47700 is abused due 
to its euphoric and analgesic effects. The adverse side effects are similar to those seen 
with traditional opioids such as nausea, cyanosis, and respiratory depression (4, 5). U-
47700 is associated with cases of intoxication (6, 7) and fatalities (8-12). In November 
2016, U-47700 was classified as a Schedule I controlled substance in the US (13). U-
49900 is a diethyl analog of U-47700 that is not scheduled in the US. Minimal literature 
is available on this compound. In Krotulski et al, the metabolism of U-47700 and U-
49900 were investigated (14). There has been one reported fatality involving the 
ingestion of U-49900 and tetrahydrofuranylfentanyl (15). U-50488 is a highly selective κ-
opioid receptor agonist studied in rat models (16). A fit for purpose validation was 
performed by Mohr et al for detecting U-50488, U-47700, and furanyl fentanyl in post 
65 
 
mortem cases. Of the 20 case samples, U-50488 was not detected. The abuse potential for 
both U-49900 and U-50488 are unknown but may rise in the future following scheduling 
of similar compounds.  
AH-7921 is a structural isomer to U-47700 developed by Allen and Hanbury 
(“AH”) in the 1970s as a potential analgesic, but discontinued due to its addictive 
properties (17). Potency and pharmacological activity is similar to that of morphine (18). 
It reappeared in 2012 on the Internet as a “research chemical” (19). Fatalities are not 
uncommon (20-23). Like U-47700, AH-7921 is a Schedule I controlled substance in the 
US (24).  
MT-45 was developed in the 1970s by Dainippon Pharmaceuticals Company as 
an analgesic alternative to morphine (25). Adverse side effects include respiratory 
distress, unconsciousness, and temporary hearing loss in a few cases (26, 27). Online 
users say that the high is “opiate-like” and “a lot better than expected” (27). Severe 
intoxications (26) and fatalities (20, 28) continue to rise. MT-45 is also classified as a 
Schedule I controlled substance (29).  
The W-series encompasses 32 compounds developed in the 1980s at the 
University of Alberta (30). In Huang et al, W-18 and W-15 were examined and 
determined to have no activity at the μ, δ, or κ opioid receptors (31). In May 2016, 
Canada scheduled W-18 as a Schedule I controlled substance, while it is not yet 
scheduled in the US (32). Very little scientific, peer-reviewed literature is available for 
W-18 or W-15 activity, prevalence, or intoxications (10). However, National Medical 
Services Laboratories has incorporated W-18 into their testing capabilities and detected it 
in at least one post-mortem case, in combination with morphine and 6-
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monoacetylmorphine in a known heroin abuser (33). No published analytical methods are 
available for detection or quantification of W-18 or W-15 in biological fluids. 
To date, few analytical methods are available for quantifying NSO in biological 
fluids.  Analytical techniques published for detecting these drugs in alternative matrices 
such as oral fluid are minimal. The goal of this study was to develop, optimize, and 
validate a method to quantify multiple NSO in oral fluid. Morphine, 6-
monoacetylmorphine (6-AM), and buprenorphine were also incorporated in order to 
identify drug mixtures or drug use trends. In the 2017 update of recommendations for 
toxicological investigation of drug-impaired driving, NSO were placed in the tier II 
category (34). Oral fluid is a useful biological matrix for determining prevalence of use 
or recent drug intake. Collection of oral fluid does not require a same-sex collector or a 
trained medical professional and can be collected under direct observation, deterring 
adulteration. In Griswold et al, NSO including U-47700 were detected in oral fluid and 
urine using a qualitative method on a liquid chromatography-quadrupole/time-of-flight 
liquid mass spectrometry (LC-QTOF-MS) in a hospital setting where heroin overdose 
was suspected (35).  Oral fluid has been evaluated as a toxicological specimen for driving 
under the influence (DUID) and was deemed a feasible option for roadside or laboratory 
analysis (36-39).  
Materials and Methods 
Chemicals and Reagents 
U-47700, U-49900, U-50488, MT-45, W-15, W-18, U-47700-d6, MT-45-d11, 
and W-18-d4 standards were obtained from Cayman Chemical (Ann Arbor, MI). 
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Buprenorphine, morphine, morphine-d3, 6-acetylmorphine, and AH-7921 were 
purchased from Cerilliant (Round Rock, TX).  
 Hexanes (Optima®), formic acid (Optima®), and ethyl acetate (HPLC grade) 
were obtained from Fisher Scientific (Fair Lawn, NJ). Methanol (LCMS grade), 
acetonitrile (LCMS grade), and dibasic sodium phosphate were obtained from J.T. Baker 
(Center Valley, MA, USA). Glacial acetic acid was obtained from Mallinckrodt 
Chemicals (St. Louis, MO). Quantisal™ Buffer was obtained from Immunalysis 
(Pomona, CA).  Ammonium formate (10 M) was obtained from Sigma-Aldrich (St. 
Louis, MO). Concentrated ammonium hydroxide was obtained from Macron Fine 
Chemicals (Center Valley, MA, USA). Monobasic sodium phosphate was obtained from 
VWR (Radnor, PA). A Millipore Direct-Q® UV Water Purification system (Billerica, 
MA) was used to purify water. PolyChrom ClinII 3 cc (35 mg) solid phase extraction 
(SPE) columns were obtained from SPEware (Baldwin Park, CA). Oral fluid was 
expectorated by non-opioid users and pooled for method development and validation. 
Each pool of oral fluid (n=4) contained five volunteers. The pooled oral fluid was 
verified by running matrix extracted blanks and analyzed with acquisition method below 
prior to use in preparing calibrators or controls.   
Instrumentation 
An Agilent 1290 Infinity Liquid Chromatograph system equipped with an Agilent 
6470 Triple Quadrupole Mass Spectrometer (Santa Clara, CA) was used for the analysis. 
Solid Phase Extraction (SPE) was performed using a CEREX-48-positive-pressure 
manifold (SPEware). Evaporation under nitrogen was performed using a TurboVap LV® 
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concentration workstation (Caliper Life Sciences, Hopkinton, MA). Data were acquired 
and analyzed using Agilent MassHunter software. 
Preparation of Standard Working Solutions 
Stock solutions were prepared at 100,000 ng/mL in methanol for each analyte. 
Methanolic mixed calibrator solutions containing all analytes were prepared via serial 
dilution creating calibrators at 10, 25, 75, 125, 250, and 500 ng/mL when fortified in oral 
fluid. Stock solutions were prepared at 10,000 ng/mL in methanol for each deuterated 
internal standard (ISTD). Mixed ISTD solution was prepared at 1000 ng/mL in methanol 
and contained all four deuterated compounds listed above. Mixed quality control (QC) 
solutions were prepared separately for low (25 ng/mL), medium (100 ng/mL), and high 
(400 ng/mL) controls when fortified in oral fluid. All standard solutions were stored at -
20 °C in amber vials. 
Extraction Procedure 
ISTD solution (25 µL) was added to 1 mL of a buffer/oral fluid mixture (750 µL 
Quantisal buffer, 250 µL drug-free oral fluid) to achieve a final concentration of 100 
ng/mL. Calibrator or QC solutions (25 µL) were added, followed by 2 mL of 0.1 M 
phosphate buffer (pH 6). Samples were vortexed, loaded onto SPE columns, and allowed 
to flow under gravity. The columns were rinsed with deionized water (1 mL) and 1 M 
acetic acid (1 mL). Cartridges were dried under 20 psi nitrogen for 5 min then washed 
with 1 mL hexane. Acidic drugs were eluted using ethyl acetate (1 mL). Following a 1 
mL methanol wash, basic drugs were eluted using 1 mL of 
dichloromethane:isopropanol:ammonium hydroxide (80:20:5) then evaporated under 
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nitrogen at 50 ºC. The samples were reconstituted in 1 mL of mobile phase A: mobile 
phase B (95:5). A total of 5 µL was injected onto the LC-MS/MS. 
Liquid chromatography 
Chromatographic separation was achieved using an Agilent Poroshell 120 EC-
C18 column (100 mm x 3.0 mm, 2.7 µm) equipped with a Poroshell 120 EC-C18 guard 
column (2.1 x 5mm, 2.7 µm). The column temperature was maintained at 40°C. 
Separation was achieved using gradient elution at 0.5 mL/min with 0.05% formic acid 
and 5 mM ammonium formate in water (mobile phase A) and 0.1% formic acid in 
acetonitrile (mobile phase B). Gradient elution consisted of a 2 min ramp from 95% to 
80% A, then a ramp to 50% A over 7 min, followed by a 2 min high organic rinse and 2 
min re-equilibration.  
Mass spectrometry 
Data were acquired in dynamic multiple reaction monitoring (MRM) mode with 
positive electrospray ionization (ESI) using a minimum of two transitions per analyte and 
internal standard (Table 2.1). Source parameters were optimized using MassHunter 
Source Optimizer and were as follows: gas temperature at 300 °C, gas flow at 10 L/min, 
nebulizer at 40 psi, sheath gas temperature at 350 °C, sheath gas flow at 12 L/min, and 








Table 2.1 Optimized liquid chromatography-tandem mass spectrometry parameters for 
morphine, 6-acetylmorphine, U-47700, AH-7921, buprenorphine, U-49900, U-50488, 
MT-45, W-18, W-15 and deuterated internal standards. 













Morphine 286.3 44 165 136 1.066 
Morphine-
d3 
 286.3 68 152 136   
6-acetylmorphine 328.3 44 165 156 2.154 
Morphine-
d3 
 328.3 80 152 156   
U-47700 329.2 37 172.9 117 4.559 
U-47700-
d6 
 329.2 61 144.9 117   
AH-7921 329.2 57 144.9 107 4.791 
U-47700-
d6 
 329.2 21 46.2 107   
Buprenorphine 468.6 44 396.2 200 4.9 
Morphine-
d3 
 468.6 150 151.9 200   
U-49900 357.1 37 172.9 120 5.102 
U-47700-
d6 
 357.1 65 144.9 120   
U-50488 369.1 49 158.9 115 5.49 
U-47700-
d6 
 369.1 37 112.1 115   
MT-45 349.5 20 182 112 6.261 
MT-45-
d11 
 349.5 93 77.1 112   
W-18 422.1 50 111 153 8.314 W-18-d4 
 422.1 50 75.1 153   
W-15 377.1 29 105 145 8.542 W-18-d4 
 377.1 97 75.1 145   
Morphine-d3 289.5 44 168.1 136 1.066 - 
 289.5 76 152 136   
U-47700-d6 335.2 37 172.9 112 4.559 - 

















MT-45-d11 360.5 20 181.5 132 6.261 - 
 360.5 93 77.1 132   
W-18-d4 426.1 53 115 143 8.314 - 
 426.1 105 78.1 143   
Q1 = quadrupole 1, Q3 = quadrupole, Ions in italics indicate quantifying transitions  
 
Validation 
This method was validated according to the Scientific Working Group for 
Forensic Toxicology guidelines (40). Four lots of pooled oral fluid (n=5 contributors) 
were used as different sources for the required parameters. Linearity was determined 
using six non-zero calibrators over five days. Limit of quantitation (LOQ) was evaluated 
as the lowest non-zero calibrator (10 ng/mL) in duplicate in three different lots over three 
days. Limit of detection (LOD) was evaluated at half the LOQ concentration in duplicate 
in three different lots over three days. Bias and precision were assessed in triplicate at 
low, medium, and high QC concentrations over five days. Matrix effects (post-extraction 
addition) and recovery were evaluated at low and high QC concentrations (n=2) in three 
different lots. Stability was evaluated at 24 h at room temperature, 72 h at 4 °C, and in the 
autosampler for 60 h at 4 °C. Dilution integrity was determined by fortifying a sample at 
1000 ng/mL and performing a 10x dilution (n=3). Carryover was evaluated by injecting a 
negative sample (ISTD only) after the highest calibrator (500 ng/mL). Interferences were 
evaluated at 10,000 ng/mL by fortifying into low QC samples and then extracted per 
above. Thirty-three common drugs were evaluated: Δ⁹-tetrahydrocannabinol, alprazolam, 
amobarbital, amphetamine, amitriptyline, butalbital, caffeine, carbamazepine, 
carisoprodol, cocaine, codeine, cotinine, cyclobenzaprine, dextromethorphan, diazepam, 
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diphenhydramine, hydrocodone, hydromorphone, ketamine, methadone, nicotine, 
nordiazepam, oxazepam, oxycodone, pentobarbital, phencyclidine, phenobarbital, 
propoxyphene, secobarbital, tetrahydrocannabinolic acid, tramadol, and zolpidem. 
Authentic Samples 
Oral fluid specimens were collected via Quantisal devices from 18 anonymous 
detainees in a Texas adult detention center in accordance with a Sam Houston State 
University Institutional Review Board (IRB) approved protocol (# 2017-11-37550). All 
subjects gave written informed consent prior to collection. Specimens were refrigerated 
(4 °C) and analyzed within 72 h. Oral fluid samples (1 mL) were extracted and analyzed 
using the validated method as described above. 
Results and Discussion  
Our goal was to develop, optimize, and validate an extraction procedure and 
analytical method to quantify NSO in oral fluid. The assay allowed for simultaneous 
extraction of AH-7921, MT-45, U-series, W-series, heroin markers (6-AM, morphine), as 
well as buprenorphine via mixed mode SPE. 
MRM transitions were optimized to minimize interferences as summarized in 
Table 2.1. Following MS optimization, chromatography was optimized by investigating 
several columns, mobile phase solvents, and mobile phase modifiers in order to achieve 
ideal separation and sensitivity. Initially, mobile phase A was only modified with 0.1% 
formic acid, but the W-series compounds demonstrated better peak shape and instrument 
response with addition of ammonium formate.  Extraction was assessed in order to attain 
highest recoveries while minimizing matrix effects. Several elution solvents for basic (2-
4% ammonium hydroxide in ethyl acetate) and acidic (n-butyl chloride, acidic methanol, 
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ether:toluene, and hexane:ethyl acetate:glacial acetic acid) fractions were investigated. To 
reduce matrix effects and improve internal standard response over the linear range, 
reconstitution volume was optimized to 1 mL. 
To our knowledge, this is the first publication with a validated method for 
extraction and quantification of W-series drugs. In Shoff et al, W-18 was included as a 
target, but was not validated in their qualitative method (10). It is suspected that their 
extraction may not recover W-18 as only the alkaline drug fraction was collected. Our 
study found that both W-18 and W-15 elute with the acidic/neutral portion of the 
extraction. W-19 was initially included in this study, but abandoned due its alkaline 
nature (no suitable internal standard) and instability in the mobile phase. Unlike W-15 
and W-18, W-19 eluted in the basic fraction of the extraction, possibly due to additional 
amine group on the phenylethyl piperidine. The analyte was suspected to have a pKa 
similar to the pH of the mobile phase due to shifting retention times.   
Residual plots were used to determine suitable calibration models and weighting 
for each analyte. A linear calibration model (1/x weighting) from 10-500 ng/mL was 
optimal for all analytes. R2 values were ≥0.9959 (Table 2.2). LOD were acceptable with 
signal to noise ratios >3, ion ratios within ±20%, and retention times within ±0.1 min at 5 




Table 2.2 Linearity, limits of detection (LOD), and lower and upper limits of quantification (LLOQ, ULOQ) for morphine, 6-
acetylmorphine, U-47700, AH-7921, buprenorphine, U-49900, U-50488, MT-45, W-18, and W-15 in oral fluid. 






(mean±SD, n = 5) 
Slope     
(mean±SD, n = 5) 
R2 
(range, n = 5) 
Morphine 5 10 500 0.0118 ± 0.009 0.0192 ± 0.001 0.9975-0.9999 
6-acetylmorphine 5 10 500 0.0225 ± 0.013 0.0268 ± 0.002 0.9973-0.9999 
U-47700 5 10 500 0.0192 ± 0.017 0.0214 ± 0.001 0.9983-0.9998 
AH-7921 5 10 500 0.0092 ± 0.009 0.0135 ± 0.001 0.9987-0.9999 
Buprenorphine 5 10 500 0.0028 ± 0.002 0.0041 ± 0.000 0.9982-0.9999 
U-49900 5 10 500 0.0069 ± 0.010 0.0125 ± 0.001 0.9988-0.9997 
U-50488 5 10 500 0.0084 ± 0.003 0.0097 ± 0.001 0.9989-0.9995 
MT-45 5 10 500 0.0160 ± 0.009 0.0084 ± 0.004 0.9962-0.9993 
W-18 5 10 500 0.0090 ± 0.010 0.0139 ± 0.001 0.9983-0.9998 
W-15 5 10 500 0.0189 ± 0.010 0.0128 ± 0.002 0.9959-0.9998 
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LOQ were acceptable with signal to noise ratios >10, ion ratios within ±20%, 
retention times within ±0.1 min, and bias/precision <±20% at 10 ng/mL. Chromatograms 
of each analyte at the LOQ are shown in Figure 2.1. Our morphine and 6-AM LOQ 
differ slightly from the proposed oral fluid cut-offs by the Substance Abuse and Mental 
Health Services Administration (15 and 2 ng/mL respectively), but are comparable to the 
limits (8 ng/mL) of a recent study evaluating field detection of drugs of abuse (37, 41). 
The LOQ for these heroin markers and buprenorphine are higher than previously 
published methods in oral fluid, but are suitable for authentic samples. In Cone et al, 
buprenorphine, morphine, and 6-AM were confirmed in authentic oral fluid samples. 
Buprenorphine (n = 263) had a mean concentration of 433.3 ng/mL, morphine (n = 4575) 
had a mean concentration of 178.9 ng/mL, and 6-AM (n = 3554) had a mean 






Figure 2.1 Extracted ion chromatogram of morphine (A), 6-acetylmorphine (B), U-47700 (C), AH-7921 (D), buprenorphine (E), 
U-49900 (F), U-50488 (G), MT-45 (H), W-18 (I), and W-15 (J) at 10 ng/mL; *Shared transitions of structural isomer AH-7921 
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Although there are limited studies involving detection of NSO, particularly in oral 
fluid, the LOQs validated in this study are anticipated to be sufficient for authentic 
samples. As previously mentioned, there are no validated qualitative or quantitative 
methods for the W-series drugs. Concentrations for MT-45, AH-7921, and the U-series 
drugs were 6-2900 ng/mL (20, 26, 28), 330-9100 ng/mL (20-23), and 1.5-1460 ng/mL (6-
12, 15) in blood, respectively. Although these concentrations ranges are broad, it is 
difficult to predict oral fluid concentrations that may be encountered. Route of 
administration and propensity to partition into oral fluid from blood may greatly affect 
oral fluid concentrations. Additionally, in cases of suspected driving under the influence 
of drugs, oral fluid may be collected sooner than blood and may better capture recent 
drug use before blood concentrations are too low for detection. 
Bias and precision data are summarized in Table 2.3.  Bias ranged from -8.8 to -




Table 2.3 Bias and precision data for morphine, 6-acetylmorphine, U-47700, AH-7921, buprenorphine, U-49900, U-
50488, MT-45, W-18, and W-15 in oral fluid at three concentrations across the linear range. 
Analyte Mean bias                                     
(%, n = 15) 
Between-run precision 
 (%CV, n = 15) 
Max within-run precision          
(%CV, n = 3) 
 Lowa Medb Highc Lowa Medb Highc Lowa Medb Highc 
Morphine -4.3 -5.3 -5.6 6.5 6.4 4.5 5.5 8.3 9.1 
6-acetylmorphine -5.8 -7.3 -6.5 6.7 6.7 5.5 8.4 11.1 9.7 
U-47700 -3.9 -4.0 -3.0 5.5 5.8 4.0 5.5 8.3 6.9 
AH-7921 -8.8 -7.2 -6.0 5.6 6.0 4.2 6.1 7.7 8.1 
Buprenorphine -3.3 -4.3 -2.5 6.1 6.6 4.8 6.2 10.3 9.3 
U-49900 -4.1 -2.9 -1.7 5.5 5.3 4.4 4.3 7.0 7.8 
U-50488 -4.2 -4.6 -2.9 5.4 5.2 4.1 4.5 7.2 7.1 
MT-45 -5.1 -3.9 -4.6 5.2 5.5 3.9 5.3 6.8 6.8 
W-18 -4.9 -6.1 -3.8 4.9 5.5 4.4 4.4 7.3 8.0 
W-15 -5.4 -6.9 -6.1 5.4 6.1 5.7 8.7 7.8 9.3 
a Low concentration was 25 ng/mL, b Medium concentration was 100 ng/mL, c High concentration was 400 ng/mL 
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Between-run precision was calculated as % coefficient of variance (CV) and 
ranged from 3.9 to 6.7%.  The maximum within-run precision was reported and ranged 
from 4.3 to 11.1%CV. Matrix effects and recovery are shown in Table 2.4. 
Table 2.4 Mean extraction recovery and matrix effect for morphine, 6-acetylmorphine, 
U-47700, AH-7921, buprenorphine, U-49900, U-50488, MT-45, W-18, and W-15 in oral 
fluid. 
Analyte Extraction efficiency                                     (%, n = 6)  
Matrix effect 
(%, n = 6) 
 Lowa Highb  Lowa Highb 
Morphine 95.1 91.3  1.0 -3.7 
6-acetylmorphine 87.5 87.6  13.7 2.8 
U-47700 87.9 89.0  -13.0 -16.4 
AH-7921 75.4 84.8  10.7 -0.9 
Buprenorphine 85.2 90.4  6.5 1.1 
U-49900 85.8 87.5  4.9 1.1 
U-50488 77.9 86.7  7.9 1.7 
MT-45 78.1 89.4  3.4 1.1 
W-18 58.2 52.2  -3.6 -3.7 
W-15 63.1 57.8  -21.1 -20.1 
U-47700-d6 84.6 85.6  -14.6 -16.2 
Morphine-d3 90.5 85.9  2.7 -3.2 
MT-45-d11 75.9 85.1  4.0 2.1 
W-18-d4 57.1 50.6  -3.5 -3.0 




All analytes had an extraction efficiency of >75% at low and high concentrations 
except the W-series. The only analyte that had matrix effects greater than ±20% was W-
15 but was reproducible in different matrix lots (%CV<15%) and did not compromise 
validation parameters including LOD, LOQ, precision, and bias. The lower extraction 
efficiency and higher matrix effects could be attributed to the acidic elution of the drug. 
Stability assessed at 24 h at room temperature, 72 h at 4 °C, and in the autosampler for 60 
h at 4 °C are presented in Table 2.5. 
Table 2.5 Fortified and extracted samples stability (% difference) for morphine, 6-
acetylmorphine, U-47700, AH-7921, buprenorphine, U-49900, U-50488, MT-45, W-18, 
and W-15 in oral fluid under different conditions at two concentrations. 
Analyte 24 h room temp  
(% difference,  
n = 3) 
 72 h 4 °C  
(% difference, n = 3) 
 60 h 
 autosampler 4 °C  
(% difference,  
n = 3) 
 Lowa Highb  Lowa Highb  Lowa Highb 
Morphine -0.3 -1.6  4.9 6.2  2.5 1.2 
6-acetylmorphine 1.2 -3.5  1.6 7.8  -0.7 0.2 
U-47700 -0.2 -3.4  5.4 4.4  -0.5 0.8 
AH-7921 7.6 4.5  9.7 8.4  0.8 2.7 
Buprenorphine 5.8 -1.1  0.1 7.3  -0.6 1.8 
U-49900 11.8 8.2  13.1 9.2  -5.7 0.1 
U-50488 12.2 8.1  12.4 9.7  -4.1 -0.7 
MT-45 0.4 -2.6  5.2 3.9  -3.3 -2.2 
W-18 -4.2 -6.6  4.5 3.6  0.7 0.3 
W-15 10.3 9.3  4.6 4.8  1.3 1.8 
a Low concentration was 25 ng/mL, b High concentration was 400 ng/mL 
 
 Analyte concentrations within 20% of initial quantification were considered 
stable and no more than 13.1% difference was observed. During method development 
and pre-validation experiments, W-19 demonstrated significant degradation over the 
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course of an analytical run in the autosampler. Due to instability, this analyte was not 
included in validation. The 10x dilution integrity was deemed acceptable if within ±20% 
of the target concentration. All analytes quantified 89-95% of targeted concentration for 
dilution integrity.  
During method development issues initially arose when assessing carryover for 
this method. There was significant carryover (>10% of LOQ peak abundance) for MT-45 
and W-series drugs. Needle rinse parameters were optimized, including rinse time, rinse 
position, and rinse solution. Carryover was no longer significant after changing the 
needle rinse to isopropanol:methanol:water:acetonitrile  (25:25:25:25). Of the 33 drugs 
evaluated for potential interferences, no qualitative or quantitative interferences were 
observed. Additionally, no endogenous interferences were observed for the various lots 
of pooled oral fluid from drug-free volunteers. 
Fentanyl analogs are also commonly encountered in heroin and counterfeit 
narcotic pills. These analytes are outside the scope of this study and will be addressed in 
a separate publication utilizing high-resolution mass spectrometry. Further, authentic 
specimens are currently being collected for a separate investigation that will include 
impairment data. However, in the limited number of samples analyzed, only morphine 
and 6-AM were detected by this method. Oral fluid was collected from 18 adults: 9 males 
(24-42 years) and 9 females (23-47 years). From the authentic samples analyzed, 
morphine was detected in 4 cases and 6-AM was detected in 3 of those 4 subjects. 
Morphine concentrations were <LOQ, 32, 104, and 146 ng/mL and 6-AM concentrations 
in those same individuals were <LOD, 15, <LOQ, and 110 ng/mL. 
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The continued analysis of authentic samples will provide valuable data since 
previous literature has only qualitatively identified NSO in oral fluid. 
Conclusion  
A method for the simultaneous quantification of morphine, 6-AM, buprenorphine, 
U-47700, U-49900, U-50488, AH-7921, MT-45, W-18, and W-15 in oral fluid was 
optimized and met SWGTOX validation criteria. The extraction technique and LC-
MS/MS parameters can also be easily translated to other biological matrices. 
Incorporation of heroin biomarkers and an opioid addiction treatment therapy will allow 
for analysis of compliance and drug use trends. This method is currently being used to 
determine drug trends in several groups. Analysis of oral fluid specimens from sensitive 
populations (i.e. DUID, prisoners, arrestees, parolees) that may be seeking alternative or 
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According to the Governors Highway Safety Association, drugs are detected more 
frequently in fatally-injured drivers than alcohol. Due to the variety of drugs (prescribed 
and/or illicit) and their various physiological effects on the body, it is difficult for law 
enforcement to detect/prosecute drug impairment. While blood and urine are typical 
biological specimens used to test for drugs, oral fluid is an attractive alternative matrix. 
Drugs are incorporated into oral fluid by oral contamination (chewing or smoking) or 
from the bloodstream. Oral fluid is non-invasive and easy to collect without the need for 
a trained professional to obtain the sample, unlike urine or blood. This study analyzes 
paired oral fluid and urine with drug recognition expert (DRE) observations. 
Authentic oral fluid samples (n=20) were collected via Quantisal™ devices from 
arrestees under an IRB approved protocol. Urine samples (n=18) were collected with EZ-
SCREEN® cups that presumptively screened for THC (cannabinoids), Opiates, 
Methamphetamine, Cocaine, Methadone, Phencyclidine, Amphetamine, 
Benzodiazepines, and Oxycodone. Impairment observations (n=18) were recorded from 
officers undergoing DRE certification.  
Oral fluid samples were screened using an Agilent Technologies 1290 Infinity 
liquid chromatograph (LC) coupled to an Agilent Technologies 6530 Accurate Mass 
Time-of-Flight mass spectrometer (MS). Personal Compound and Database Libraries 
were produced in-house containing 64 drugs of abuse. An Agilent 1290 Infinity LC 
system equipped with an Agilent 6470 Triple Quadrupole MS was used for quantification 
of buprenorphine, heroin markers (6-acetylmorphine, morphine), and synthetic opioids.   
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Subjects were 23-54 years old; 11 (55%) were male and 9 (45%) were female. 
Evaluator opinion of drug class was confirmed in oral fluid 90% of time and in urine 85% 
of the time in reference to scope of testing by the LC-MS methods employed (excludes 
cannabis and CNS depressants). Data indicate that oral fluid may be a viable source for 
confirming driving under the influence of drugs (DUID).  
 





According to the Governors Highway Safety Association (GHSA), 44% of 
fatally-injured drivers tested positive for drugs in 2016, which was higher than alcohol 
with 38% of fatally-injured drivers tested positive for alcohol. Due to the variety of drugs 
(prescribed and/or illicit) and their various physiological effects on the body, it is difficult 
for law enforcement to detect/prosecute drug impairment. According to the International 
Association of Chiefs of Police (IACP), there were over 30,000 Drug Recognition Expert 
(DRE) evaluations performed in 2017 in the US. The most abundant evaluator opinion 
was cannabis, then central nervous system (CNS) stimulants, followed by CNS 
depressants, and narcotic analgesics (1). Depending on state laws, proof of impairment 
could be needed in order to prosecute someone suspected of DUID. Previous studies 
indicate that the tests performed during DRE examinations are beneficial impairment 
indicators (2-4). 
In 2017, there were over 8,000 certified DRE in the US (1). While training more 
DRE officers may help reduce DUID related fatalities, improving drug detection and 
identification may also aid in this public safety issue. A potential tool for improvement in 
drug testing is consideration of alternative matrices, such as oral fluid. Oral fluid may be 
collected roadside as it is non-evasive, easy to transport, and does not need a trained 
professional to collect. As of April 2018, states that allow oral fluid collection are 
Arizona, Arkansas, Colorado, Georgia, Illinois, Indiana, Kansas, Louisiana, Missouri, 
Nevada, New York, Oklahoma, South Dakota, Utah, and Wyoming (5). These 
participating states only make up 30% of the US and while it is legal for oral fluid to be 
collected, few states are currently collecting due to lack of capabilities.  Police officers in 
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European countries prefer oral fluid opposed to blood, urine or sweat due to its ease of 
use, non-invasive nature, and lowered risk of infection transmission (6). Oral fluid 
collection with a roadside portable device has the benefit of screening the suspect’s 
specimen within minutes (7-9). Krotulski et al demonstrated that the Alere DDS® 2 was 
reliable and suitably robust in the field by comparing results from the device to 
confirmation results and assessing true positives, true negatives, false positives, and false 
negatives (10). Roadside screening devices are limited in scope and sensitivity. For 
evidentiary testing, oral fluid can be collected with various devices, such as the 
Quantisal™ collection device, for comprehensive laboratory analyses such as liquid 
chromatography-mass spectrometry (LC/MS). With the emergence of novel psychoactive 
substances (NPS), analyzing oral fluid on a sensitive instrument such as a liquid 
chromatograph accurate mass time-of-flight mass spectrometer (LC-QTOF-MS), can 
allow for retrospective analysis of the accumulated data. Some NPS such as U-47700 
have been detected in oral fluid samples (11).  
 Countries outside the US, such as Australia, Belgium, and France, have 
implemented either screening and/or confirmation in roadside oral fluid collection (12). 
Established cut-off concentrations for Δ9-tetrahydrocannabinol (THC), CNS stimulants, 
and narcotic analgesics ranging from 5-25 ng/mL are implemented for confirmatory 
analysis in Belgium (12). This range is similar to the confirmatory analysis cut-off range 
(2-15 ng/mL) proposed for workplace drug testing by the Substance Abuse and Mental 
Health Services Administration (SAMHSA) for the same drug classes (13).  Michigan 
recently completed a pilot study to evaluate oral fluid roadside analysis where oral fluid 
samples were screened with the Alere DDS® 2, collected with Quantisal collection device 
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(if subject consented) and compared to blood draws. Of the 92 roadside oral fluid tests, 
88 were confirmed in blood or oral fluid collected by the Quantisal device. Although 
further evaluation will be performed, this study demonstrates the viability of oral fluid 
used for suspected DUID investigations in the US (14).  
Our study aimed to compare presumptive urine test results and confirmatory oral fluid 
test results with DRE evaluations performed by officers in training in an effort to assess 
use of alternative matrices for toxicology during DRE examinations.  
Methods  
Subjects 
Participants (n=20) in this study were recruited from detainee centers in Texas 
(Dallas and San Antonio). Demographic information can be seen in Table 3.1.  
Table 3.1 Subject demographics 
Sample Age Sex Race Location 
01 37 M Hispanic San Antonio  
02 32 F Hispanic  San Antonio  
03 27 F Hispanic San Antonio  
04 36 F White San Antonio  
05 23 F Hispanic San Antonio  
06 27 M Hispanic  San Antonio  
07 34 M Black San Antonio  
08 27 M Black San Antonio  
09 25 F White San Antonio  
10 36 F Hispanic  San Antonio  
11 32 F Hispanic  San Antonio  
12 47 F Hispanic  San Antonio  
13 29 M White San Antonio  
14 24 M Hispanic  San Antonio  
15 35 M Hispanic  San Antonio  
16 42 M White San Antonio  
17 31 F Black San Antonio  
18 35 M White San Antonio  
95 
 
Sample Age Sex Race Location 
19 54 M Black Dallas 
20 46 M White Dallas 
     
DRE Examinations 
DRE examinations were performed by officers undergoing Drug Evaluation and 
Classification Program (DEC/DRE) certification. Part of the curriculum includes drug 
recognition field certification with persons under the influence of drugs. Law 
enforcement recruited subjects within the detention centers based on clues of impairment. 
Subjects were incentivized by food, water, or a phone call to participate in the training. 
Participation was optional and completely anonymous. Officers used the 12-step DRE 
protocol to perform their examinations: 1) breath alcohol test, 2) interview of the 
arresting officer, 3) preliminary examination and first pulse, 4) eye examination, 5) 
divided attention psychophysical tests, 6) vital signs and second pulse, 7) dark room 
examinations, 8) examination of muscle tone, 9) check for injection sites and third pulse, 
10) subject’s statements and other observations, 11) analysis and opinions of the 
evaluator, and 12) toxicological examination (15). 
Urine Samples 
Urine was collected during the DRE examination from subjects using a 
MEDTOX® EZ-SCREEN® (Burlington, NC) cup, which presumptively screened for: : 
amphetamines (300 ng/mL), benzodiazepines (200 ng/mL), cocaine (100 ng/mL), 
methadone (200 ng/mL), methamphetamine (1000 ng/mL), opiates (100 ng/mL), 
oxycodone (100 ng/mL), phencyclidine (PCP) (25 ng/mL), and cannabinoids (40 ng/mL). 
Adequate volume was verified for each specimen. Cups were read within 15 min by field 
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instructor while DRE examinations were continued by trainees. Urine results were 
blinded to trainees until DRE opinions were rendered to instructor.  
Oral Fluid Specimens 
Quantisal devices were used to obtain oral fluid from subjects in accordance with 
a Sam Houston State University Institutional Review Board (IRB) approved protocol (# 
2017-11-37550). All subjects gave informed consent prior to collection. Oral fluid was 
collected during DRE examinations within 30 minutes of urine specimen collection. 
Samples were extracted and analyzed using validated methods (16,17). Oral fluid 
samples (1 mL) were fortified with internal standard and extracted using SPEware 
PolyChrom ClinII 3 cc (35 mg) (Baldwin Park, CA) solid phase extraction (SPE) 
cartridges. Briefly, samples were buffered (100 mM), loaded onto cartridges, then 
washed, and dried. For screening, basic drugs were eluted with 5% ammonium hydroxide 
in ethyl acetate. For confirmation, acidic and basic drugs were eluted with ethyl acetate 
and dichloromethane:isopropyl alcohol with 5% ammonium hydroxide, respectively. An 
Agilent 1290 Infinity liquid chromatograph coupled to an Agilent 6530 Accurate Mass 
Time-of-Flight mass spectrometer (LC-QTOF-MS) was used to screen samples for 
common drugs of abuse shown in Table 3.2 below.  
Table 3.2 Analytes included in PCDL categorized by DRE classification (n=64) 
DRE Classification Compounds 
CNS Depressant Alprazolam, Amytriptyline, Carisoprodol, 




CNS Stimulant Amphetamine, Caffeine, Cotinine, Cocaine, 
Methamphetamine, Nicotine, Pseudoephedrine 
Hallucinogens 25B-NBOMe, 25C-NBOMe, 25D-NBOMe, 25E-
NBOMe, 25H-NBOMe, 25I-NBOMe, 25N-NBOMe, 
LSD, MDMA, Mesc-NBOMe 
Narcotic Analgesics 4-ANPP, 6-AM, 7-hydroxymitragynine, 
Acetaminophen, Acetylfentanyl, AH-7921, Alfentanil, 
Buprenorphine, Butyrylfentanyl, Carfentanil, Cis-methyl 
fentanyl, Codeine, Fentanyl, Furanylfentanyl, Furanyl 
norfentanyl, Hydrocodone, Hydromorphone, Isobutyryl 
fentanyl, Meperidine, Mephedrone, Methadone, 
Mitragynine, Morphine, MT-45, N,N-didesmethyl-U-
47700, N-desmethyl-U-47700, Norcarfentanil, 
Norfentanyl, Oxycodone, Oxymorphone, Remifentanil, 
Sufentanil, U-47700, U-49900, U-50488, Valerylfentanyl 
Dissociative Anesthetics Dextromethorphan, Ketamine, PCP 
 
An Agilent 1290 Infinity II liquid chromatograph coupled to an Agilent 6470 
triple quadruple mass spectrometer was used to confirm and quantify heroin markers and 
buprenorphine. Oral fluid samples were fortified with a drug mixture at 0.1, 0.25, 0.5, 
1.0, 2.5, 10 and 100 ng/mL in three pooled sources assessed in duplicate over three days. 
The cutoff concentrations were determined to be: amphetamine (2.5 ng/mL), 
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methamphetamine (2.5 ng/mL), cocaine (0.25 ng/mL), morphine (1.0 ng/mL), 6-AM (1.0 
ng/mL), codeine (100 ng/mL), and methadone (0.25 ng/mL).” 
Limitations  
 Methods used in this study were optimized for the detection and quantification of 
synthetic opioids in order to monitor prevalence in populations (16,17). After sample 
collection and analysis, the authors felt that although no synthetics were detected, data 
aggregated from DRE examinations paired with oral fluid and presumptive urine results 
were important to disseminate to the forensic community. Cannabinoid use is prevalent 
as demonstrated by the presumptive urine cups. Although confirmatory testing would be 
preferred to further correlate matrices for the cannabis category, urine samples collected 
by the DRE training officers were promptly destroyed in line with their privacy protocol 
and oral fluid samples were consumed during analytical testing and therefore could not 
be analyzed externally. Further, THC was outside the analytical scope of the LC-MS 
method at the time of analysis.  
Results and Discussion 
The subjects were 23-54 years old and consisted of 11 males and 9 females. There 
were a total of 18 urine samples and 20 oral fluid samples collected and analyzed, as two 
subjects (08 and 16) withdrew from the DRE examinations and therefore urine specimens 
were not collected. Table 3.3 summarizes the drug classes detected in urine and oral 






Table 3.3 Toxicological findings paired with DRE opinion 
Sample Drugs Admitted to 
Using 




Cocaine, Methamphetamine, Opiate, 
THC 
Amphetamine, Cocaine,  
Methamphetamine,  
Morphine (145 ng/mL),  
6-AM (109 ng/mL) 
Narcotic Analgesics 
02 Speedballs and Ice Amphetamine, Benzodiazepine, 
Cocaine, Opiate 
Amphetamine, Cocaine, 
Codeine, Methamphetamine,  
Morphine (32.2 ng/mL) ,  
6-AM (15.2 ng/mL) 
Narcotic Analgesics 
03 Heroin Opiate Morphine Narcotic Analgesics 
04 Heroin Amphetamine, Cocaine, Opiate, THC Amphetamine, Codeine, 
Methamphetamine,  
Morphine (103 ng/mL) ,  
6-AM (6.8 ng/mL) 
Narcotic Analgesics 
05 Heroin and Meth Amphetamine, Cocaine, Opiate, THC Methamphetamine, 
Morphine (<LOQ),  
6-AM 
CNS Stimulant, CNS 
Depressant, Cannabis 








07 Max (Synthetic 
Cannabis) 





Sample Drugs Admitted to 
Using 
Urine Oral Fluid Evaluator Opinion 









10 LSD, Pot, and Meth Amphetamine, THC Amphetamine, Cocaine, 
Methamphetamine 
Cannabis 
11 Methadone, Heroin, 
Methamphetamine 

















Cocaine, Methamphetamine, THC 
Amphetamine, 
Methamphetamine 
CNS Stimulant, CNS 
Depressant, Cannabis 
14 Cocaine, Marijuana, 
Xanax 
Benzodiazepine, Cocaine, THC Cocaine CNS Stimulant, 
Cannabis 
15 Weed and K2 Amphetamine, Cocaine, THC Amphetamine, 
Methamphetamine 
CNS Stimulant, CNS 
Depressant, 
 Cannabis 







Cocaine, Opiate, Methadone 















*participant only provided oral fluid sample 
Sample Drugs Admitted to 
Using 
Urine Oral Fluid Evaluator Opinion 
19 Marijuana Benzodiazepine, Opiate, THC Cocaine, Morphine Alcohol, CNS 
Depressant, Narcotic 
Analgesics  
20 Heroin Cocaine, Opiate, THC Amphetamine, 
Methamphetamine, 
Morphine, 6-AM 




The evaluator opinion was confirmed in oral fluid 90% of the time, while 
confirmed in urine 85% of the time (within the scope of each test). In Figure 3.1, the 
pairing of oral fluid and urine positive identifications is depicted.  
 
Low limits of detection were not achieved for all compounds due to optimization 
of the method to different target analytes. However, the cutoffs presented are comparable 
to or lower than the urine screening system. Logan et al reports several recommended 
screening method cutoff values for various drugs in blood, urine, and oral fluid (18). The 
recommended cutoff values range from 10- 20 ng/mL in oral fluid for compounds 
investigated in the present study. While not all compounds have a recommended 
screening cutoff value, the LODs presented here are comparable to or lower than those 
recommended are. These achieved lower limits of detection ensure that proper 
identifications can be made in oral fluid. 





Of the 20 subjects, 9 admitted to using marijuana. With the presumptive 
urinalysis, 14 were positive for THC and the DRE identified cannabis intoxication for 7 
subjects. Positive urine results for THC does not necessarily indicate that the subject was 
under the influence at the time of the evaluation, since the detection window for urine is 
wide. The LC-MS methods used in this study were not optimized for the detection of 
cannabinoids, so THC was not detected in oral fluid. Although this study was not able to 
detect cannabinoids in oral fluid, previous studies have detected THC in screening device 
and confirmatory tests (19,20).  
CNS Stimulants  
Methamphetamine use was self-identified by 9 of the 20 subjects, with 5 positive 
identifications of methamphetamine in urine and 16 positive identifications in oral fluid 
as seen in Figure 1. Amphetamine was detected in 13 of the urine samples and in 14 of 
the oral fluid samples. Differences in detection rates can be attributed to differences in 
detection windows between the two matrices. The two subjects that did not complete 
DRE examinations tested positive for methamphetamine and amphetamine, which also 
contributes to the differences in detection rates as there were no paired urine specimens. 
There were two subjects that admitted to using cocaine, while 11 were positive in urine 
samples and 6 positives in oral fluid. The discrepancy between the oral fluid and urine 
results could be attributed to the target analyte of the urine cup (benzoylecgonine) which 
has a longer detection window in urine.  
A total of 15 subjects were positive for at least one or more CNS stimulant in 




intoxication for 8 subjects. Poly-drug use could cause some impairment clues to mask 
others (21). In Table 3.4, a summary of DRE examinations is shown, which includes 





Table 3.4 Vitals, nystagmus, psychophysical tests, and physical response for subjects 
      BP=Blood Pressure, HR=Heart Rate, BPM=Beats Per Minute, HGN= Horizontal Gaze Nystagmus 
 
 Vitals         









Turn One Leg Stand 
Modified Romberg 
Balance  Muscle 
Tone Pupil Size 
Reaction 
to 











01 95.9 110/58 45 No None 4 2 2 72 3 Flaccid Normal Slow 
02 96.9 130/72 81 No None 2 3 4 39 2 Flaccid Normal Slow 
03 97.7 118/70 79 No None 2 2 1 58 2 Normal  Normal Normal 
04 98.7 124/78 73 No None 2 2 0 28 2 Flaccid Normal  Normal 
05 99.4 108/70 93 Yes Present 3 2 2 18 2 - Dilated  Slow 
06 98.2 138/100 76 No None 3 2 1 25 2 Rigid Dilated Normal 
07 97.8 138/74 73 No None 3 0 2 47 2 Normal Normal Slow 
09 99.8 150/92 127 No Present 1 1 3 25 2 Flaccid Dilated Normal 
10 98.6 118/72 82 No None 2 0 3 44 - Flaccid Normal Normal 
11 98.5 118/76 69 Yes Present 2 2 2 22 1 Rigid Normal Normal 
12 96.0 122/80 63 No Present 3 3 2 25 3 Flaccid Constricted Little 
13 97.3 144/92 103 Yes Present 4 1 1 14 2 Flaccid Dilated Slow 
14 97.0 142/78 65 No None 6 2 4 30 - Rigid Dilated  Normal 
15 97.0 152/104 94 Yes Present 3 3 4 51 2 Flaccid Dilated Slow 
17 97.6 112/72 60 Yes Present 3 2 3 19 2 Flaccid Normal Normal 
18 98.0 150/110 81 No None 4 2 1 33 3 Flaccid Normal Little 
19 96 98/66 76 Yes Present 5 3 3 90 3 Flaccid - - 




An example of poly-drug use with masking clues is Subject 01. He demonstrated 
low average heart rate (45 beats per minute, BPM), slowed estimation of time (72 s to 
estimate the passage of 30 s), pupils with slow reaction to light, and flaccid muscle tone. 
All of these clues are indicative of being under the influence of narcotic analgesics, but in 
both urine and oral fluid, cocaine and methamphetamine were present along with narcotic 
analgesics. Depending on time administered, one drug may have greater effect on 
subject’s behavior during the time of evaluation. Subject 09 presented multiple clues of 
being under the influence of a CNS stimulant: elevated blood pressure (150/92) and heart 
rate (127 BPM), fast estimation of 30 s (25 s), and dilated pupils.    
Narcotic Analgesics 
The use of heroin or “speedballs” was admitted by 7 of the subjects, while there 
were 9 positive identifications of opiates in urine and 8 positive results of morphine or 6-
acetylmorphine (6-AM) in oral fluid. Quantitative concentrations of morphine and 6-AM 
for Subjects 01, 02, and 04 were assessed. Morphine concentrations were 145 ng/mL, 
32.2 ng/mL, and 103 ng/mL, respectively. Corresponding 6-AM concentrations were 109 
ng/mL, 15.2 ng/mL, 6.8 ng/mL, respectively. There were 3 subjects that admitted to 
using methadone, while 2 were positive in both urine and oral fluid. A total of 10 narcotic 
analgesics (opiates and methadone) were identified in both urine and oral fluid. In one 
case, the DRE indicated narcotic analgesics but was not confirmed by either urine or oral 
fluid. For Subject 18, signs of stimulant use were present such as high blood pressure 
(150/110), but the only sign of narcotic analgesic was flaccid muscle tone and a “little” 





CNS Depressants  
Self-reported use of Xanax was indicated by 3 subjects and 9 subjects were 
positive for benzodiazepines in urine. The LC-MS screening method was not optimized 
for benzodiazepines, so these cases were not confirmed in oral fluid. The evaluators 
called CNS depressant for 6 of the subjects and were confirmed in urine in 4 subjects. 
Subject 15 presented with clues of CNS stimulant impairment, but also had flaccid 
muscle tone and slow reaction to light. However, oral fluid and urine results were 
positive for CNS stimulants and cannabis. Subject 05 also showed clues of CNS 
stimulant impairment accompanied with flaccid muscle tone and slow reaction to light. 
Oral fluid and urine were positive for CNS stimulants, narcotic analgesics, and cannabis. 
It is possible that the evaluator misinterpreted the presence of a narcotic analgesic as a 
CNS depressant.   
Hallucinogens, Inhalants, and Dissociative Anesthetics 
Only one subject admitted to taking a hallucinogen (LSD) but could not be 
confirmed in oral fluid or urine as it was outside the scope of both methods. A 
hallucinogen was only identified by the evaluator for Subject 17, along with CNS 
depressants and narcotic analgesics. This subject demonstrated signs of poly-drug 
intoxication and fell asleep while providing the oral fluid sample. This subject was 
positive for every panel except oxycodone on the EZ-Screen urine cup. The interaction of 
multiple drugs may have been incorrectly interpreted as hallucinogen intoxication or 
perhaps a drug was missed by the toxicological testing due to limitations of both 
analytical tests. No inhalants were detected in either matrix and inhalant impairment was 




anesthetic PCP was identified in Subject 17’s urine sample but signs of impairment from 
that drug were not observed by the DRE.  
Conclusion 
Given the analytical scope of the LC-MS methods (excluding CNS depressants 
and cannabis), there were 20 identifications of drug class impairment in 18 subjects. The 
evaluator opinion was confirmed with oral fluid results in 18/20 occurrences (90%). In 
urine, there were 33 separate identifications of drug class impairment that were 
confirmed in 28 instances of DRE opinion for 18 subjects (85%). Differences in 
confirmation rates can be attributed to extended detection window of urine and the lack 
of experience by the officers due to training environment. As is the difficulty with NPS, 
synthetic drug use may be missed or misinterpreted by DRE examination. As such, 
Subject 07 admitted to using “Max” (a synthetic cannabinoid) but cannabis impairment 
was indicated by the officer. Synthetic cannabinoids may present as a variety of drug 
impairment types but were outside the scope of both the urine and oral fluid tests. 
Overall, toxicological results between urine and oral fluid paired with DRE evaluations 
were comparable. Data, while limited, add to the growing amount of literature that oral 
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Purpose: The objective of this study was to develop, optimize, and validate a 
method for the simultaneous quantification of U-47700, AH-7921, U-49900, U-50488, 
MT-45, W-18, and W-15 in whole blood using liquid chromatography – tandem mass 
spectrometry (LC – MS/MS). 
Methods: Blood samples (500 µL) were fortified with mixed calibrator or quality 
control (25 µL) and internal standard (10 µL) solutions. Analytes were isolated via a solid-
phase extraction procedure. Analysis was performed using an Agilent 1290 Infinity II 
liquid chromatograph coupled to an Agilent 6470 triple quadrupole mass spectrometer.  
The method was validated in accordance with Scientific Working Group for Forensic 
Toxicology (SWGTOX) standard practices for method validation in forensic toxicology 
and applied to the analysis of postmortem blood specimens. 
Results: Lower limits of quantification were 0.25-1 ng/mL and the upper limits of 
quantification were 100 ng/mL. The coefficients of determination (R2) for the calibration 
curves were >0.99. Analytical bias, within-run imprecision, and between-run imprecision 
were within ±15%, ≤16%, and ≤17%, respectively. All analytes were found to be stable at 
room temperature for 24 h, refrigerated (4°C) for 72 h, and in the autosampler (4°C) for 72 
h. Authentic blood samples (n=30) were analyzed using the validated method. Mean 
(range) U-47700 concentrations were 214 (3.2 – 1448) ng/mL in 15 cases.  
Conclusions: A quantification method for seven synthetic opioids (U-47700, AH-
7921, U-49900, U-50488, MT-45, W-18, and W-15) in whole blood was developed, 




validation in forensic toxicology. This sensitive method was successfully applied to 
postmortem casework.  
 






The growing opioid epidemic has been classified by the U.S. Department of Health and 
Human Services as a public health emergency. Opioid abuse has been on the rise for almost 
two decades, with overdose deaths increasing from 8,050 to 33,091 between 1999 and 2015 
according to a report by the Center for Disease Control and Prevention (CDC) (1). The 
increase in fatal opioid overdoses is primarily attributed to deaths involving synthetic 
opioids other than methadone, which according to the CDC, increased by 100% between 
2015 and 2016 (2).  
Numerous synthetic opioids developed in the 1970s and 1980s for their potential 
medical use, including U-47700, AH-7921, U-49900, U-50488, MT-45, W-18, and W-15, 
have recently reemerged as drugs of abuse. The Upjohn Company developed U-47700, U-
49900, and U-50488 for their potential use in pain relief in the 1970s. U-47700, a μ- and 
κ-opioid receptor agonist, possesses a potency approximately 7.5 times greater than 
morphine (3, 4). U-50488 acts as an agonist on the κ-opioid receptor (5). AH-7921 was 
developed in 1976 by Allen and Handburys Ltd. for its analgesic properties. AH-7921, a 
μ- and κ-opioid receptor agonist, is equipotent with morphine (3, 6). Dainippon 
Pharmaceutical Co. Ltd. developed MT-45 for use as an analgesic and anti-inflammatory 
in the 1970s. MT-45, a μ-, κ-, and δ-opioid receptor agonist, is equipotent with morphine 
(6, 7). In the 1980s, a university in Canada developed a W-series of opioids, including W-
18 and W-15 for their potential as analgesics (8). However, these compounds were each 
abandoned before advancing to clinical trials. 
Overdoses have already been reported in the literature involving many of these 




involving U-49900, U-50488, W-18, and W-15 could be forthcoming due to their 
increasing popularity. The numerous deaths and potential dangers associated with these 
synthetic opioids, have led many countries including the U.S. to schedule these drugs as 
controlled substances. Currently, U-47700, AH-7921, and MT-45 are classified by the 
Drug Enforcement Administration as Schedule I controlled substances.  
The rise in abuse of these synthetic opioids in combination with many scheduled as 
controlled substances has led to an increased need for analytical methods. Lack of 
inexpensive and simplistic analytical methods available for synthetic opioids could be 
contributing to delayed toxicological analysis and under-identification (22). The current 
analytical methods existing for these synthetic opioids are limited, but methods have been 
reported for U-47700, AH-7921, U-50488, MT-45, and W-18 (3, 7, 12, 17-19, 23-24). To 
our knowledge, methods have not yet been reported for the simultaneous quantification of 
these synthetic opioids or for the quantification of W-18 or W-15 in blood.  
 
This study focuses on the development, optimization, and validation of a 
quantification method for seven synthetic opioids, U-47700, AH-7921, MT-45, W-18, W-




15, U-49900, and U-50488 (Figure 4.1) in whole blood. This method requires minimal 
sample preparation prior to the isolation of these synthetic opioids via solid-phase 
extraction (SPE). Analysis is performed using liquid chromatography – triple quadrupole 
mass spectrometry (LC – MS/MS). This study provides an efficient, comprehensive 
method for the quantification of these seven synthetic opioids in whole blood.  
Materials and Methods 
Materials 
U-47700, U-49900, U-50488, MT-45, W-18, W-15, U-47700-d6, MT-45-d11, and W-18-d4 
were acquired from Cayman Chemical Company (Ann Arbor, MI, USA). AH-7921 was 
purchased from Cerilliant Corporation (Round Rock, TX, USA). Cerex® Clin II (3 mL, 35 
mg) SPE columns were acquired from Tecan (Baldwin Park, CA). Blank matrix 
(defibrinated bovine blood) was obtained from Quad Five (Ryegate, MT, USA). De-
identified, postmortem samples from adjudicated cases were received from National 
Medical Services (NMS) Labs under a Sam Houston State University Institutional Review 
Board (IRB) approved protocol. 
Ultrapure water was prepared via a Millipore Direct-Q® 3 UV Water Purification 
System (Billerica, MA, USA). Common chemicals used were of the highest purity 
commercially available. 
Instrumentation 
SPE utilized a CEREX-48 positive-pressure manifold (SPEware Corporation, Baldwin 
Park, CA). Evaporation by nitrogen gas was performed with a Caliper Life Sciences 
TurboVap® LV concentration workstation (Hopkinton, MA, USA). Analytes were 




triple quadrupole mass spectrometer (Santa Clara, CA, USA). Data were acquired using 
Agilent MassHunter Workstation version B.07 software.  
Preparation of Standards 
Individual analyte stock solutions (100,000 ng/mL) were prepared in methanol. Mixed 
analyte calibrator and quality control (QC) solutions were prepared from individual analyte 
stock solutions in methanol. The calibrators were fortified at 0.25, 1, 5, 10, 25, 50, 100 
ng/mL for U-47700, AH-7921, U-49900, U-50488, MT-45, and W-15 and 1, 5, 10, 25, 50, 
100 ng/mL for W-18 in blood. The low, medium, and high QC samples were fortified in 
blood at 0.75 (2.5 ng/mL for W-18), 20, and 80 ng/mL for U-47700, AH-7921, U-49900, 
U-50488, MT-45, W-18 and W-15, respectively. A mixed internal standard (ISTD) 
solution was prepared in methanol, resulting in 20 ng/mL for U-47700-d6, MT-45-d11, and 
W-18-d4 when fortified into blood. All standard solutions were stored in amber vials at -
20°C. 
Sample Preparation and Extraction 
Blank blood (500 µL) was fortified with mixed calibrator or QC solution (25 µL) and ISTD 
solution (10 µL). Blood samples were buffered with 100 mM pH 6 phosphate solution (2.5 
mL), vortex mixed, and transferred onto SPE columns. SPE column washes and elutions 
were performed with each 2 mL volume. SPE columns were washed with deionized water, 
1 M acetic acid, dried under positive pressure (5 min), and washed with hexane. Acidic 
and neutral analytes were eluted with ethyl acetate. A methanol wash was performed prior 
to the elution of basic analytes with dichloromethane/isopropanol (80/20, v/v) with 5% 
ammonium hydroxide. Combined elutions were evaporated under nitrogen at 50 °C, 




(3500 rpm, 5 min). Samples were transferred to autosampler vials and injected onto the LC 
– MS/MS (5 µL).   
Liquid Chromatography 
Analyte separations were performed on an Agilent Poroshell 120 EC-C18 column (100 x 
2.1 mm i.d., particle size 2.7 µm) with matching guard (5 x 2.1 mm, 2.7 µm) using a 
gradient elution at 0.5 mL/min. The gradient of 0.05 % formic acid with 5 mM ammonium 
formate in water (A) and 0.1 % formic acid in acetonitrile (B) was increased from 20 % to 
50 % B over 5 min, increased to 90 % B over 2 min, held for 2 min, decreased to 20 % B 
over 0.10 min, and re-equilibrated for 1.90 min. The column oven was held at 40 °C.  
Mass Spectrometry 
Ion source parameters were optimized using Agilent MassHunter Source Optimizer 
software. Nitrogen drying gas temperature and flow rate were 350 ℃ and 13 L/min, 
respectively. Nebulizer pressure was 45 psi. Ultrapure nitrogen sheath gas temperature and 
flow were 350 ℃ and 12 L/min, respectively. Capillary voltage was 4500 V, and nozzle 
voltage was 500 V. Data were acquired in dynamic multiple reaction monitoring mode via 
positive electrospray ionization. A minimum of two transitions optimized by Agilent 








Table 4.1 Optimized liquid chromatography-tandem mass spectrometry parameters for 
U-47700, AH-7921, U-49900, U-50488, MT-45, W-18, W-15, and internal standards, U-


















U-47700 329.2 172.9 37 117 2.738 U-47700-d6 
 329.2 144.9 61 117   
AH-7921 329.2 144.9 57 107 2.987 U-47700-d6 
 329.2 46.2 21 107   
U-49900 357.1 172.9 37 120 3.263 U-47700-d6 
 357.1 144.9 65 120   
U-50488 369.1 158.9 49 115 3.665 U-47700-d6 
 369.1 112.1 37 115   
MT-45 349.5 181.0 20 112 4.511 MT-45-d11 
 349.5 77.1 93 112   
W-18 422.1 111.0 50 153 6.392 W-18-d4 
 422.1 75.1 50 153   
W-15 377.1 111.0 41 145 6.640 W-18-d4 
 377.1 75.1 97 145   
U-47700-
d6 
335.2 172.9 37 112 2.733 - 
 335.2 144.9 57 112   
MT-45-
d11 
360.5 181.0 20 132 4.491 - 
 360.5 77.1 93 132   
W-18-d4 426.1 115.0 53 143 6.391 - 






Method validation was performed in accordance with the Scientific Working Group for 
Forensic Toxicology (SWGTOX) standard practices for method validation in forensic 
toxicology (25). Calibration model was evaluated from non-zero calibrators (≥6) over 5 
runs. Limit of detection (LOD) and lower limit of quantification (LLOQ) were each 
evaluated in 3 blood sources in duplicate over 3 runs. LOD retention time (within ±10% of 
calibrators), peak shape, mean signal to noise ratio (>10), and ion ratios (within ±20% of 
calibrators) were monitored. LOD imprecision was calculated from the mean relative 
response. LLOQ bias and imprecision were each evaluated from the calculated 
concentrations in addition to meeting or exceeding LOD criteria. Bias and imprecision 
were assessed at three QC concentrations in triplicate over 5 runs as target concentration 
(%) and coefficient of variation (CV) (%), respectively.  
Carryover was evaluated by analyzing a negative sample (ISTD only) directly 
following a high calibrator over 5 runs. Low QC samples were fortified with common drugs 
of abuse (n = 32) to assess interferences (Table 4.2).  
 
Table 4.2 Common drugs of abuse for interference studies 
Alprazolam Amobarbital Amphetamine Amitriptyline  
Butalbital Caffeine Carbamazepine Carisoprodol  
Cocaine Codeine Cotinine Cyclobenzaprine  
Dextromethorphan Diazepam Diphenhydramine Hydrocodone  
Hydromorphone Ketamine Methadone Nicotine  
Nordiazepam Oxazepam Oxycodone Pentobarbital  








Ionization suppression and enhancement and extraction recovery were evaluated 
from pre-extraction and post-extraction addition of six blood sources fortified at low and 
high QC concentrations (26). Ionization suppression and enhancement were calculated as 
the ratio of the mean area of post-extraction fortified samples to neat samples, minus one, 
as a percentage. Extraction recovery was determined as the percentage of the ratio of the 
mean area of pre-extraction to post-extraction fortified samples.   
Dilution integrity (1:10) was evaluated at 2.5 times the high QC concentration in 
duplicate. Analyte stability was assessed in fortified blood at low and high QC 
concentrations in triplicate at room temperature (20 °C) for 24 h and 4°C for 72 h, as well 
as extracted samples in the refrigerated autosampler (4 °C) for 72 h. Bias and imprecision 
were assessed by comparing mean concentrations of fresh QC samples to mean 
concentrations at the various conditions for fortified stability and to mean initial (t0) 
concentration for the processed sample stability. 
Postmortem Samples 
A total of 30 postmortem blood samples were received in the absence of 
demographic or case information. Due to the viscosity of postmortem samples, an 
additional centrifugation step was added to sample preparation before loading onto the 
SPE columns to prevent clogging. Samples (500 µL) were fortified with ISTD and 
extracted as described with calibrators and QC samples. Dilutions, when needed, were 
prepared using blank whole blood.   
Results and Discussion 
Optimization of the extraction method involved the assessment of various 




acetate/acetic acid (49:49:2, v/v/v), and n-butyl chloride) and basic (2% ammonium 
hydroxide in ethyl acetate, and 5% ammonium hydroxide in dichloromethane/isopropanol 
(80/20, v/v) ) elution solvents, the addition of a dichloromethane wash, and the evaluation 
of various wash and elution volumes. The final extraction method achieved improved 
matrix effects and extraction efficiency, particularly for the analytes eluting in the 
acidic/neutral fraction (W-18 and W-15) (27). Chromatography optimization included the 
addition of ammonium formate to the aqueous mobile phase, which resulted in improved 
peak shape and response for W-18 and W-15.  
LODs, LLOQs, upper limits of quantification (ULOQ), and coefficients of 





Table 4.3 Limit of detection (LOD), lower limit of quantification (LLOQ), upper limit of quantification (ULOQ), and mean y-









(mean ± SD, n = 5) 
Slope 
(mean ± SD, n = 5) 
R2 
(range, n = 5) 
U-47700 0.125 0.25 100 0.0009 ± 0.0007 0.0510 ± 0.0045 0.9967-0.9996 
AH-7921 0.125 0.25 100 -0.0010 ± 0.0015 0.0344 ± 0.0029 0.9957-0.9999 
U-49900 0.125 0.25 100 -0.0004 ± 0.0017 0.0434 ± 0.0037 0.9971-0.9999 
U-50488 0.125 0.25 100 -0.0004 ± 0.0007 0.0138 ± 0.0011 0.9968-0.9996 
MT-45 0.125 0.25 100 0.0012 ± 0.0017 0.0648 ± 0.0046 0.9942-0.9996 
W-18 0.25 1 100 0.0005 ± 0.0122 0.0767 ± 0.0073 0.9982-0.9996 





LODs were 0.125 ng/mL (U-47700, AH-7921, U-49900, U-50488, MT-45, and W-
15) and 0.25 ng/mL (W-18). LLOQs were 0.25 ng/mL (U-47700, AH-7921, U-49900, U-
50488, MT-45, and W-15) and 1.0 ng/mL (W-18). Calibration curves were comprised of 
seven non-zero calibrators (U-47700, AH-7921, U-49900, U-50488, MT-45, and W-15) 
and six non-zero calibrators (W-18). SWGTOX requires a minimum of six non-zero 
calibrators be used, which was met for each analyte in this method. AH-7921, U-49900, 
U-50488, W-18, and W-15 utilized linear calibration models with 1/x weighting, while U-
47700 and MT-45 necessitated 1/x2 weighting. The calibration curves were considered 
acceptable with all R2 >0.99. 
Recent methods for U-47700 have LLOQs of 1, 1.6, and 312.5 ng/mL (3, 11, 17). 
A method reported for AH-7921 obtained an LLOQ of 10 ng/mL (21). Methods for U-
50488 and MT-45 each reported an LLOQ of 1 ng/mL (7, 17). This method achieved 
LLOQs of 0.25 ng/mL for each analyte, except W-18 (1.0 ng/mL) (Table 4.3). The 
increased sensitivity of this method could potentially be used to quantify low levels of these 









The LOD relative peak area imprecision (≤18.6%) and mean signal to noise (≥10.6) 
demonstrated acceptable reproducibility and analyte response. LLOQ demonstrated 
acceptable bias and imprecision which were within ±16.9% and ≤13.7% CV, respectively. 
Representative chromatograms for each analyte at their LLOQs are represented in Figure 
4.2 above. This method met acceptable bias for three QC concentrations, which were each 
within ±14.5% (Table 4.4). Within-run and between-run imprecisions met acceptable 





Figure 4.2 Multiple reaction monitoring chromatograms for quantifying 
transitions for a U-47700, b AH-7921, c U-49900, d U-50488, e MT-45, f W-18, 
and g W-15 at their LLOQs (0.25 ng/mL for U-47700, AH-7921, U-49900, U-




Table 4.4 Bias results at three quality control (QC) concentrations for U-47700, AH-
7921, U-49900, U-50488, MT-45, W-18, and W-15 
Analyte 
Bias 
(%, n = 15) 
Lowa Medb Highc 
U-47700 -12.6 -0.8 2.1 
AH-7921 -8.9 -1.5 0.6 
U-49900 -11.6 -0.5 2.4 
U-50488 -7.1 -0.8 2.8 
MT-45 -14.5 2.0 3.2 
W-18 -13.0 3.1 2.6 
W-15 -12.1 5.8 3.8 
aLow concentration: 0.75 ng/mL for U-47700, AH-7921, U-49900, U-50488, MT-45, and 
W-15, 2.5 ng/mL for W-18 
bMed concentration: 20 ng/mL for U-47700, AH-7921, U-49900, U-50488, MT-45, W-18, 
and W-15 
cHigh concentration: 80 ng/mL for U-47700, AH-7921, U-49900, U-50488, MT-45, W-18, 
and W-15 
 
Table 4.5 Imprecision at three QC concentrations for U-47700, AH-7921, U-49900, U-
50488, MT-45, W-18, and W-15 
Analyte 
Imprecision 






Lowa Medb Highc Lowa Medb Highc Lowa Medb Highc 
U-47700 3.8 5.8 7.7 7.7 9.1 13.7 5.5 11.4 8.2 
AH-7921 4.5 4.3 7.8 6.4 9.1 15.8 5.5 10.7 8.4 
U-49900 5.2 5.9 7.5 9.0 9.4 15.5 6.2 11.9 7.7 
U-50488 3.0 5.4 7.3 7.0 9.5 16.0 7.8 10.9 7.8 












Lowa Medb Highc Lowa Medb Highc Lowa Medb Highc 
W-18 4.8 6.0 6.7 9.3 9.9 11.9 5.9 16.1 8.9 
W-15 7.6 5.5 7.7 13.0 9.1 12.3 8.5 15.2 10.1 
 
Carryover was negligible with analyte responses from carryover experiments <20% 
of the LOD. The extracted low QC samples fortified with various interferences were 
accurately quantified within ±19.9%. Therefore, interference from 32 common drugs of 
abuse (Table 4.2) was insignificant. Endogenous interferences were undetected in three 
different blank blood sources and no significant peaks for the analytes of interest were 
observed in negative (ISTD only) samples.  
Ionization suppression and enhancement for each analyte (±20.8%) met acceptable 
criteria, except for U-50488 low QC (28.4%) (Table 4.6). Although ionization suppression 
and enhancement exceeded requirements, reproducibility was demonstrated between 6 
blood sources (≤12.4% CV). Extraction recoveries (62.6-96.6%) were comparable between 
analytes and their matched deuterated ISTDs (Table 4.6). For analytes with no 
commercially available deuterated ISTD, the ISTD with the closest matrix effects, 
extraction elution fraction, and extraction recovery was chosen and met acceptable criteria 





Table 4.6 Ionization suppression and enhancement and extraction efficiency results for 
U-47700, AH-7921, U-49900, U-50488, MT-45, W-18, W-15, U47700-d6, MT45-d11, 




(%, n = 6) 
Extraction Efficiency  
(%, n = 6) 
Lowa Highb Lowa Highb 
U-47700 12.7 1.5 88.1 92.0 
AH-7921 19.7 -2.7 80.3 88.2 
U-49900 6.6 -1.3 88.0 89.3 
U-50488 28.4 -2.9 85.2 91.2 
MT-45 7.9 -3.4 78.5 85.9 
W-18 11.8 4.8 63.1 66.5 
W-15 15.4 12.7 72.3 72.5 
U47700-d6 8.8 10.8 86.0 96.6 
MT45-d11 10.8 11.0 76.4 88.3 
W18-d4 15.9 20.8 62.6 67.6 
aLow concentrations: 0.75 ng/mL for U-47700, AH-7921, U-49900, U-50488, MT-45, and 
W-15; 2.5 ng/mL for W-18 
bHigh concentrations: 80 ng/mL for U-47700, AH-7921, U-49900, U-50488, MT-45, W-
18, and W-15 
 
Dilution integrity samples fortified at 2.5 times the high QC were accurately 
quantified (±17.1%), with the exception of W-18 (-23.8%). All analytes were found to be 
stable under each condition assessed: 24 h room temperature (-7.9 to 7.3%), 72 h at 4°C (-





Table 4.7 Bias results for the stability of U-47700, AH-7921, U-49900, U-50488, MT-




24 h room temp.  
(%bias, n = 3) 
 72 h 4°C  
(%bias, n = 3) 
 72 h autosampler  
(%bias, n = 3) 
Lowa Highb  Lowa Highb  Lowa Highb 
U-47700 7.3 -2.0  -7.9 -11.5  -1.6 -3.3 
AH-7921 -7.8 -0.3  -10.7 -10.9  -3.8 0.0 
U-49900 6.9 0.8  -7.9 -10.5  1.5 -1.7 
U-50488 7.0 3.0  -11.2 -9.5  -1.6 -1.1 
MT-45 -7.9 -6.8  -12.1 -16.8  -0.4 -0.9 
W-18 7.1 -2.8  0.2 -15.2  0.3 1.3 
W-15 3.7 0.9  -2.1 -10.8  -1.1 1.2 
aLow concentrations: 0.75 ng/mL for U-47700, AH-7921, U-49900, U-50488, MT-45, and 
W-15, 2.5 ng/mL for W-18 
bHigh concentrations: 80 ng/mL for U-47700, AH-7921, U-49900, U-50488, MT-45, W-
18, and W-15 
 
Of the 30 postmortem samples, 15 were positive for U-47700 (Table 4.8). These 
samples were received without any temperature preservation and were exposed to extreme 
Texas temperatures for >8 h. Due to this, drug concentrations may have been affected. U-
47700 concentrations ranged from 3.2-1450 ng/mL with median and mean of 109 and 214 
ng/mL, respectively. 
Table 4.8 Concentrations of U-47700 in postmortem blood samples 
Sample  Source (blood) U-47700 concentration (ng/mL) 
1 Cardiac  1450a  
2 Peripheral ND 
3 Subclavian ND 




Sample  Source (blood) U-47700 concentration (ng/mL) 
5 Femoral  ND 
6 Peripheral ND 
7 Peripheral 133b 
8 Cardiac  ND 
9 Not Specified  190b 
10 Peripheral ND 
11 Iliac  425b 
12 Femoral ND 
13 Iliac 36.0 
14 Femoral ND 
15 Cardiac  ND 
16 Peripheral ND 
17 Peripheral 3.2 
18 Femoral 4.2 
19 Peripheral ND 
20 Cardiac 354b 
21 Femoral  ND 
22 Iliac 60.6 
23 Femoral 101 
24 Femoral ND 
25 Femoral 43.1 
26 Femoral ND 
27 Femoral 53.7 
28 Femoral 118b 
29 Femoral ND 
30 Iliac 109b 
ND not detected 
a One hundred-fold dilution 
b Ten-fold dilution 
 
 The concentration from Sample 1 (1450 ng/mL) is comparable to the concentration 
found in Elliot et al (11), although the blood source for that sample was peripheral blood 
while this sample was from cardiac blood (8). It can be anticipated that if a peripheral blood 
sample was paired with the cardiac sample of Sample 1, the concentration could be lower 
due to the “modest potential” of postmortem redistribution determined by McIntyre et al 
(15).  All of our U-47700 concentrations were comparable to those reported in previous 




ranging from 0.090-1460 ng/mL (3, 11, 14-17, 28), while driving intoxication cases were 
3.4-16 ng/mL (29). Cases in which fentanyl analogs were also detected, were reported to 
have U-47700 concentrations from 0.090-490 ng/mL. While not detected in these samples, 
AH-7921 and MT-45 blood concentrations in fatalities were 330-9100 ng/mL (18, 20, 21) 
and 520-2900 ng/mL (7, 21), respectively. The linear range of this method is sufficiently 
low for the detection of these analytes in the majority of the reported cases. For cases with 
unexpectedly high concentrations, dilution was assessed and met acceptable criteria and 
would be useful for quantification in those scenarios as well. Therefore, this method is 
applicable for the analysis of novel synthetic opioids (NSO) in acute and fatal intoxication 
cases. 
Conclusions 
A comprehensive method for the quantification of U-47700, AH-7921, U-49900, 
U-50488, MT-45, W-18, and W-15 in blood using LC-MS/MS was successfully 
developed, optimized, and validated. To our knowledge, this is the first quantification 
method reported for W-18 and W-15 in blood. This method required minimal sample 
preparation and achieved increased sensitivity as compared to previously reported 
studies. Applications of this method include analyses of NSO driving intoxication and 
fatal intoxication cases.  
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Recently, there has been an increase in overdose deaths due to novel synthetic 
opioids (NSO). Due to backlogs experienced by many forensic laboratories, it is 
important to understand drug stability in a variety of storage conditions. The objective of 
this study was to investigate the stability of AH-7921, U-47700, U-49900, U-50488, MT-
45, W-15, and W-18 in blood at various temperatures over a 36-week period. NSO were 
generally stable over the 36-week period (66%-118%) at low and high concentrations 
when blood samples were stored in the refrigerator or freezer. Most analytes were stable 
for at least 2 weeks at room temperature (77%-120%). At the elevated temperature 
(35°C), analytes were generally stable for at least 14 days (75%-109%). This study has 
determined the stability of several NSO at various temperatures over a 36-week period. 
These results reflect the forensic significance of keeping samples stored at proper 
temperatures. Blood samples suspected to contain synthetic opioids should be stored 
refrigerated or frozen, when possible, in order to preserve analyte stability, especially at 
low concentrations. 







Novel psychoactive substances (NPS) have had detrimental impact on drug abuse 
worldwide. Under the umbrella of NPS, novel synthetic opioids (NSO) have emerged as 
fentanyl and non-fentanyl derivatives. According to United Nations Office on Drugs and 
Crime (UNODC), there were 62 different synthetic opioids reported to their Early 
Warning Advisory (EWA) by 2019, resulting in a 110% increase from the previous three 
years (1). Between 2016 and 2017, there were over 28,000 synthetic opioid related 
overdose fatalities in the United States (2). During the same period of time, there were 
over 15,000 overdose deaths involving heroin in the United States as well.  These 
synthetic opioids have the potential to be dangerously more potent than natural opioids.   
NSO such as U-47700, MT-45, and AH-7921 are just a few compounds that have 
emerged in casework across the nation. U-47700 is part of the U-series of drugs 
developed by the Upjohn Company in the 1970’s. Other compounds in the U-series 
include U-49900 and U-50488. While there are very few reports involving U-49900 and 
U-50488 (3-5), U-47700 has been involved in numerous fatalities and intoxications (3,6-
15).  The stereoisomer of U-477700, AH-7921, and MT-45 have also been associated 
with fatalities and intoxications (16-21). The W-series was developed in the 1980s by the 
University of Alberta and consisted of 32 compounds, including W-18 and W-15. There 
is minimal information available about these compounds. Recently, a report in Belgium 
had identified a heroin-like powder to contain W-18 (22). Structures of the seven NSO 





Figure 5.1 Structures of seven novel synthetic opioids 
While long-term stability studies are limited for these NSO, some analytes have 
been evaluated in various conditions. Mohr et al evaluated the stability of two of the U-
series drugs, U-47700 and U-50488, when performing a fit for purpose validation (3). 
Two concentrations (5 ng/mL and 80 ng/mL) in blood were evaluated at refrigerated and 
frozen temperatures over 10 days. It was concluded that both analytes were stable over 
the 10 days at both temperatures. Stability of both of these analytes along with other 
fentanyl derivatives was also evaluated by Qin et al (23). Stability was assessed at three 
concentrations (0.2 ng/mL, 5 ng/mL, and 30 ng/mL) in whole blood at four different 
conditions: 1 month in the freezer, 3 freeze/thaw cycles, 24 hr at 4°C, and 24 hr at room 
temperature. At all four conditions and at the three concentrations, both analytes 
remained stable.  U-47700 was also evaluated by Rojek et al at 25 ng/mL in three 
different temperatures (-30°, 3°C and 20°C) for 21 days in blood (13). It was observed 
that U-47700 was stable over the 21 days, even at the ambient temperature of 20°C. 
Similarly, the stereoisomer of U-47700 (AH-7921) was found to be stable at a higher 
concentration (2,000 ng/mL) at room temperature (20-23°C) for 28 days in blood and 
plasma (24). Papsun et al evaluated MT-45 stability in fortified blood and determined 




(20). Case samples from this experiment (blood, urine, bile, and vitreous humor) were 
also retested approximately 12 months after original testing and MT-45 concentrations 
had degraded by approximately 50%. However, this degradation could not be determined 
and may be due to the nature of the authentic sample.  
Due to backlogs experienced by many forensic laboratories, it is important to 
understand drug stability in a variety of storage conditions. In this study, the goal was to 
investigate the stability of AH-7921, U-47700, U-49900, U-50488, MT-45, W-15, and 
W-18 in blood at various temperatures over 36 weeks. 
Materials and Methods  
Chemicals and Reagents  
All standards and deuterated internal standards: MT-45, U-47700, U-49900, U-
50488, W-15, W-18, U-47700-d6, MT-45-d11 and W-18-d4 were purchased from 
Cayman Chemical (Ann Arbor, MI, USA). Reagents and solvents for extraction were 
analytical grade or higher. LCMS grade methanol (J.T. Baker, Center Valley, MA, USA) 
and Optima® formic acid (Fisher Scientific, Fair Lawn, NJ, USA) were used for mobile 
phase preparation. Bovine blood preserved with sodium oxalate was purchased from 
Quad Five (Ryegate, Montana, USA). Cerex® Clin II (3 mL, 35 mg) solid-phase 
extraction (SPE) columns were purchased from SPEware (Baldwin, Park, CA, USA). A 
Millipore Direct-Q UV Water Purification system (Billerica, MA, USA) was used to 
purify water. BD Vacutainer™ tubes (10 mL, 16 x 100mm) without preservative were 





Extraction was performed using a CEREX-48-positive-pressure manifold 
(SPEware). An Agilent 1290 Infinity II Liquid Chromatograph system equipped with an 
Agilent 6470 Triple Quadrupole Mass Spectrometer (Santa Clara, CA, USA) was used 
for analysis. Data were analyzed and acquired using Agilent MassHunter software. A 
Turbovap LV® concentration workstation (Caliper Life Sciences, Hopkinton, MA, USA) 
was used for evaporation by nitrogen. 
Liquid chromatography  
Separation was achieved using our previously published method with limit of 
detection and quantification at 0.125 and 0.25-1 ng/mL, respectively (25). Mobile phase 
A consisted of 5 mM ammonium formate with 0.05% formic acid in water and mobile 
phase B consisted of 0.1% formic acid in methanol. An injection volume of 5 µL was 
used.  
Preparation of Blood  
Blood (100 mL) was fortified with aqueous standards at 0.75 ng/mL (2.5 ng/mL 
for W-18) and 80 ng/mL to represent low (LQC) and high quality control (HQC) 
concentrations, respectively. The fortified blood was equally disbursed into empty 
vacutainer tubes and placed into appropriate temperature settings: frozen (-20°C), 
refrigerated (4°C), room temperature (~25°C), and elevated temperature (35°C). Aliquots 
were taken from each tube immediately after preparation to represent T0. A total of 9 time 






Samples were extracted using a previously validated method (25). An additional 
protein precipitation step was added to reduce solvent usage and time. Blood (0.5 mL) 
was fortified with internal standard then ice cold acetonitrile (1 mL) was added. Samples 
were then centrifuged (2360 x g) for 5 mins and decanted in a new tube. Briefly, samples 
were buffered (100 mM phosphate buffer, pH 6), loaded onto Cerex® Clin ll cartridges, 
then washed, and dried. Acidic and basic drugs were eluted with ethyl acetate and 
dichloromethane: isopropyl alcohol with 5% ammonium hydroxide, respectively. 
Combined elution fractions were dried under nitrogen at 50°C and reconstituted in 0.25 
mL of A/B mobile phase (60:40, v/v). 
Results 
The range of concentrations from the two aliquots are represented as error bars 
with the mean of each set represented by the data point in the following figures. The 
mean of the concentrations from time zero (T0) was used as a baseline for the stability 
experiment. Stability was accessed as %difference from the established baseline 
concentration and deemed acceptable between ±20%. 
Stability at Frozen Temperature (-20°C) 
The seven analytes were evaluated at -20°C at two concentrations (LQC and 





U-47700, U-49900, W-18, and W-15 were stable through the 36-week evaluation 
at both concentrations. At the low concentration, AH-7921, U-50488, and MT-45 were 
stable for at least 28 days at the frozen temperature. There was slight variability seen after 
the 28-day time point, although never exceeding more than 30% loss in the low 
concentration. In the HQC, all analytes were stable for the entire evaluation except for 
MT-45, which demonstrated 24% loss by the last time point compared to T0.  
Figure 5.2 Frozen blood stability of U-47700, U-49900, AH-7921, U-50488, MT-45, 





Stability at Refrigerated Temperature (4°C) 
Analytes were evaluated at 4°C at two concentrations (LQC and HQC) as shown 
in Figure 5.3 below. 
 
Figure 5.3 Refrigerated blood stability of U-47700, U-49900, AH-7921, U-50488, MT-
45, W-18, and W-15 at a) 0.75 ng/mL (2.5 ng/mL for W-18) (LQC) and b) 80 ng/mL 
(HQC) 
 
All analytes except for AH-7921 and U-50488 were stable at the low 
concentration throughout the 36-week experiment. AH-7921 and U-50488 were stable for 
28 days then began to decline, although the loss never exceeded 37%. At the high 




Stability at Room Temperature (25°C) 
Analytes were evaluated at room temperature and the results are shown in Figure 
5.4 below. 
 
Figure 5.4 Room temperature blood stability of U-47700, U-49900, AH-7921, U-50488, 
MT-45, W-18, and W-15 at a) 0.75 ng/mL (2.5 ng/mL for W-18) (LQC) and b) 80 ng/mL 
(HQC) 
 
At room temperature, all analytes were stable during the first 14 days at the low 
concentration. After 21 days, AH-7921 and U-50488 fell below acceptance criteria. After 
28 days, MT-45 also fell out of acceptance criteria. At the high concentration, all analytes 




Stability at Elevated Temperature (35°C) 
Analytes were evaluated at an elevated temperature to simulate if a sample was 
subject to high heat during transportation. Stability of all seven analytes at the elevated 
temperature is shown in Figure 5.5. 
 
Figure 5.5 Room temperature stability of U-47700, U-49900, AH-7921, U-50488, MT-
45, W-18, and W-15 at a) 0.75 ng/mL (2.5 ng/mL for W-18) (LQC) and b) 80 ng/mL 
(HQC) 
Similar to the room temperature condition, all analytes were stable for two weeks 
at the low concentration. AH-7921 and U-50488 were deemed unstable (70 and 74%) 
after 21 days and MT-45 at 28 days (79%). At the high concentration, all analytes except 




days. U-47700 and U-49900 were deemed unstable at 252 days. U-50488 was the only 
analyte that was stable throughout the 36 weeks. There was enhancement observed in the 
W-series beginning at 112 days which resulted in concentrations >100% compared to T0. 
Discussion  
All analytes were stable at the 4 evaluated conditions in blood for two weeks at 
the low concentration. There was variability observed in the low concentration for AH-
7921, U-50488, and MT-45.  The only study that has evaluated any of these analytes at a 
low concentration similar to the current study was Qin et al, with 0.2 ng/mL (23). The 
findings from the current study are aligned with their U-47700 and U-50488 short term 
stability studies. The stability of U-47700 is comparable to previous studies where it was 
determined to be stable for at least for 21 days frozen, refrigerated, and at room 
temperature (3,13). The only previous study involving stability of MT-45 was Papsun et 
al. While our findings for MT-45 stability are similar to those assessed in fortified 
samples, the instability in the authentic samples has yet to be replicated in vitro. In 
general, most analytes were stable at the high concentration throughout the study with the 
exception of the elevated temperature. Additional experiments were done to assess 
increasing concentration observed with the W-series analytes. It was determined that 
there was suppression of the internal standard from the matrix by plotting the response of 
the internal standard over time for each temperature condition. An additional discovery 
during this evaluation was that there was a difference in concentrations between 
vacutainers that had been opened compared to those that were sampled for the first time. 
Multiple vacutainers were placed in each temperature setting and were used until 




tube, there would be variability in the concentration. Although the difference was not 
large, this could contribute to the variability of analytes at the low concentration and may 
not necessarily indicate true degradation. 
Conclusions  
This study determined the stability of several NSO at various temperatures over a 
36-week period. To the authors knowledge, this is the first long-term stability study 
involving these seven NSO and the data support the forensic significance of proper 
sample storage. However, blood samples suspected to contain synthetic opioids, 
particularly at low concentrations, should be stored refrigerated or frozen, when possible, 
in order to preserve analyte stability. Samples should be analyzed within 4 weeks in order 
to capture true concentrations, although analyte loss did not exceed 40%  beyond this 
timeframe.  
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Novel Synthetic Opioids (NSO) have caused a recent epidemic both nationally 
and globally. NSO have gained popularity in the illicit drug market and have brought 
about an increase in fentanyl and its derivatives, as well as other chemically unrelated 
opioid agonists. U-47700, a non-fentanyl analog analgesic opioid, was first developed by 
The Upjohn Company and has a reported potency of 7.5 times that of morphine. Like 
many NSO, U-47700 is usually sold as a research chemical that can be purchased online 
but can also be found in “Gray Death” which is a mixture of fentanyl(s), heroin, and U-
47700. With the emergence of these NSO, there is a need for laboratories to be able to 
detect these drugs in various matrices. In this study, a liquid chromatography tandem 
mass spectrometry (LC-MS/MS) method was optimized and validated to detect and 
quantify U-47700 and its metabolites, N-desmethyl-U-47700 and N,N-didesmethyl-U-
47700, in 100 µL human plasma using an optimized solid phase extraction procedure.  A 
small sample size (100 µL) was utilized for a future pharmacokinetic study in rats. The 
method was validated according to SWGTOX guidelines, including: precision and bias, 
linearity, carryover, interferences, matrix effects, limit of detection (LOD), limit of 
quantification (LOQ), dilution integrity, and stability. The LOD were 0.05 ng/mL for U-
47700 and N-desmethyl-U-47700 and 0.1 ng/mL for N,N-didesmethyl-U-47700. Linear 
ranges for U-47700 and N-desmethyl-U-47700 were 0.1-100 ng/mL and 0.5-100 ng/mL 
for N,N-didesmethyl-U-47700. Matrix effects were analyzed following the post-
extraction addition approach and were <5%, indicating little ion suppression or 
enhancement. Extraction recovery was >79%. Analytes were stable in all conditions and 




validated in rat plasm with bias (2.1-6.2%) and precision (-14.7-15.7%) within acceptable 
limits. Matrix effects and extraction efficiency was comparable to human plasma 
validation. Postmortem whole samples (n=15) were analyzed with the validated method.  
U-47700, N-desmethyl-U-47700 and N,N-didesmethyl-U-47700 concentration ranges 
were 1.1-1367 ng/mL, 4.0-1400 ng/mL and 0.3-658 ng/mL, respectively.  
 





Novel psychoactive substances (NPS), the synthetic substitutes for classic drugs 
of abuse, are a worldwide problem. With the ease of internet purchases and increased 
manufacturing capacity of foreign countries, NPS are emerging at a rapid rate (1). It is 
believed that NPS are a trending problem to bypass current drug control laws by being 
marketed as legal alternatives to controlled drugs (2,3). NPS are often considered a 
“safer” alternative to illicit drugs (4). Though the most common NPS are stimulants and 
cannabinoids, there has been an increase in the number of novel synthetic opioids (NSO) 
in the drug market across the nation (5). These NSO are commonly encountered in heroin 
or counterfeit pain pills (6) and are fairly easy to obtain (7,8). Opioids are highly 
addictive drugs and remain a major problem in the United States (7). In 2016, over 
40,000 fatal drug overdoses in the US were related to opioids (9). However, identification 
of NSO is challenging for toxicologists due to unknown compounds, lack of reference 
materials, and low concentrations in biological samples due to high potency. 
Additionally, pharmacology is unknown or data are limited, therefore metabolites and 
windows of detection are not well known. NSO are a serious issue for the public who are 
unaware of the dangers associated with these drugs (10,11) and users often administer the 
synthetic drugs unknowingly (6). 
An emerging NSO that is considered a non-fentanyl benzamide and a heroin 
adulterant is 3,4-dichloro-N-[-2-(dimethylamino) cyclohexyl]-N-methyl benzamide, or 
U-47700. In the 1970s, this drug was originally investigated by The Upjohn Company as 
a chemical with analgesic and therapeutic properties (6,12) but was never made available 




agonist with a potency of the (1R, 2R) isomer of 7.5 times greater than morphine (12-14). 
Agonists which preferentially bind to the µ-receptors over delta (ƍ) or kappa (ƙ) receptors 
are more likely to be associated with severe respiratory depression and increased 
addiction potential (15).  U-47700 exhibits opioid-like properties with analgesic and 
euphoric effects (12). On the streets, this drug is commonly known as “pink” (16). U-
47700 is commonly detected with fentanyl or fentanyl analogs (17-19). When these two 
drugs are cut into heroin, the combination is known as “Gray Death.” U-47700 can be 
administered via oral consumption, inhalation, insufflation, intravenous injection, or 
intrarectal administration (12).  Common effects of this drug include those that are 
similar to opioids including analgesia, sedation, euphoria, itching, hypothermia, 
respiratory depression, miosis and epistaxis (12). U-47700 overdose, like fentanyl, can be 
reversed by naloxone (19-21). In 2016, U-47700 was emergency classified as a Schedule 
I compound by the Drug Enforcement Administration (DEA) (7,22). There is very little 
pharmacological data published for U-47700, which makes detection and data 
interpretation difficult (12). However, it is known that this newly emerging drug has led 
to at least 46 fatalities and has been associated with 88 seized drug samples submitted to 
state and national crime laboratories in the United States (3,7,12).   
In order to extend detection windows for NPS, toxicologists often seek to identify 
metabolites in biological samples. However, without controlled administration studies in 
humans, this is a difficult challenge and requires extensive use of in vitro metabolic 
assays or analysis of urine specimens after suspected U-47700 intake. Elliott et al were 
the first to report U-47700 related fatalities as well as identify potential metabolites in 




serum using high resolution LC-MS (20). They also concluded that 4N-desmethyl-U-
47700 (dm-U-47700) and N-didesmethyl-U-47700 (ddm-U-47700) were the major phase 
I metabolites. Confirmation of the major metabolites is key to understanding 
pharmacology of the drug and interpreting toxicological data. In a separate study, those 
same metabolites were also identified in casework, though the true identity could not be 
confirmed without examining metabolism directly (21). Krotulski et al performed in vitro 
metabolism with human liver microsomes and confirmed in authentic urine: N-
desmethyl-U-47700 (dm-U-47700), N,N-didesmethyl-U-47700 (ddm-U-47700), N-
desmethyl-hydroxyl-U-47700, and N,N-didesmethyl-hydroxyl-U-47700, with the major 
metabolite being dm-U-47700 (13).  
 
The presence of dm-U-47700 and ddm-U-47700 (structures in Figure 6.1) were 
confirmed by liquid chromatography coupled to a time of flight quadrupole (LC-QTOF). 
Figure 6.1 Structure of U-47700 (top), N-desmethyl-U-47700 (bottom, left) and N,N-




Lastly, Richeval et al found dm-U-47700, ddm-U-47700, and N-desmethyl-hydroxy-U-
47700 using human liver microsomes in vitro experiments. They also were able to detect 
two N,N-didesmethyl-hydroxy-U-47700 metabolites in a urine sample from an authentic 
case (24). There are currently no reference standards available for the hydroxylated 
metabolites. However, there are no fully validated, routine analytical methods available 
to detect and quantify U-47700 and its metabolites.  
Previous studies have detected potential metabolites of U-47700 using gas-
chromatography mass-spectrometry (GC-MS), liquid chromatography coupled to a 
quadrupole time-of-flight mass spectrometer (LC-QTOF), or LC-tandem mass 
spectrometry (LC-MS/MS). U-47700 has been detected in blood (14,17,23,28,30,31), 
serum (20,27), and urine (20, 21, 23-24,27, 29, 30). To date, no methods exist for the 
quantification of U-47700 and its metabolites.  
The goal of this study is to develop and validate an analytical method to detect 
and quantify U-47700 and its metabolites in plasma at low limits of quantification in a 
small sample size (100 µL). The ultimate goal of the research is to examine U-47700 and 
its metabolites in rat plasma following controlled intravenous drug administration. 
Animal models are essential to understanding pharmacokinetics (PK) and 
pharmacodynamics (PD) of NPS in an effort to understand pharmacology of these rapidly 
emerging compounds. The data from the rat study will be paramount to understanding 
effects and metabolism of this drug as very little information is currently available. 
One of the major goals of this study was to develop, optimize, and validate a 
quantitative method for analysis of U-47700 and its metabolites in human plasma using a 




study with controlled intravenous U-47700 drug administration. Rats are small mammals 
and only a small volume of blood can be drawn from them. Additionally, forensic 
toxicology laboratories are often specimen limited and analytical techniques which do not 
require a large sample volume are favored. 
Materials and Methods 
Chemicals and Reagents 
U-47700, N-desmethyl-U-47700, N,N-didesmethyl-U-47700, and internal 
standard (ISTD), d6-U-47700, were purchased as methanolic solutions from Cayman 
Chemical (Ann Arbor, MI, US). Pooled human plasma with K2 EDTA anticoagulant was 
purchased from Innovative Research (Novi, MI) and stored in the freezer at -20 °C. 
Pooled rat plasma from drug-naïve rats was received from National Institute on Drug 
Abuse (Baltimore, MD, US). Solid phase extraction (SPE) was performed using 
PolyChrom Clin II (3 mL, 35 mg) SPE columns (SPEWare, Baldwin Park, CA) on a 
SPEWare System 48™ Pressure Processor. A BiotageTurboVap LV® (Charlotte, NC, 
US) equipped with nitrogen gas was used for solvent evaporation.  Acetic acid (ACS 
reagent) was purchased from Mallinckrodt Pharmaceuticals (St. Louis, MO, US). Formic 
acid (LC-MS grade), dibasic sodium phosphate (ACS reagent), and monobasic sodium 
phosphate (ACS grade) were purchased from Sigma-Aldrich (St. Louis, MO, US). 
Deionized water was purified using a Millipore Direct-Q® 3UV system (Burlington, 
MA, US). Ammonium hydroxide (ACS reagent), hexane (analytical grade), methanol 
(LC-MS grade), and ethyl acetate (LC-MS grade) used in sample preparation and 
extraction were obtained from J.T. Baker (Center Valley, MA, US).  LC-MS grade 




Preparation of Standard Solutions 
Stock solutions of all analytes were prepared at 100,000 ng/mL (except ISTD at 
10,000 ng/mL) in methanol. Mixed methanolic solutions for calibrators were prepared via 
serial dilution, resulting in concentrations of 500, 250, 125, 50, 12.5, 2.5, and 0.5 ng/mL, 
which produced the following concentrations when fortified in plasma: 100, 50, 25, 10, 
2.5, 0.5, and 0.1 ng/mL. Mixed methanolic solutions for quality controls (QC) were 
prepared separately via serial dilution, resulting in concentrations of High 400, Medium 
150, and Low 1.5 (7.5 for ddm-U-47700) ng/mL, which produced the following 
concentrations when fortified in plasma: 80, 30, and 0.3 (1.5 for ddm-U-47700) ng/mL. A 
methanolic ISTD solution was prepared at 100 ng/mL, resulting in 20 ng/mL when 
fortified in plasma. All solutions were stored in amber vials at -20°C.  
Solid Phase Extraction 
 Plasma (100 µL) was fortified with 20 µL of appropriate calibrator or QC 
solution. Samples and negative controls were also fortified with 20 µL ISTD solution. To 
all samples, 900 µL of phosphate buffer (100 mM, pH 6.0) was added and vortexed to 
mix. The mixture was loaded to the SPE column and washed with 1 mL deionized water 
and 1 mL acetic acid (1 M). The column was dried at maximum pressure under nitrogen 
for 5 min and then washed with 1 mL each: hexane, ethyl acetate, and methanol. Analytes 
were eluted with 1 mL 80:20 mixture of dicholormethane:isopropanol (v/v) with 5% 
concentrated ammonium hydroxide. The elution solvent was evaporated to dryness under 
nitrogen at 50 °C and reconstituted in 50 µL 60:40 mobile phase A:B. The aqueous 
mobile phase (A) consisted of 5 mM ammonium formate with 0.05% formic acid in 




methanol. Samples were centrifuged at 1276 g for 1 min before transferring to an 
autosampler vial. A total of 10 µL was injected onto the LC-MS/MS for analysis.  
Instrumentation 
Liquid Chromatography 
Analysis was performed on an Agilent 1290 Infinity II Liquid Chromatograph 
coupled to an Agilent 6470 Triple Quadrupole Mass Spectrometer (Santa Clara, CA, US). 
Analyte separation occurred across an Agilent ZORBAX Eclipse Plus C18 column (1.8 
μm, 2.1 x 50 mm) with a matching guard column. The column temperature was held at 30 
°C. Separation was achieved using isocratic elution with mobile phase A:B at 60:40 at a 
0.4 mL/min flow rate with a run time of 8 min.  
Mass Spectrometry  
Electrospray ionization was operated in positive mode. A multiple reaction 
monitoring (MRM) method was used to detect the analytes with one transition for 
quantification and one transition for qualification. Data acquisition and analysis was 
performed using Agilent MassHunter Workstation software (Santa Clara, CA, US).  The 
gas temperature was set at 300°C with a gas flow of 13 L/min. The nebulizer was at 45 
psi. The sheath gas was at 350°C with a flow of 12 L/min. The capillary voltage was set 








Table 6.1 Optimized mass spectrometry parameters; Q1 –quadrupole 1, Q3 – quadrupole 
3, CE - collision energy, RT - retention time, ITSD – internal standard; quantifying 
transitions are italicized 











U-47700 329.2 172.9 108 20 32 2.380 U-47700-d6 
 329.2 144.9  20 56   
N-desmethyl 
-U-47700 
315.2 172.9 108 20 32 2.572 U-47700-d6 
 315.2 144.9  20 52   
N,N-didesmethyl 
-U-47700 
301.1 189.9 108 20 20 2.800 U-47700-d6 
 301.1 144.9  20 56   
U-47700-d6 335.2 172.9 108 20 36 2.378 - 
 335.2 144.9  20 60   
 
Method Validation  
Method validation was carried out according to the standard practices for method 
validation of the Scientific Working Group for Forensic Toxicologists (SWGTOX) (29). 
Validation parameters evaluated included calibration models and linearity, limits of 
detection (LOD), limits of quantification (LOQ), bias, precision, ion 
suppression/enhancement, recovery, interference studies, carryover, and dilution 
integrity. Calibration models over a working range were determined using 7 non-zero 
calibrators over 5 days, except for ddm-U-47700 (6 non-zero calibrators). Linearity was 
achieved using the least squares model and considered acceptable when R2 > 0.99. LODs 
and LOQs were established by evaluating decreasing analyte concentrations. Once 
established, LODs and LOQs were analyzed in triplicate over three days. LODs were 




signal to noise ratio ≥3, and retention time within ± 0.1 min. LOQs were considered 
acceptable by meeting LOD criteria as well as signal to noise ratio ≥10 and precision and 
bias within 20%. 
Bias and precision were determined at three different QC concentrations in 
triplicate over 5 days. Bias (%) and precision (% coefficient of variation, CV) were 
considered acceptable within ±20%. Within-day and between-day precision were 
calculated at each QC concentration. Carryover was evaluated on three days by injecting 
an extracted negative sample (ISTD only) following the injection of the highest 
calibrator. Carryover was considered negligible if peaks fell below LOD criteria. 
Endogenous interferences were evaluated by analyzing blank matrix with and 
without internal standard daily. Samples fortified with ISTD were examined for presence 
of non-deuterated analytes. Additionally, samples were prepared at 50 ng/mL in duplicate 
in hemolyzed plasma (5 - 40% hemolysis) to ensure proper quantification of analytes and 
to check for interferences. Ion suppression and enhancement, or matrix effects, were 
determined using post-extraction addition (30) over 4 days in triplicate at 50 ng/mL. 
Matrix effects were determined by taking the mean response of the post-extraction 
fortified samples divided by the mean response of the neat standards. The recovery was 
calculated by taking the mean response of the extracted samples over the mean response 
of the post-extraction fortified samples. Matrix effects were considered acceptable when 
they fell within ±25% with acceptable precision (<15% CV).  
Exogenous interferences (10000 ng/mL) were fortified into low QC samples 
(n=3) and extracted as described above. The compounds evaluated included Δ⁹-




caffeine, carbamazepine, carisoprodol, cocaine, codeine, cotinine, cyclobenzaprine, 
dextromethorphan, diazepam, diphenhydramine, hydrocodone, hydromorphone, 
ketamine, methadone, nicotine, nordiazepam, oxazepam, oxycodone, pentobarbital, 
phencyclidine, phenobarbital, propoxyphene, secobarbital, tetrahydrocannabinolic acid, 
tramadol, and zolpidem. Exogenous interferences were considered acceptable if there 
were no co-eluting peaks and if the QCs quantified within ±20% of target.  
Dilution integrity was examined by performing a 1:10 dilution of a sample 
fortified at 2.5 times the highest QC (200 ng/mL) in triplicate. Stability was assessed in 
triplicate at low and high QC concentrations at room temperature (24 h, 20 ° C), 
refrigerated (72 h, 4 °C), and after three freeze/thaw cycles (-20 °C). Processed samples 
were also evaluated in the autosampler (72 hours, 4 °C). Dilution and stability were 
considered acceptable if bias was within ±20%. 
Rat Plasma Cross-Validation  
Cross-validation was performed in rat plasma using the optimized extraction and 
acquisition methods. QCs at low, medium, and high concentrations in were prepared in 
plasma from drug-naïve rats in triplicate and analyzed over three days against calibration 
curves prepared with human plasma. Precision, bias, matrix effects, and recovery were 
assessed as described above.  
Authentic Samples  
A total of 15 postmortem blood samples were received and analyzed as described 
above. However, an additional centrifugation step was added to sample preparation 
before loading onto the SPE columns to prevent clogging. QCs at low, medium, and high 




calibration curves prepared with plasma. Precision, bias, matrix effects, and recovery 
were assessed as described above.  
Results and Discussion 
Method Development 
Solid phase extraction was optimized for a small sample size (100 µL) and low 
LOQ due to nature of future applications (controlled drug administration to rats). 
Extensive method development took place to minimize interferences and maximize 
instrument response for the metabolites. Chromatographic separation of analytes was 
initially investigated with mobile phase A as 5 mM ammonium formate with 0.05% 
formic acid in deionized water and mobile phase B with 0.01% formic acid in 
acetonitrile. Starting mobile phase composition and several different gradients were 
evaluated in order to achieve sufficient separation. Ultimately, isocratic elution was 
explored at several different mobile phase compositions (90:10, 80:20, and 60:40 A:B). 
The isocratic gradient at 60:40 resulted in the best resolution for all analytes. Despite 
chromatography optimization, there was a small unknown peak in ddm-U-47700’s 
extracted ion chromatogram (Figure 6.2, left).  
Figure 6.2 Comparison of ddm-U-47700 eluted with acetonitrile (left) and methanol 




This shoulder was from an unknown source and reproducible in neat and 
extracted samples for both the quantifying and qualifying transitions. To eliminate this 
unknown shoulder, various columns were assessed including: Agilent ZORBAX Eclipse 
C18 and Agilent 120 Poroshell C18-EC. The ZORBAX column improved peak shape 
compared to the Poroshell but did not offer complete separation from the interference. 
Next, mobile phase B composition was switched from 0.1% formic acid in acetonitrile to 
0.1% formic acid in methanol. Though acetonitrile is commonly used in laboratories, due 
to its ability to wash the column more thoroughly and lack of increased back-pressure, 
only methanol was able to separate the interference from the analyte peak of interest. The 
shoulder was separated from the analyte and eluted on its own approximately one minute 
later (Figure 6.2, right). This separation was achieved in all neat and extracted samples , 
therefore methanol was used in the final method. This interferant was also observed in an 
authentic specimen presented by Vogliardi (27). After separation, the peak was shown to 
share the same monitored transitions of ddm-U-47700 which could possible be attributed 
to related compounds, synthetic bioproducts, or metabolites. 
Method Validation 
Linearity was determined using a 1/x2 weighting. Least squares regression was 
used with 7 non-zero calibrators, except ddm-U-47700 (6 non-zero calibrators). 
Calibration curves resulted in R2 values ≥ 0.996 for U-47700, dm-U-47700, and ddm-U-






Table 6.2 Linearity, limit of detection (LOD), limit of quantification (LOQ) and linear 










(mean ± sd, n=6) 
Slope 

















 The LOD were 0.05 ng/mL for U-47700 and dm-U4, and 0.1 ng/mL for ddm-U4. 
The LOQ were found to be 0.1 for U-47700 and dm-U-47700 (Calibrator 1) and 0.5 
ng/mL for ddm-U-47700 (Calibrator 2). Bias and precision at the LOQ were within -8.8 - 
14.4% and 0.005 - 0.111 % CV, respectively. Analyte response was linear from the LOQ 
to 100 ng/mL, as summarized in Table 6.2. Extracted ion chromatogram for U-47700 and 
its metabolites at the LOQ are depicted in Figure 6.3.  The limits of quantification for U-
47700 are comparable to or better than those reported elsewhere: 0.3125 ng/mL and 1 
ng/mL (14,21,23).   
Bias and precision results for three QC concentrations prepared in human plasma 
are displayed in Table 6.3. For all analytes, bias ranged from -1.6 to -9.2%. Between-run 
precision was 2.9 - 7.6% CV. Maximum within-run precision was 2.8 - 13.6% CV. All of 
these data ranges within 15% indicate acceptable bias and precision for all analytes 





Table 6.3 Bias and Precision data for analytes in human plasma at three quality control 










  LQCa MQCb HQCc LQC MQC HQC LQC MQC HQC 
U-47700 -6.0 -2.3 -2.7 6.5 5.2 3.1 13.6 8.6 2.8 
N-desmethyl-U-
47700 
-9.2 -4.6 -5.2 7.6 4.5 2.9 12.3 6.9 5.0 
N,N-didesmethyl-U-
47700 
-8.3 -4.8 -1.6 6.5 4.4 3.0 9.9 7.2 4.3 
a Low QC concentration: 0.3 ng/mL (except 1.5 ng/mL for N,N-didesmethyl-U-47700) 
b Medium QC concentration: 30 ng/mL for all analytes 
c High concentration were 80 ng/mL for all analytes 
Matrix effects were analyzed to determine ion suppression and enhancement 
using post-extraction addition. In the same set of samples, extraction recovery was also 
evaluated. Due to limited rat plasma supply, only one lot of pooled plasma was available. 
Samples were analyzed at 50 ng/mL for matrix effects and recovery, as summarized in 
Table 6.4.  
Table 6.4 Extraction efficiency and matrix effects evaluated at 50 ng/mL in human 
plasma 






U-47700 79.4 4.7 
N-desmethyl-U-47700 79.9 0.2 
N,N-didesmethyl-U-47700 84.5 3.9 
U-47700-d6 88.0 -5.4 
 
Analyte recovery ranged from 79.4 - 88.0% and matrix effects were -5.4 - 4.7%, 




sufficiently matched the parent drug and metabolites in terms of matrix effects and 
recovery. Matrix effects were within the ±25% acceptable SWGTOX guidelines. During 
this study, a second internal standard became commercially available, d3-N-desmethyl-U-
47700. This internal standard was evaluated as a possible addition to the assay. However, 
due to the location of the deuterium on the molecule, the product ions and matrix effects 
differed from the non-deuterated metabolite and did not offer improvement in calibration. 
Endogenous interferences were evaluated in blank plasma and hemolyzed plasma. 
No interfering peaks were detected. In addition, QCs prepared in hemolyzed plasma 
quantified within ±7.2% of targeted concentration when analyzed against a non-
hemolyzed plasma calibration curve. Negative samples (ISTD only) were evaluated for 
presence of non-deuterated analytes and no peaks were detected. Interferences of 
common drugs of abuse were evaluated by evaluating 32 basic, acidic and neutral drugs. 
Interferences were fortified at 10000 ng/mL into low QCs (n=4) and evaluated for bias. 
The QC samples containing interference mixtures quantified with ±16.7% of targeted 
concentration, and was considered acceptable.  
Table 6.5 Fortified and processed sample stability at two quality control (QC) 
concentrations in human plasma stored in various conditions 
Analyte   
24 h 22°C 
(%, n=3)   
72 h 4°C 
(%, n=3)   
3 freeze/thaw 
cycles 




    LQCa HQCc   LQC HQC   LQC HQC   LQC HQC 
U-47700  -5.0 -0.9   -2.7 -1.9  -2.9 -1.5  3.7 4.2 
N-desemthyl 
-U-47700  -9.1 -3.4   -2.2 -2.2  -9.3 -2.0  -2.0 0.0 
N,N-didesmethyl- 
U-47700  -10.6 -5.0   -5.6 -6.7  -5.7 -4.0  -3.1 -4.1 
a Low QC concentration: 0.3 ng/mL (except 1.5 ng/mL for N,N-didesmethyl-U-47700) 




When determining carryover, analytes in the negative were evaluated to 
determine if they met or exceeded LOD criteria in terms of peak area and ion ratio. No 
carryover was observed. For dilution integrity, bias was -3.0 - 2.6% and was considered 
acceptable. Results from the stability studies are summarized in Table 6.5. Bias for all 
the stability studies were calculated and ranged from -10.6 - 4.2% and was also 
considered acceptable.  
Rat Plasma Cross-Validation  
The cross validation results are shown in Table 6.6 below. Precision and bias 
were evaluated and found acceptable. Matrix effects and extraction efficiency were also 
determined to be within SWGTOX criteria and comparable to human plasma data. These 
are the desired results to be applied towards a future animal model study to determine 

















a Low QC concentration: 0.3 ng/mL (except 1.5 ng/mL for N,N-didesmethyl-U-47700) 
b Medium QC concentration: 30 ng/mL for all analytes 
c High concentration were 80 ng/mL for all analytes 
Analyte 
Bias 
(%, n=9)   
Between-run 
imprecision 










a MQCb HQCa   LQC MQC HQC   LQC MQC HQC 
 LQC HQC LQC HQC 
U-47700 5.5 4.9 1.9  -10.8 -8.5 1.9  6.1 15.7 2.0  86.3 86.2 0.8 2.4 
N-desmethyl-U-47700 6.0 5.9 2.8  -8.9 -8.8 2.8  5.6 14.4 4.5  90.7 86.4 0.2 3.5 
N,N-didesmethyl-U-47700 6.6 6.2 2.1  -14.7 -10.1 2.1  7.3 14.7 1.7  87.9 82.4 -0.1 -1.6 




Authentic Samples  
A fit for purpose validation of blood was performed to ensure that quantifiable 
concentrations of these analytes could be obtained using the validated plasma method. 
Precision and bias were within acceptable criteria (range: -8.4 – 13.3 % CV), while 
matrix effects displayed slight enhancement (15 – 35 %) for all analytes. Postmortem 
blood samples (n=15) were analyzed and concentrations are shown in Table 6.7. Mean 
(range) concentrations were 232 (1.1-1367), 289 (4.0-1400), and 136 (0.3-658) ng/mL for 
U-47700, dm-U-47700, and ddm-U-47700, respectively. 











(Blood) (ng/mL) (ng/mL) (ng/mL) 
1 Cardiac  1367 1177 658 
4 Femoral  145 465 402 
7 Peripheral  144 258 195 
9 Not specified 208 109 8.1 
11 Iliac  543 33.0 1.6 
13 Iliac  38.5 4.0 0.3 
17 Peripheral 1.1 ND ND 
18 Femoral 4.2 15.8 17.0 
20 Cardiac  431 1400 361 
22 Iliac  68.3 56.7 16.4 















(ng/mL) (ng/mL) (ng/mL) 
25 Femoral  46.6 28.0 12.1 
27 Femoral 50.7 14.1 12.5 
28 Femoral  207 225 85.5 
30 Iliac  126 253 129 
 Mean  233 289 136 
 Median  126 82.9 16.7 
 Min 1.1 4.0 0.3 
 Max 1367 1400 658 
ND=Not Detected  
 Concentrations for U-47700 were comparable to previous literature ranges 17-1,460 
ng/mL in blood (14,20,23). In Jones et al, urine and serum concentrations were reported 
for U-47700, dm-U-47700, and ddm-U-47700. The metabolite concentrations were 
approximated based on the response of U-47700.  Although this was not a validated 
quantitative method, the concentration of dm-U-47700 in urine was almost 5 times higher 
than the parent drug [19]. This result is comparable to that of sample 20, which was a 
blood sample, in this study. In one study, U-47700 was detected at higher concentrations 
in blood compared to urine [21], while a different study found the opposite to be true 
[16]. However, without knowledge of dose or time of administration, data are difficult to 
interpret. Further, concentrations detected in postmortem cases can be challenging due to 
potential for postmortem redistribution. In McIntyre et al, U-47700 concentrations in 




central to peripheral blood concentrations as well as the liver to peripheral blood 
concentrations indicated that U-47700 may exhibit postmortem redistribution. For the 
present study, injection or consumption times of these drugs are unknown, therefore 
pharmacokinetic studies are needed to understand the parent-metabolite half-lives of 
these drugs. Though it is not uncommon for U-47700 to be detected with other drugs 
such as fentanyl, alprazolam, and other synthetics, for the scope of this study, we were 
only interested in quantifying U-47700 and its metabolites (17,26,32).  
Conclusions 
A method for the detection and quantification of U-47700 and its metabolites was 
developed and validated following SWGTOX guidelines using a low sample volume. The 
method validation parameters met acceptability criteria. This is the first method, to our 
knowledge, which quantifies two phase I metabolites of U-47700: N-desmethyl-U-47700 
and N,N-didesmethyl-U-47700. The final method was sensitive and limits of 
quantification are sufficiently low to detect intoxicating or fatal concentrations of these 
analytes. Further studies need to be assessed to validate a quantitative method in blood, 
however when analyzed against plasma calibrators, this method was able to detect and 
quantify these analytes in authentic postmortem blood samples. The future goal of this 
study is to analyze rat plasma following administration of U-47700 in a controlled 
environment in order to assess PK and PD. Animal models are used to study PD/PK so 
scientists can better understand the drug without risking the well-being of humans. 
Animal models are crucial to studying novel psychoactive substances and can produce 
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Originally developed as a potential analgesic in the 1970’s, U-47700 was the first 
U-series opioid to emerge on the illicit market. Metabolic studies using structural 
elucidation and human liver microsomes previously determined four major metabolites. 
Of these metabolites, only two are commercially available (N-desthmethyl-U-4700 and 
N,N-didesmethyl-U-47700). To date, there are no pharmacological studies in animal or 
human models for U-47700. This study’s goal was to evaluate pharmacokinetics and 
pharmacodynamics of U-47700 through an animal model. Rats were injected with 0 
(saline), 0.3, 1.0 or 3.0 mg/kg U-47700. Blood samples were collected at 15, 30, 60, 120, 
240, 480 min after injection for quantification of U-47700 and its metabolites. 
Pharmacodynamic effects, including hot plate latency, catalepsy, and core temperature, 
were also assessed at the same time points. It was determined that doses of U-47700 had 
a positive correlation with the behaviors observed which further demonstrates the 










According to the National Forensic Laboratory Information System (NFLIS), 
there were over 180,000 reports of narcotic analgesics in United States in 2018 (1). The 
opioid epidemic that the United States is facing is all encompassing, which includes 
prescription and illicit drugs with a trend towards the use of novel synthetic opioids 
(NSO). U-47700 is one such NSO that emerged globally between 2015 and 2016 (2,3). 
Originally developed as a potential analgesic by the Upjohn Company in the 1970’s, U-
47700 was the first U-series opioid to emerge. It was determined to be a selective µ-
receptor agonist and 7.5 times more potent than morphine (4). While pharmacological 
information is minimal, it is theorized that U-47700 is abused due to its euphoric and 
potential analgesic effects. Fatal intoxications are not uncommon with the abuse of U-
47700. Blood concentrations found in fatal intoxication range from 7.8-3040 ng/mL (5-
18), with most cases involving another illicit drug or other opioids. Acute intoxications 
are prevalent as well for U-47700 with blood concentrations ranging from 94-351 ng/mL 
(19,20). 
Metabolism studies have been performed to determine metabolites for U-47700. 
Krotulski et al was the first to perform a metabolic study to identify four metabolites 
using human liver microsomes (HLMs) and verified those metabolites with authentic 
urine specimens (21). The major metabolite identified was N-desmethyl-U-47700. 
Richeval et al also conducted a metabolism study using HLMs and verified predicted 
metabolites in authentic specimens (11). The same metabolites predicted in Krotulski et 
al were predicted in Richeval et al, with an additional positional isomer of the 




elucidation on authentic samples to predict metabolites and have determined the same 
metabolites (9,22). There have been two quantitative methods developed for U-47700 
and its metabolites (23,24). Rojek et al developed and validated a method to detect U-
47700 and its metabolites in blood and applied the method to postmortem blood samples 
(N=12). Smith et al optimized, developed, and validated a sensitive method for the 
quantification of U-47700, N-desmethyl-U-47700, and N,N-didesmethyl-U-47700 in 
plasma utilizing liquid chromatography tandem mass spectrometry (LC-MS/MS) and 
cross validated in rat plasma (23).  A major difference observed between the two methods 
was that during optimization, Smith et al was able to chromatographically separate a 
N,N-didesmethyl-U-47700 interferant.    
In order to better understand the biological effects of U-47700 and other synthetic 
opioids, Baumann et al conducted a rat study to examine opioid receptor interaction and 
antinociceptive effects (25). It was determined that U-47700 was 31 times more potent 
than morphine in regards to the tail flick assay and confirmed that U-47700 was a 
selective µ agonist. It was also concluded that in vivo potency cannot be predicted by in 
vitro binding affinity. In order to understand the true pharmacology of U-47700, 
pharmacokinetic (PK) profiles are needed and metabolite bioactivity should be evaluated.  
To date no studies have been conducted to fully determine the pharmacokinetic 
and pharmacodynamic properties of U-47700 in human or animal models. In order to 
better understand this compound, in vivo studies using animal models are necessary. In 
the present study, the analytical method developed by Smith et al (23) was used to 
quantify U-47700 and its metabolites in rat plasma following subcutaneous (sc) 




collected at several time points in conjunction with a battery of behavior and 
physiological measures in order to assess U-47700 pharmacodynamics and PK.  
Materials and Methods  
Reagents and Standards  
Chemicals and reagents commonly used for extraction and LC-MS/MS were the 
highest purity available. U-47700, N-desmethyl-U-47700, N,N-didesmethyl-U-47700, 
and U-47700-d6 were purchased from Cayman Chemical Company (Ann Arbor, MI, 
USA) . Pooled blank male Sprague Dawley rat plasma preserved with sodium heparin 
was obtained from BioIVT (Medford, MA, USA).    
Animals and Surgery 
Sprague-Dawley (male) rats (250-400g) were housed (lights on for 12 hours) with 
free access to water and food, with controlled temperature (22±2 °C) and humidity 
(45%±5%). These experiments followed the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals. Study procedures were approved by NIDA IRP 
Animal Care and Use Committee (ACUC). Two weeks were allowed for acclimation 
prior to surgeries and experiments.  
Surgeries for PK experiments consisted of implantation of IPTT-300 transponder 
(Bio Medic Data Systems, Seaford, DE, USA) for monitoring body temperature and a 
catheter in the right jugular vein. Rats were allowed a week for recovery.  
PK Experiments  
Rats were moved from their acclimated environments to the testing room and 
given 1 h to acclimate. In order to facilitate blood collection through the catheters, 0.3 




received subcutaneous (sc) of 0 (saline), 0.3, 1.0, or 3.0 mg/kg of U-47700. Blood (0.30 
mL) was collected before injection and at 15, 30, 60, 120, 240, and 480 min 
subsequently. Equal amounts of saline were infused after each blood collection in order 
to maintain osmotic homeostasis and volume. Blood was transferred to 1.5 mL tubes 
fortified with 5 µL of 250 nM sodium metabisulfite and 5 µL of 1000 IU heparin and 
then centrifuged at 3000 rpm for 10 min. After centrifugation, plasma was decanted and 
stored at -80 °C and shipped frozen for analysis.  
Behavior assessments (90 seconds) were accompanied with blood collections at 
15, 30, 60, 120, 240, and 480 min. Catalepsy was evaluated by placing the rats in an 
uncomfortable position and recording the amount of time it took for the rat to return to a 
normal position. Catalepsy was scored similar to published methods (26).  Briefly, three 
endpoints were considered at each time point: 1) immobility, 2) flattened body posture, 
and 3) splayed limbs; each of these endpoints was scored as either absent “1” or present 
“2” at each time point prior to blood withdrawal, so the minimum summed score for no 
symptoms is “3” and the maximum score for the all symptoms present is “6”. Analgesic 
effects were evaluated by a hot plate latency study. Rats were placed on hot plate and 
time was recorded as to when the rat tried to jump off plate or exhibit behaviors such as 
licking its paws. The maximum allotted time allowed for this study was 45 seconds. After 
behavior observations, core temperatures were recorded at each time point. 
Quantification of U-47700 and its Metabolites in Plasma 
Plasma was analyzed by a previously validated method (Smith et al) (23). Briefly, 
internal standard was added to plasma (100 µL) and buffered before loading on solid 




(80:20, v/v) with 5% ammonium hydroxide, then dried under nitrogen and reconstituted 
in 50 µL of 5 mM ammonium formate with 0.05% formic acid in water: 0.1% formic 
acid in methanol (60:40, v/v). 
Samples were analyzed on an Agilent 1290 Infinity II Liquid Chromatograph 
system equipped with an Agilent 6470 Triple Quadrupole Mass Spectrometer (Santa 
Clara, CA, USA). Agilent MassHunter Software was used for data acquisition and 
analysis of U-47700, N-desmethyl-U-47700, and N,N-didesmethyl-U-47700. Linear 
ranges for U-47700 and N-desmethyl-U-47700 were 0.1-100 ng/mL and 0.5-100 ng/mL 
for N,N-didesmethyl-U-47700. The limit of detection were 0.05 ng/mL for U-47700 and 
N-desmethyl-U-47700 and 0.1 ng/mL for N,N-didesmethyl-U-47700.  
Data Analysis  
Plasma PK data were analyzed using APL Pharmacokinetic Modeling Program 
(PKMP) to determine non-compartmental PK parameters such as half-life, area under the 
curve, and Cmax. Possible non-linearity was evaluated by calculating expected values for 
area under the curve (AUC) values and comparing with observed values. The 0.3 mg/kg 
values were multiplied by 1/3 and 10 in order to calculate the expected AUC values for 
the 1 and 3 mg/kg doses, respectively. The data from observed and expected AUC were 
compared using nonparametric t-tests and results were evaluated using two-way 





Results and Discussion  
PKs of U-47700 and its Metabolites  
Time-concentration profiles for plasma U-47700, N-desmethyl-U-47700, and 
N,N-didesmethyl-U-47700 after sc injection of 0.3, 1.0, and 3.0 mg/kg U-47700 are 








































Figure 7.1. Concentration-time profiles for U-47700, N-desmethyl-U-47700, and N,N-didesmethyl-U-47700 after sc injection of U-
47700. Data are mean ± SEM for n=5-6 rats per group. 
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Data depicted in Figure 7.1 were used to derive PK constants presented in Table 
7.1.  
Table 7.1 Pharmacokinetic constants (mean±SEM) for plasma U-47700, N-desmethyl-U-
47700, and N,N-didesmethyl-U-47700 after subcutaneous U-47700 administration at 0.3, 
1.0, and 3.0 mg/kg to rats (N=5-6 per group)   











U-47700 0.3 40±3 15 2169±164 82±9 0.27±0.09 
 1.0 110±13 38±17 9872±1063 68±4 0.84±0.3 
 3.0 173±9 24±9 26692±2861 102±16 8±4 
N-desmethyl-
U-47700 0.3 9±4 80±13 1289±306 110±7 0.46±0.10 
 1.0 46±11 75±15 8158±1526 136±17 4±1 




0.3 32±11 90±13 6427±1890 126±10 3±1 
 1.0 108±26 160±25 34463±9920 301±84 32±17 
 3.0 236±31 384±59 69834±5492 - 191±46 
 
U-47700 plasma concentrations increased in a dose-related way. The Cmax values 
were 40, 110, and 173 ng/mL for the 0.3, 1.0, and 3.0 mg/kg U-47700 doses and the 
corresponding AUC values were 2169, 9872, and 26692 min x ng/mL, respectively. 
Antemortem U-47700 concentrations have been reported between 7.6-251 ng/mL in 
blood and serum (19,20,22,27,28). Of these concentrations, Jones et al was the only to 
report a concentration of U-47700 (228 ng/mL in serum) that did not have any other 
illicit drugs of abuse identified (22). Given that interspecies extrapolation is difficult to 
determine and the blood to plasma ratios for U-47700 are unknown, the determined Cmax 
values for U-47700 (40-173 ng/mL) are feasible concentrations applicable to the forensic 
casework.  Tmax for U-47700 was observed within the first 60 min with values of 15, 38, 
and 24 min and t1/2 values of 82, 68, and 102 for the corresponding doses (0.3, 1.0, and 
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3.0 mg/kg U-47700). Koch et al determined the half-life of U-47700 in a patient, prior to 
death, to be 6 hours (15). Half-life was calculated by taking several blood serum samples 
during hospitalization and plotting concentration-time curve. The proposed half-life from 
Koch et al and the current study do not align, but the differences could be attributed to 
the limited sample size and lack of sufficient descending data points in PK curve.  N-
desmethyl-U-47700 Cmax values were a third of those of U-47700, while N,N-
didesmethyl-U-47700 Cmax values were comparable to those of U-47700. Tmax values for 
N-desmethyl-U-47700 were 80, 75, and 168 min for the respective doses 0.3, 1.0, and 3.0 
mg/kg U-47700. For the 3.0 mg/kg dose, there were not enough descending data after 
Tmax as seen in Figure 7.1. Due to this, t1/2 could not be determined for 3.0 mg/kg. 
However, t1/2 values of N-desmethyl-U-47700 were 110 and 136 min for 0.3 and 1.0 
mg/kg U-47700.  AUC values for N-desmethyl-U-47700 were 1289, 8158, and 33,881 
for 0.3, 1.0, and 3.0 mg/kg U-47700, respectively. Cmax values for N,N-didesmethyl-U-
47700 were comparable to that of U-47700. Similarly to N-desmethyl-U-47700, N,N-
didesmethyl-U-47700 does not have enough data to determine  t1/2  for 3.0 mg/kg U-
47700 due to increasing concentrations over the 480 min. Values for t1/2 for N,N-
didesmethyl-U-47700 were 126 and 301 min for 0.3 and 1.0 mg/kg U-47700. N,N-
didesmethyl-U-47700 displayed the largest AUC for all three analytes with values of 
6427, 34,463, and 69,834 min x ng/mL for 0.3, 1.0 and 3.0 mg/kg U-47700. 
Pharmacokinetic plots represent free, non-conjugated analytes as hydrolysis was not 
performed.  
By comparing the expected AUC to the observed AUC, the possibility of a non-
linear accumulation of U-47700 and metabolites was evaluated.  This data is shown in 
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Figure 7.2 for U-47700, N-desmethyl-U-47700, and N,N-didesmethyl-U-47700.  The 
only analyte with observed AUC values greater than expected AUC was N-desmethyl-U-
47700, but the difference was only statistically significant for the 3.0 mg/kg U-47700 
dose (T(9)=2.433, p=0.038). Although there was a significant difference observed at 3.0 
mg/kg for N-desmethyl-U-47700, this difference is due to incomplete elimination of the 

























































Figure 7.2 Comparison of expected vs observed AUC for U-47700, N-desmethyl-U-47700, and N,N-didesmethyl-U-47700 after 




 Pharmacodynamic Effects of U-47700   
The PK values shown in Figure 7.1 correspond to the pharmacodynamic data 
shown in Figure 7.3. Rats that received saline (0 mg/kg U-47700) scored a time of 
approximately 12 seconds during the hot plate latency study. Rats demonstrated increased 
hot plate latency 15-30 mins after sc injection at all three doses. Rats that received 1.0 
and 3.0 mg/kg U-47700 reached the appointed ceiling of 45 seconds at 30 mins post sc 
injection. Core body temperatures for rats that received saline, 0.3 and 1.0 mg/kg U-
47700 were between 36.8-38.3°C. Rats that received the 3.0 mg/kg U-47700 dose 
exhibited lowered body temperatures that lasted 120 mins after sc injection. In a human, 
lower body temperature is an indicator of being under the influence of narcotic analgesics 
used by drug recognition evaluators. Similar to the hot plate latency study, rats scored the 
highest (4-6) 15-30 min after sc injection during the catalepsy assessment. Rats that 
received the 3.0 mg/kg U-47700 injection reached the appointed ceiling score of 6 at the 
30 min time point.   
To correlate the PK data with the pharmacodynamic studies, hysteresis plots were 
formed between the observed behavioral or physiological measures and the 
corresponding plasma U-47700 concentrations. These graphs are shown in Figure 7.4 
below. At the 1.0 and 3.0 mg/kg doses, the hysteresis progression was determined to be 
counter clockwise for hot plate latencyand catalepsy. The highest plasma concentrations 
of U-47700 at these doses was achieved at 30 min and this corresponded to the highest 
score for the catalepsy study and the longest amount of time in the hot plate latency 
study. In Crugten et al, it was determined that the characterization of morphine and 
morphine-6-glucuronide plasma concentration and antinociceptive effects produced a 
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counter clockwise hysteresis as well. It was concluded that the lag between 
concentrations and effects reflected time to cross the blood-brain barrier (29). The 
counter clockwise relationship observed in the current study could also be due to crossing 
the blood-brain barrier. Another possibility could be that one of the metabolites is 
pharmacologically active and could be competing for the receptor or contributing to the 



























































Figure 7.3 Pharmacodynamic data for rats receiving saline or subcutaneous U-47700 injection of 0.3, 1.0, and 3.0 mg/kg (N=5-6 per 
































































































































Figure 7.4 Relationship between values from catalepsy and hot plate latency studies 
(mean, n=5-6) and mean plasma U-47700 concentrations in rats after sc U-47700 
injection at 0.3, 1.0, and 3.0 mg/kg doses. Arrows represent hysteresis curve progression 




To the author’s knowledge, this is the first pharmacokinetic study for U-47700 
and its metabolites in rats. All analytes were determined to have linear accumulation, 
with the exception of N-desmethyl-U-47700 after the high dose of U-47700. It is 
hypothesized that additional time points beyond 480 min could possibly give a more 
defined determination of this metabolites’ linearity of accumulation. Correlations 
between PK and pharmacodynamic data concluded that U-47700 exhibits a counter 
clockwise hysteresis progression over time. Further studies testing the bioactivity of the 
metabolites are needed to evaluate what causes the delay of action observed by the 
counter clockwise hysteresis. Peak plasma concentrations for U-47700 were achieved 
within the first hour and had positive correlations with the observed behaviors. These 
positive correlations reinforce the theory that U-47700 is a potent analgesic. Knowledge 
of these PK profiles is beneficial to the forensic community for improved interpretation 
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According to EMCDDA, there were 179 different synthetic cannabinoids reported 
as of 2017. In the US, 5F-MDMB-PINACA, or 5F-ADB, accounted for 28% of 
cannabinoid seizures 2016-2018. The synthetic cannabinoid, 5F-MDMB-PICA, is 
structurally similar to 5F-MDMB-PINACA with an indole group replacing the indazole. 
Limited data exist from in vivo or in vitro metabolic studies of these synthetic 
cannabinoids, so potential metabolites to identify use may be missed. The goals of this 
study were to 1) investigate 5F-MDMB-PICA and 5F-MDMB-PINACA in vitro 
metabolism utilizing human hepatocytes; 2) verify in vitro metabolites by analyzing 
authentic case specimens; and 3) identify the potency and efficacy of 5F-MDMB-PICA 
and 5F-MDMB-PINACA by examining activity at the CB1 receptor. Biotransformations 
found in this study included phase I transformations and phase II transformations. A total 
of 22 5F-MDMB-PICA metabolites (A1 to A22) were identified. From hepatocyte 
incubations and urine samples, 21 metabolites (B1 to B21) were identified with 3 
compounds unique to urine specimens for 5F-MDMB-PINACA. Phase II glucuronides 
were identified in 5F-MDMB-PICA (n=3) and 5F-MDMB-PINACA (n=5).  For both 
compounds, ester hydrolysis and ester hydrolysis in combination with oxidative 
defluorination were the most prevalent metabolites produced in vitro. Additionally, the 
conversion of ester hydrolysis with oxidative defluorination to pentanoic acid for the first 
time was identified for 5F-MDMB-PICA. Therefore, these metabolites would be 
potentially good biomarkers for screening urine of suspected intoxication of 5F-MDMB-
PICA or 5F-MDMB-PINACA. Both 5F-MDMB-PICA and 5F-MDMB-PINACA were 
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acting as full agonists at the CB1 receptor with higher efficacy and similar potency as 
JWH-018. 
 
Keywords:  5F-MDMB-PICA, 5F-ADB, MDMB-2201, Hepatocyte Metabolism, 




The emergence of novel psychoactive substances (NPS) has had a detrimental 
global impact. Synthetic cannabinoids are some of the first NPS that increased 
dramatically in the early century and started the epidemic seen today. Substances such as 
“Spice” or “K2” were commonly found at gas stations or smoke shops across the United 
States (1) and in vending machines in Japan (2). These substances were frequently found 
to contain the “JWH” series of synthetic cannabinoids with JWH-018 being the most 
predominant. Since their arrival, the number of synthetic cannabinoids has grown rapidly. 
According to the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), as of 2017 there had been 179 different synthetic cannabinoids reported to 
them (3). In the United States, there were 24,501 identifications of synthetic cannabinoids 
reported to National Forensic Laboratory Information System (NFLIS) in 2017 (4). The 
synthetic cannabinoid, 5F-MDMB-PINACA or 5F-ADB, accounted for 28% of those 
identifications in 2017 (4).  
The synthetic cannabinoid, 5F-MDMB-PICA , first identified in herbal incense 
packages by Risseeuw et al (5), is structurally similar to 5F-MDMB-PINACA but the 
indazole has been replaced by an indole group. It has gained popularity in recreational 
use and between 2016 and 2018, there have been 340 reports containing 5F-MDMB-
PICA according to NFLIS (6). In 2018, it was placed as a schedule I substance in the 
United States (7). The fluoropentyl side chain of 5F-MDMB-PICA, shared with 5F-
MDMB-PINACA, indicates high potency at the CB1 receptor (8).  This was verified by 
Banister et al using the FLIPRTM assay (9). 5F-MDMB-PICA was shown to be a full 
agonist at the CB1 receptor with an EC50 concentration of 0.45 nM, similar to 5F-
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MDMB-PINACA (0.59 nM). In contrast, Noble et al showed 5F-MDMB-PICA to have 
an EC50 value of 3.3 nM and an efficacy three times that of the full agonist JWH-018 
using a β-arrestin based assay (8). This study aligns with previous studies, using a 
complimentary aequorin-luminescence based approach measuring the intracellular Ca2+ 
changes. 
Parent structures of synthetic cannabinoids are often difficult to detect in 
biological matrices, so metabolism studies are needed to improve detection of newly 
emerging synthetics.  Mogler et al used pooled human liver microsome assays to identify 
phase I metabolites of 5F-MDMB-PICA. Authentic urine samples (n=24) were also 
analyzed and 12 phase I metabolites were identified with the ester hydrolysis metabolite 
being the most abundant (10).  
Although there is information available involving in vivo and in vitro metabolism 
studies of 5F-MDMB-PICA and 5F-MDMB-PINACA, potential metabolites have not 
been identified using human hepatocytes. While human liver microsomes are beneficial 
for discovering metabolites, they are unable to produce some phase II metabolites, unlike 
human hepatocytes which can help characterize both phase I and phase II metabolites 
(11). Also metabolites produced by human hepatocyte incubations tend to have 
concentrations more similar to those observed in vivo (11). 
The specific goals of this study were to 1) investigate the metabolism of 5F-
MDMB-PICA and confirm 5F-MDMB-PINACA metabolism utilizing human hepatocyte 
incubations to identify in vitro metabolites; 2) examine authentic case specimens that 
involved these synthetic cannabinoids in order to verify metabolites identified by 
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hepatocyte incubations; and 3) identify the potency and efficacy of 5F-MDMB-PICA and 
5F-MDMB-PINACA on the activation of the CB1 receptor.  
Materials and Methods  
Chemicals and Reagents  
A MilliQ Gradient 10 production unit from Millipore (Billerica, MA, USA) was 
used for in-house ultra-pure water production. 5F-MDMB-PICA and 5F-MDMB-
PINACA were purchased from Chiron (Trondheim, Norway).  JWH-018 was purchased 
from THC Pharm (Frankfurt am Maine, Germany). InVitro Gro HT and cryopreserved 
mixed gender human hepatocytes LiverPoolTM (20-donor) were acquired from 
Bioreclamation IVT (Brussels, Belgium). HEPES buffer, L-glutamine, DMEM/HAM’s 
F12, and Williams E buffer were acquired from ThermoFisher (Gothenburg, Sweden). 
Coelenterazine h was obtained from Nanolight® Technology (Pinetop, AZ, USA). 
Acetonitrile, formic acid, methanol, and water liquid chromatography mass spectrometry 
(LC-MS) grade from Fisher Scientific (Gothenburg, Sweden). Ammonium formate, 
digitonin, protease-free BSA, and ATP were purchased from Fluka (Sigma-Aldrich, 
Stockholm, Sweden). The β-glucuronidase/arylsulfatase (Helix pomatia) mixture was 
from Roche (Mannheim, Germany).  
Human Hepatocytes Incubation  
Thawed cryopreserved human hepatocytes were added into InVitro Gro HT 
Medium. The cell solution was centrifuged at 100 g for 5 min at room temperature. The 
supernatant was discarded and the pellet was re-suspended in a mixture of 2 mM 
Williams E medium supplemented with L-glutamine and 20 mM HEPES buffer. An 
additional washing was performed. The Trypan Blue (0.4% v/v) exclusion method was 
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utilized for the cell viability (91%) determination. 5F-MDMB-PICA and 5F-MDMB-
PINACA were incubated with hepatocytes in 96-well-plates (105 cells/0.1 mL/well) with 
a final concentration of 5 µmol/L. Ice cold acetonitrile was used to end incubations after 
1, 3, and 5 h. Baseline (t0) samples contained hepatocytes and acetonitrile before drugs 
were added. Positive controls consisted of CYP substrates: caffeine, bupropion, 
diclofenac, omeprazole, dextromethorphan, chlorzoxazone, and midazolam. Negative 
controls contained incubations without drug standards. Degradation controls were 
incubations without addition of hepatocytes.  
Authentic Urine Sample Preparation  
Postmortem (n=3) and antemortem (n=1) urine samples were analyzed with and 
without hydrolysis. Urine (100 µL) with 300 µL of 1 M sodium acetate buffer (pH 5) was 
incubated for 2 h at 40 °C with 10 µL of glucuronidase/arylsulfatase (4.5 U/mL and 14 
U/mL, respectively) in autosampler vials for hydrolysis. For non-hydrolyzed samples, 10 
µL of the sodium acetate buffer was added instead of enzyme.  After incubation, 
unopened vials were placed in the autosampler for analysis.     
Authentic Urine Samples  
Urine from three cases that presented with positive results for 5F-MDMB-PICA 
in blood were analyzed for metabolites to corroborate the hepatocyte findings. Two cases 
were autopsy cases that are described below and the third was from a suspected DUID 
(no case history available). In addition an autopsy case positive for 5F-MDMB-PINACA 





A 47 year old male with a history of drug abuse and diagnosed with type I 
diabetes was found lying on the floor of his bathroom. The post-mortem examination 
revealed pulmonary edema (combined weight 1745 g), fatty liver and underweight with a 
BMI of 15.9. Toxicological analysis showed no ethanol but 0.45 part per thousand of 
acetone in femoral blood as well as 0.60 part per thousand in urine. Vitreous glucose was 
78.4 mmol/L and the femoral blood had an elevated BHB at >1000 µg/g. The only 
exogenous compound found was 0.28 ng/g 5F-MDMB-PICA in femoral blood. The 
investigation concluded that the cause of death was diabetic ketoacidosis. 
Case 2 
A 49 year old male with a history of alcohol and drug abuse was found dead 
outside. The post-mortem examination was unremarkable and no underlying pathology 
was found. The toxicological analysis revealed no ethanol but 0.13 part per thousand of 
acetone in femoral blood as well as 0.74 part per thousand in urine. Glucose was negative 
but the femoral blood had an elevated BHB at >1000 µg/g. The only exogenous 
compound found was 0.32 ng 5F-MDMB-PICA/g femoral blood. The investigation 
concluded that the cause of death was ketoacidosis possibly with a contribution from his 
drug use. 
Liquid Chromatography and High Resolution Mass-Spectrometry for 
Metabolite Identification 
An Agilent 1290 infinity ultra-high performance liquid chromatography system 
coupled with an Agilent 6550 iFunnel quadrupole time-of-flight (QTOF) mass 
spectrometer equipped with a Dual Agilent Jet Stream electrospray ionization source 
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(Santa Clara, CA, USA) was used for analysis. Agilent MassHunter software was used 
for data acquisition and analysis.   
Chromatographic separation was achieved using an Acquity HSS T3 column (150 
mm x 2.1 mm, 1.8µm) from Waters (Sollentuna, Sweden). Column temperature was 
maintained at 60 °C. Injection volume was 5 µL. Mobile phases were 0.05% formic acid 
in 10 mM ammonium formate (mobile phase A) and 0.05% formic acid in acetonitrile 
(mobile phase B).  Gradient elution at 0.5 mL/min was initiated with 99% A and a 0.6 
min hold, switched to 80% A at 0.7 minutes, then ramped to 20% A over 13 minutes 
followed by a 3 minute rinse of high organic (5:95, A:B) and a 2 minute re-equilibration 
(99:1, A:B) for a total runtime of 19 min.    
Auto tandem mass spectrometry (MS/MS) acquisition was performed in positive 
mode with the following parameters: MS range 100 to 950 m/z, threshold of 5000 for 
precursor selection, drying gas temperature at 150 °C, drying gas flow at 18 L/min, 
sheath gas temperature at 375 °C, sheath gas flow at 11 L/min, nebulizer at 50 psi, and 
fragmentor at 380 V. During acquisition, automated calibration was in place.  
Metabolite Identification  
Data from hepatocyte incubations and urine samples was processed using a 
Personal Compound Database and Library (PCDL) generated in-house using MassHunter 
PCDL Manager. Potential metabolites for 5F-MDMB-PICA and 5F-MDMB-PINACA 
were predicted using the following biotransformations either alone or in combination: 
phase I transformations (amide hydrolysis, butanoic acid formation at the indole/indazole 
side chain, carboxylation, dehydrogenation, dihydrodiol formation, dihydroxylation, ester 
hydrolysis, ketone formation, N-dealkylation, hydroxylation, oxidative defluorination, 
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oxidative defluorination to pentanoic acid, propionic acid formation at the 
indole/indazole side chain) and phase II transformations (glucuronidation and sulfation). 
Criteria for metabolite identification were as follows: mass error of less than ± 5 ppm for 
protonated molecule, MS/MS spectra showing plausible product ions, retention time 
feasible for the structures, appropriate peak shape and absence in negative controls. 
Receptor Activation  
Analysis of receptor activation was carried out on AequoScreen recombinant 
CHO-K1 cell lines purchased from Perkin Elmer (Groningen, Netherlands) expressing 
the human CB1 receptor (ES-110-A) according to the manufacturer specifications. 
Specifically, cells have been quickly thawed in BSA medium that was previously 
warmed to 37 °C. Cells were centrifuged at 150 g for 5 min at room temperature and the 
cells were re-suspended with BSA medium (1 mL) in order to have 3x105 cells/mL in a 
20 mL tube. Coelenterazine was added to achieve a final concentration of 2.5 µM in BSA 
medium. The cells were incubated at room temperature in the dark during rotation for 
three hours. 5F-MDMB-PICA and 5F-MDMB-PINACA were prepared in 96-well-plates 
at descending concentrations using serial dilutions. The concentrations were 20,000, 
4,000, 800, 160, 32, 6.4, 1.28, 0.256, 0.0512, 0.01024 ng/mL in each well. JWH-018 was 
also analyzed as a reference agonist for the CB1 receptor. Digitonin was used as a 
positive control for the coelenterazine cell loading and blank wells with no drug used as 
negative controls. The activation at each drug concentration was determined using a 
Tecan SparkTM 10M (Switzerland) as 50 µL cell suspension was added to the well (15000 
cells).  The Spark 10M reading protocol was set to 200 luminosity readings and the cells 
were added to each well at reading cycle #10 (baseline) and luminescence registration 
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was conducted for ~25 s. Data was fitted to the Hill equation using GraphPad Software, 
Prism version 8. Statistical differences were investigated using one-way ANOVA.  
Results 
Metabolic Profile of 5F-MDMB-PICA 
From hepatocyte incubations and urine samples, 22 metabolites (A1 to A22) were 
identified for 5F-MDMB-PICA in this study with mass errors within ±3.27 ppm (Figure 






Figure 8.1 Extracted Ion Chromatograms (EIC) of hepatocyte incubations and urine samples yielding the most metabolites: 1a) first 
hour incubation of 5F-MDMB-PICA with hepatocytes, 1b) metabolites found in antemortem case 4 urine, 2a) first hour incubation 




 These metabolites are summarized in Table 8.1 in retention time order. 
Metabolites were formed via carboxylation (A16) or hydroxylation on the aliphatic chain 
(A20) or aromatic ring (A18) followed by glucuronidation (A4); N-dealkylation (A15) 
followed by hydroxylation on the aromatic ring (A3); oxidative defluorination (A19) 
followed by conversion to pentanoic acid (A17); oxidative defluorination with conversion 
to propionic acid (A14). Oxidative defluorination pathway also subsequently underwent 
hydroxylation on the aromatic ring (A5, A9) followed by N-dealkylation (A3) or 
glucuronidation (A1).  The ester hydrolysis (A21) metabolite was further metabolized via 
hydroxylation (A8, A10, A13), glucuronidation (A12), or dehydrogenation (A22) 
followed by N-dealkylation (A2), or ester hydrolysis with oxidative defluorination (A11) 
followed by dehydrogenation (A7), or conversion to pentanoic acid (A6). The proposed 










Table 8.1 5F-MDMB-PICA metabolite identification in order of retention time  








































hydroxylation on aromatic ring+ 
glucuronidation 
4.06 566.2476 (C27H38N2O11) 













A2 Ester hydrolysis+ N-dealkylation+ dehydrogenation 4.66 
272.1161 
(C15H16N2O3) 










68307 144.0447 NA 
A3 N-dealkylation+ hydroxylation on aromatic ring 5.11 
304.1423 
(C16H20N2O4) 










ND 160.0394 NA 
A4 Hydroxylation on aromatic ring+ glucuronidation 5.35 
568.2432 
(C27H37FN2O10) 













A5 Oxidative defluorination+ hydroxylation on aromatic ring 5.82 
390.2155 
(C21H30N2O5) 













A6 Ester hydrolysis+ oxidative defluorination to pentanoic acid 5.83 
374.1842 
(C20H26N2O5) 













A7 Ester hydrolysis+ oxidative defluorination+ dehydrogenation 5.95 
358.1893 
(C20H26N2O4) 













A8 Ester hydrolysis+ hydroxylation on aliphatic chain 5.95 
378.1955 
(C20H27FN2O4) 













A9 Oxidative defluorination+ hydroxylation on aromatic ring 6.02 
390.2155 
(C21H30N2O5) 




































































A13 Ester hydrolysis+ hydroxylation at t-butyl 6.34 
378.1955 
(C20H27FN2O4) 













A14 Propionic acid 6.90 360.1685 (C19H24N2O5) 













A15 N-dealkylation 7.17 288.1474 (C16H20N2O3) 










ND 144.0443 NA 
A16 Carboxylation at t-butyl 7.66 406.1904 (C21H27FN2O5) 













A17 Oxidative defluorination to pentanoic acid 7.94 
388.1998 
(C21H28N2O5) 






















































A18 Hydroxylation on aromatic ring  8.32 392.2111 (C21H29FN2O4) 













A19 Oxidative defluorination 8.36 374.2206 (C21H30N2O4) 













A20 Hydroxylation on aliphatic chain 8.44 392.2111 (C21H29FN2O4) 













A21 Ester hydrolysis 8.64 362.2006 (C20H27FN2O3) 













A22 Ester hydrolysis+ dehydrogenation 8.70 360.1849 (C20H25FN2O3) 













P 5F-MDMB-PICA 10.94 376.2162 (C21H29FN2O3) 

















The two most abundant metabolites after the 5 h incubation with hepatocytes were 
ester hydrolysis (A21) and ester hydrolysis with oxidative defluorination (A11). The Case 
4 antemortem urine had the most metabolites observed (A2, A3, A6, A8-10, A12-A14, 
A17-A19, and A21-A22), while case 1 had a couple metabolites (A6 and A21) and case 2 
only had a single metabolite identified (A21). The ester hydrolysis product was the only 
metabolite present in all incubation time points and authentic urine specimens. 5F-
MDMB-PICA was not detected in any of the urine specimens, but was dominant in all 
hepatocyte incubations. The mass spectra of 5F‐MDMB‐PICA and the 9 most abundant 
metabolites present in urine from Case 4 are shown in Figure S3 in the Supporting 
Information. 5F‐MDMB‐PINACA tentatively identified metabolites (Table S1), proposed 
metabolic pathway (Figure S1), and mass spectra from metabolites found in authentic 
(Figure S3) are provided in the Supporting Information. 
Receptor Activation  
Dose response curves for the full concentration range used are shown in Figure 
8.3 after normalization to the digitonin response. Both 5F-MDMB-PICA and 5F-MDMB-
PINACA are full agonists reaching 83% and 88% of the digitonin signal, respectively. 
Compared to JWH-018 they were significantly more effective in activating the CB1 
receptor, reaching an efficacy of 129 % (5F-MDMB-PICA, p<0.05) and 136% (5F-





Figure 8.3 Receptor curves normalized to digitonin for JWH-018, 5F-MDMB-PICA, and 
5F-MDMB-PINACA, error bars signify standard deviation 
 
In Table 8.2, the effective concentration values (EC) expressed both in ng/ml and 
M including the 95% confidence intervals are shown for JWH-018, 5F-MDMB-PICA, 
and 5F-MDMB-PINACA. There was no significant difference in comparison of EC50 
values of 5F-MDMB-PICA, 5F-MDMB-PINACA and JWH-018 using one-way 
ANOVA, p=0.05.  
Table 8.2 Effective concentrations for synthetic cannabinoids 
Compound 





JWH-018 36.6 12.48 27.2 to 49.1 9.29 to 16.77 
5F-MDMB-
PINACA 15.7 5.94 12.0 to 21.6 
4.53 to 8.15 
5F-MDMB-PICA 27.6 10.37 21.7 to 35.0 8.17 to 13.18 
 
Discussion  
As seen in Figure 8.3, both compounds have comparable potency to JWH-018, 
but both have slightly higher efficacy. The EC50 for 5F-MDMB-PINACA and 5F-
MDMB-PICA are comparable to each other which was also reported by Banister et al 
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(9). However, our EC50 values are around 60x higher than those reported by Banister et al 
(9)  and Noble et al report an EC50 value for 5F-MDMB-PICA 8x lower than in the 
present study (8).  Noble et al also report 5F-MDMB-PICA to be 13x more potent than 
JWH-018 while our results indicate similar potency. In our study, 5F-MDMB-PICA was 
also found to have an Emax 30 % higher than that of JWH-018. This result differ from 
what has been reported by Noble et al, with an Emax 3 times higher than that of JWH-018. 
The differences between our results and those reported by Noble et al could be attributed 
to the different techniques and intracellular pathways used to determine receptor activity 
between this study and Noble et al, which monitored the interaction between βarr2 and 
CB1 and CB2 receptors (8). This study is aequorin-luminescence based on Ca2+ flux. This 
method is based on the activation of the calcium sensitive apoaequorin/aequorin system 
where coelenterazine is converted by the aequorin upon activation. After the G-protein 
activation, the second messenger phospholipase C is activated, with succeeding 
diacylglycerol and inositoltriphosphate production and intracellular calcium ions release 
(12). The calcium release activates the apoaequorin/aequorin system and with 
coelenterazine as substrate luminescence is produced. That said, substantial differences 
were also seen when comparing our results to those of Banister et al even though they 
also used an assay based on Ca2+ flux (FLIPRTM). Taken together, our results as well as 
those reported by Banister et al (9) and Noble et al (8) illustrate that efficacy and potency 
estimates are method specific and highlight the need to use several different assays to 
describe the potency of a CB1 agonist. 
Although the cause of death in both Case 1 and 2 was attributed to diabetic 
ketoacidosis, the presence of synthetic cannabinoids cannot be excluded as a contributing 
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or underlying factor. Hess et al presented a fatality that involved several synthetic 
cannabinoids where cause of the death was also assumed to be from diabetic 
ketoacidosis(13). The decedent in their study and from the present study (Case 1) had a 
history of diabetes. However, the decedent in Case 2 had no history of diabetes which is 
similar to what was reported by Demirci et al (14). 5F-MDMB-PICA is a full agonist to 
the CB1 receptor and may produce severe adverse side effects such as hyperglycemia(13). 
In cases of ketoacidosis with or without history of diabetes, comprehensive toxicology 
screens may be valuable in determining root cause.  
For both compounds, ester hydrolysis and ester hydrolysis in combination with oxidative 
defluorination were the most prevalent metabolites produced in vitro. At least one of 
these biotransformations were present in each of the case samples presented. 
Authentic Urines 
In the postmortem urine samples, a total of 2 metabolites were identified (A6 and 
A21). The ester hydrolysis (A21) was identified in the case 2 sample following 
hydrolysis, indicating cleavage of the glucuronide.  In the antemortem urine sample, 14 
metabolites (A2, A3, A6, A8-A10, A12-A14, A17-A19, and A21-A22) were found, with 
2 metabolites (A8 and A14) not produced in vitro. Variation in the numbers of 
metabolites in the 3 different case samples is difficult to interpret as time of 
administration is unknown but the low number of metabolites in the post mortem samples 
suggest administration shortly prior to death. Evidence of phase II hydrolytic cleavage 
was evident in most metabolites, especially with metabolites A3, A9, A19, and A22 as 
they were identified only after hydrolysis. In all 3 cases, ester hydrolysis was the most 
abundant metabolite, which is consistent with the study by Mogler et al (10). Further, the 
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metabolites produced in these in vitro and in vivo samples aligned with the 12 identified 
by Mogler et al (10), with the exception that the amide hydrolysis was not detected in the 
present study . However, A6 was not identified by Mogler et al (10). This metabolite was 
present in two of the three urine cases presented, with being the most abundant 
metabolite found in Case 1. The corresponding metabolite for 5F-MDMB-PINACA (B7), 
was found in all incubations of the present study and was the second most abundant 
metabolite found in Case 3.  Yeter et al ranked this metabolite second most abundant 
metabolite found in both hydrolyzed and non-hydrolyzed authentic urine samples (n=30) 
(16). Based on the structural similarity to 5F-MDMB-PINACA and urine findings of the 
present study, A6 is likely to be a major metabolite in urine for 5F-MDMB-PICA. To the 
author’s knowledge, this is the first report identifying A6 as a suitable marker for 
screening.   
The ranking for hepatocyte incubations and urine samples share the same 
metabolite for the top ranking (A21). Although A6 is not in the top 3–5 metabolites in 
hepatocyte incubations, due to its abundance in two of the three urine specimens and 
previous data about the corresponding metabolite for 5F‐MDMB‐PINACA, it is given the 
second top ranking for urine samples. 
Conclusion  
Based on the aequorin-luminescence method used for this study, the EC50 at the 
CB1 receptor for 5F-MDMB-PICA and 5F-MDMB-PINACA were found to be 
comparable to each other and JWH-018. The EC50-value of 5F-MDMB-PICA was found 
to be 27.6 nM, 8 to 60 times lower than indicated by other assays, indicating that 5F-
MDMB-PICA might be less potent than previously believed.  For both compounds, ester 
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hydrolysis and ester hydrolysis in combination with oxidative defluorination were the 
most abundant metabolites produced in vitro. Additionally, we described the conversion 
of ester hydrolysis with oxidative defluorination to pentanoic acid (A6) for the first time 
for 5F-MDMB-PICA. At least one of these biotransformations were present in each of 
the case samples presented and are in agreement with previous literature. Therefore, these 
metabolites would be potentially good biomarkers for screening urine of suspected 
intoxication of 5F-MDMB-PICA or 5F-MDMB-PINACA. However, these metabolites 
are not specific to the consumption of 5F-MDMB-PICA or 5F-MDMB-PINACA, i.e., 
they can be formed from drugs of similar structures. Therefore, based on the hepatocyte 
incubation abundance, ester hydrolysis (A21), and ester hydrolysis with oxidative 
defluorination to pentanoic acid (A6), based on authentic urine data, are recommended to 
be monitored for the purpose of screening/confirmation. As parent drug was not present 
in the urine samples analyzed, metabolites may be of utmost importance when 
determining drug intake. 
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The age of NPS has no immediate end in sight. The only way to overcome the 
emergence of NPS is by identifying obstacles that can help alleviate the difficulties that 
arise when analyzing samples that possibly contain NPS.  Prevalence plays key role in 
the emergence of NPS as the illicit drug community and drug market are constantly 
changing which new high is sought after. Although the oral fluid method that was 
developed to help determine prevalence of NSO in certain communities (such as prison 
detainees) did not detect such compounds in a limited sample size, valuable information 
was obtained during these collections. The evaluator opinion of drug class was confirmed 
in oral fluid 90% of time and in urine 85% of the time in reference to scope of testing. 
Data indicate that oral fluid may be a viable source for confirming driving under the 
influence of drugs (DUID).  This information is important to the forensic community as 
some states, such as Alabama, have started to incorporate oral fluid as a matrix of interest 
within their analytical testing.  
Knowledge of drug stability is necessary when dealing with compounds such as 
NPS. Toxicologists need to know if compounds are not detected because they are truly 
absent from the sample or if the compounds have degraded. Through the 36-week study 
that was conducted, the stability of seven NSO was determined. Even at elevated 
temperatures, all analytes were deemed stable (within 20% of target concentration) for at 
least two weeks at low concentrations. For blood samples that may contain these NSO, it 




order to preserve analyte stability. Additionally, samples should be analyzed within a 
month in order to determine accurate concentration of the synthetic opioids.  
Understanding the pharmacology of a NPS is essential to properly interpret 
impairment of individuals under the influence of a possible NPS. It was determined that 
doses of U-47700 in an animal model had a positive correlation with observed behaviors, 
further demonstrating the analgesic effects of this novel synthetic opioid. Knowing the 
possible pharmacological effects of U-47700 as well as the pharmacokinetic profiles of 
the drug and its metabolites will allow forensic toxicologists to better interpret 
toxicological data for possible intoxications.   
Metabolism studies are essential for determining NPS use, especially when 
synthetic cannabinoids are suspected as parent drug may no longer be detectable. Using 
human liver microsomes, there were 22 metabolites identified for 5F-MDMB-PICA and 
21 metabolites identified for 5F-MDMB-PINACA. For both compounds, ester hydrolysis 
and ester hydrolysis in combination with oxidative defluorination were the most abundant 
metabolites in vitro and in vivo. In the authentic urine samples, parent compounds were 
not identified, further demonstrating the need for metabolic studies to identify potential 
biomarkers. Without identification of metabolites, synthetic cannabinoids could go 
undetected in toxicological examinations.  
Using any of the previously described approaches (evaluating prevalence, 
determining instability, characterizing pharmacokinetics, or identifying potential 
biomarkers) will allow the forensic community to develop useful processes for ensuring 
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Supplemental Information for Chapter VIII 
S1. Materials and Methods  
S1.1 Case 3 
A 51 year old male was found unconscious in his apartment. After cardiac arrest 
resuscitation was unsuccessful and he was pronounced dead at the arrival to hospital. In the 
apartment there were signs of drug use as well as suspected drugs. The post-mortem examination 
revealed a fatty liver, arteriosclerosis, enlarged heart and pulmonary embolism. The toxicological 
analysis showed a number of medications including mirtazapine, clomipramine, and diazepam, 
and new psychoactive substances including dibutylone, diclazepam, N-ethyl-4-
methylnorpentedrone, norfludiazepam, and 5F-MDMB-PINACA. The cause of death was 
attributed to pulmonary embolism with a possible contribution from drug use. 
S2. Results  
S2.1 Metabolic Profile of 5F-MDMB-PINACA 
A total of 21 5F-MDMB-PINACA metabolites (B1 to B21) were identified with low 
mass error (within ±3.33 ppm), with 3 compounds unique to urine specimens. Extracted ion 
chromatograms of the hepatocyte incubation yielding the most metabolites (2a) and case 3 
hydrolyzed urine (2b) are shown in Figure 2. Metabolites (in retention time order) and rankings 
are shown in Supplemental Table 1. The rank was determined by the 3 hr incubation abundance 






Supplemental Table 1. 5F-MDMB-PINACA metabolite identification in order of retention time    
































Fragments Rank  
B1 Ester hydrolysis+ oxidative defluorination+ glucuronidation 4.53 
537.2322 
(C25H35N3O10) 









B2 Ester hydrolysis+ oxidative defluorination+ glucuronidation 4.62 
537.2322 
(C25H35N3O10) 









B3 Ester hydrolysis+ oxidative defluorination+ glucuronidation 4.74 
537.2322 
(C25H35N3O10) 









B4 Ester hydrolysis+ N-dealkylation+ dehydrogenation 4.96 
273.1113 
(C14H15N3O3) 






ND 145.0399 NA 
B5 Oxidative defluorination+ glucuronidation 5.92 551.2479 (C26H37N3O10) 









B6 Amide hydrolysis 5.93 250.1118 (C13H15FN2O2) 









B7 Ester hydrolysis+ oxidative defluorination to pentanoic acid 6.09 
375.1794 
(C19H25N3O5) 









B8 Ester hydrolysis+ hydroxylation on aliphatic chain 6.26 
379.1907 
(C19H26FN3O4) 









B9 Ester hydrolysis+ oxidative defluorination+ dehydrogenation 6.32 
359.1845 
(C19H25N3O4) 









B10 Ester hydrolysis+ oxidative defluorination 6.39 361.2002 (C19H27N3O4) 









B11 Ester hydrolysis+ glucuronidation 6.45 539.2279 (C25H34FN3O9) 









B12 Ester hydrolysis+ hydroxylation at t-butyl 6.53 379.1907 (C19H26FN3O4) 









B13 N-dealkylation 7.56 289.1426 (C15H19N3O3) 









B14 Carboxylation at t-butyl 8.32 407.1857 (C20H26FN3O5) 









B15 Oxidative defluorination to pentanoic acid 8.51 389.1951 (C20H27N3O5) 









B16 Hydroxylation at aliphatic chain 8.85 393.2064 (C20H28FN3O4) 









B17 Hydroxylation at aliphatic chain 8.98 393.2064 (C20H28FN3O4) 









B18 Oxidative defluorination 9.00 375.2158 (C20H29N3O4) 









B19 Hydroxylation at t-butyl  9.03 393.2064 (C20H28FN3O4) 









B20 Ester hydrolysis 9.31 363.1958 (C19H26FN3O3) 














































Fragments Rank  
B21 Ester hydrolysis+ dehydrogenation 9.41 361.1802 (C19H24FN3O3) 









P 5F-MDMB-PINACA 11.83 377.2115 (C20H28FN3O3) 












The biotransformations that were observed were similar to those of 5F-MDMB-
PICA and the proposed metabolic pathway is depicted in Supplemental Figure 1. 
 





S2.2 Mass fragmentation of 5F-MDMB-PICA and 5F-MDMB-PINACA 
The two main fragments used to characterize 5F-MDMB-PICA were m/z 
232.1132 (containing the indole with the fluoropentyl side chain) and 144.0444 (the 
indole group) (Supplemental Figure 2). The mass spectra of 5F-MDMB-PICA and 9 
most abundant metabolites identified in case 4 are shown in Supplemental Figure 2. 














Supplemental Figure 2. Mass spectra of 5F-MDMB-PICA and 9 most abundant 




The following were used as characteristic fragments of the 5F-MDMB-PINACA: 
m/z 233.1085 (containing the indazole and fluoropentyl side chain), 213.1022 (the 
indazole and side chain without the fluorine), 177.0459 (containing the indazole group 
with fluoromethyl group) and 145.0396 (containing the indazole group) (Supplemental 
Figure 3). There are two structures shown for the fragment 177.0459 in Supplemental 
Figure 2. One was proposed by Diao et al when characterizing the metabolism of THJ-
2201 (a fluorinated analogue of THJ-018) 11 and the other is the proposed structure 
containing the fluoromethyl group from this study . Changes to these fragments helped 
identify where biotransformations took place. The mass spectra of 5F-MDMB-PINACA 
and the 9 most abundant metabolites found in the urine sample from case 3 are shown in 





Supplemental Figure 3. Mass spectra of 5F-MDMB-PINACA and 9 most 




S3. Discussion  
S3.1 5F-MDMB-PICA Hydroxylations  
5F-MDMB-PICA produced many hydroxylated metabolites. As mentioned 
before, fragments m/z 232 (containing the indole group with fluoropentyl chain) and 144 
(containing the indole group) were used to characterize 5F-MDMB-PICA. Modifications 
of +15.995 Da to either of these fragments were indicative of hydroxylation. The 
metabolite A20 had hydroxylation on the fluoropentyl side chain due to the conservation 
of m/z 144 and shift of m/z 248. A18 produced shifts of both characteristic fragments to 
m/z 248 and 160, concluding that the hydroxylation occurred on the aromatic ring. These 
fragments were present in A4 as well and a shift of +176.0309 Da in the m/z of the 
protonated molecule due to glucuronidation. A10 hydroxylation on the indole ring also 
had fragments m/z 248 and 160 present, but the ester hydrolysis shifted the molecular 
mass by -14.016 Da. A8 was produced by hydroxylation and ester hydrolysis as well. 
While the m/z 144 fragment was conserved, a shift of +15.995 Da on the m/z 232 
fragment to m/z 248 indicated hydroxylation on the aliphatic side chain. A13 was another 
metabolite produced by the combination of ester hydrolysis and hydroxylation, but 
presence of both m/z 232 and 144 indicated that hydroxylation occurred on the tert-
leucinate group. The fragment m/z 160 was used to characterize A3 due to N-dealkylation 
occurring with the hydroxylation. With the presence of the m/z 160, hydroxylation was 
on the indole group.  
S3.2 Oxidative Defluorination and Carboxylation of 5F-MDMB-PICA 
Oxidative defluorination is characterized by the shift -1.996 Da with the fragment 




defluorination. A11 also possesses these fragments, but shifts -14.016 Da due to 
additional ester hydrolysis. Another shift of -2.016 Da, A7 contains dehydrogenation with 
oxidative defluorination and ester hydrolysis. A5 and A9 possessed fragments m/z 246 
(indicating both oxidative defluorination and a hydroxylation) and 160. With a shift on 
both fragments of +15.995 Da, the hydroxylation occurred on the aromatic ring of the 
indole. The same hydroxylation was present in A1, but in combination with 
glucuronidation with a shift +176.0309 Da. 
The hydroxyl formed by oxidative defluorination is further converted into a 
pentanoic acid and shifts +13.980 Da. This is characterized with fragment m/z 244 as 
produced by A6 and A17.  Another carboxylation observed was a conversion to propionic 
acid, A14. This metabolite was determined using the characteristic fragments m/z 216 
(containing the indole with propionic acid) and 144. This metabolite was also tentatively 
identified in Mogler et al 10.  A16 retained both m/z 232 and 144 which would indicate 
carboxylation occurring at the t-butyl group. Although there was not an intermediate 
metabolite with hydroxylation observed, there was a similar biotransformation found 
with 5F-MDMB-PINACA (B19).  
S3.3 Ester Hydrolysis and Other Biotransformations 
Ester hydrolysis appeared in 10 of the 22 metabolites tentatively identified. Shifts 
to the molecular mass were used to identify this biotransformation. A21 contained 
fragments m/z 232 and 144 with a shift of -14.016 Da to the molecular mass indicative of 
ester hydrolysis.  An additional shift of -2.016 Da to the molecular mass of A22 was 
indicative of ester hydrolysis in combination with dehydrogenation. N-dealkylation had 




contained fragments m/z 232 and 144 with an exact mass of 566.2476 due to 
glucuronidation. 
S3.4 Hydroxylations of 5F-MDMB-PINACA   
B16, B17, and B19 were formed as a result of 5F-MDMB-PINACA 
hydroxylation. For B16 and B17, the fragments m/z 145 and 177, which contain the 
indazole group, were conserved, while the other fragments had an addition of +15.995 
Da, indicating that the hydroxylation was on the pentyl chain. For B19, the fragments m/z 
233 and 213 containing the intact fluoropentyl indazole group was observed, suggesting 
the hydroxylation on the tert-leucinate group.  
S3.5 5F-MDMB-PINACA Oxidative Defluorination  
The fragments m/z 231 indicating hydroxypentyl side chain and the m/z 213 
indicating an indazole with the side chain without the fluorine were used as characteristic 
fragments for the identification of B9, B10, and B18 as metabolites with oxidative 
defluorination. Other biotransformations found in association with oxidative 
defluorination were conversion to pentanoic acid (B7, B15) and glucuronidation (B1-B3, 
B5).  The fragments that were indicative of conversion to pentanoic acid were m/z 245, 
227, and 217. B5 conserved the same fragments used to characterize B18 (231, 213, 175, 
and 145), but had a m/z of 553 which indicates that glucuronidation had occurred.  The 
same can be applied to B1-B3, but these metabolites had a protonated molecule mass of 
538.2389 due to the ester hydrolysis.  
S3.6 Hydrolytic Biotransformations and N-dealkylation of 5F-MDMB-PINACA 
Amide hydrolysis (B6) at m/z 251 and ester hydrolysis (B20) at m/z 364 shared 




conservation of the indazole and fluoropentyl chain. Ester hydrolysis in combination with 
dehydrogenation (B21) or glucuronidation (B11) also share these fragments, but are 
differentiated with their m/z at 362 and 540.  N-dealkylation (B13) had two fragments 
used to indicate its presence (230 and 145). Ester hydrolysis with N-dealkylation and 
dehydrogenation (B4) was characterized only by m/z 145. 
S3.7 Authentic Urine 
There were 12 metabolites (B6-B8, B10-B12, B14, B15, B18-B21) tentatively 
identified in the Case 3 sample and of those, 3 metabolites (B6, B11, and B19) were not 
produced in vitro.  B18 and B19 were found in the hydrolyzed sample and not in the non-
hydrolyzed sample, indicating that hydrolysis of the phase II conjugation had occurred. 
The glucuronidated product of B18 (B5) was not detected in vivo. Further, no conjugated 
metabolites of B19 were observed in vitro or in vivo, probably due to low abundance in 
the urine. The most abundant metabolite found in this sample was ester hydrolysis (B20), 
which was already previously identified in literature 15-17.  Of the 12 metabolites, 2 
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